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It is claimed that the first blood transfusion took place in 1492 when the dying Pope Innocent VII was 
given blood from three young men, with fatal results for all four. Most reliable records suggest the first 
transfusions were stimulated by Harvey's description of the circulation in 1628. Jean Denis (1667) of 
Montpellier appears to have been the first to transfuse blood from animals to humans and Lower did the 
same later in the year. In 1818 a desperate James Blundell gave blood successfully to a woman, near 
death with an acute post partum haemorrhage. Blood was collected from an onlooker into a primitive 
apparatus. Anticoagulation and the 33% risk of ABO incompatability was not known. 
Nowadays most anaesthetists accept that blood and its products will be readily available whenever he or 
she needs them. In South Africa in 1988 over 700,000 units of blood were transfused. The average turn 
round for a unit of blood is 8-1 o days in the Western Province Blood Transfusion Service and 
anaesthetists are probably responsible for at least 50% of all red cell products used. Unfortunately it has 
been stated that the anaesthetist often has little knowledge of the problems associated with the 
collection of blood, its preservation, fractionation, distribution and the ways in which it can be used. 
(Marshall and Bird, 1983). It was to assess the knowledge and transfusion practices of South African 
anaesthetists that the following survey was undertaken. 
METHOD 
The survey consisted of a 22 question Questionnaire with 63 part questions (Appendix 1) was completed 
prior to a lecture on blood component therapy given at the academic meetings of the Anaesthetic 
Departments at eight principle teaching hospitals in South Africa. These hospitals were Groote Schuur 
Hospital, Cape Town; King Edward VIII Hospital, Durban, Johannesburg General Hospital and 
Baragwanath Hospital, Johannesburg; J.G. Strijdom Hospital, Johannesburg; Garankuwa Hospital 
(serviced by Medunsa), Pretoria; and the Ubertas Hospital, Bloemfontein. Tygerberg Hospital 
Anaesthetic Department and the remainder of the Western Cape membership of the South African 
Society of Anaesthetists (SASA) were sent the Questionnaire by post. • 
RESULTS (see separate page) 
The results are annotated in the text according to answers given by area: 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total 
No X No X No No No X No X No X No X No X 
The separate columns for NTvl and STvl were due to the author not being able to determine which 
hospital they worked at, although the area had been stated. There were 6 respondents in these columns. 
The answers were also annotated according to the years of anaesthetic experience of the respondents; 
.1-5 years; 6-20 years or more than 20 years. 
2 Introduction 
Answer 1-5 6-20 >20 
No % No % No % 
Three hundred and thirty one replies were collected. 315 from anaesthetists in full-time teaching hospital 
practice, and 16 from practitioners with part-time appointments. 
PERCENTAGE RETURN 
TOTAL REPLIES 








W.CAPE NATAL O.F.S. N.TVL. S.TVL. 
-Each Area 
Note that the returns included 84% of the total number of 
anaesthetists in teaching hospitals of the Western Cape, 
63% of Natal, 62% of the Orange Free State, 55% of 
Northern Transvaal (Pretoria and Medunsa) and 51% of 









EXPERIENCE IN YEARS 
PERCENTAGE BY GROUP 
17 
<6 YRS <20 YRS •20 YRS 
-PRIVATE &\\\1 PART-TIME CJl FULL-TIME 
Note that the majority of those respondents with 6-20 years 













<6 YRS <20 YRS >20 YRS 
-ALL AREAS 
Note that 171 of the respondents had less than six years 
anaesthetic experience; 107 had less than 20 years and 27 had 
more than 20 years. 
A 63 % overall reply rate for a five page detailed Questionnaire is considered by most researchers to be a 
very good return for a survey. The probable reason for the good return was that a lecture entitled "The 
Blood and Blood Component Therapy in the Peri-operative Period" was given by the author of the survey 
at the Department's weekly Academic Meeting. The attending anaesthetists were requested to fill in the 
Questionnaire prior to the lecture and did not have recourse to books or discussion. This is unlike postal 
surveys of Anaesthetists' practices such as reported by Stehling et al {1987) and Kowalyshyn et al 
{1972). To try and 'capture' those anaesthetists who were not present at the lecture, Questionnaires 
were left for them with the Department's Secretary. The detailed hand-out of the lecture was only given 
to those who had completed the Questionnaire and then only two to three weeks after the lecture. 
However, this small number of respondents would have been able to look up the correct answers in the 
text books, if they were so inclined, as in any postal survey. 
The returned Questionnaires were individually scrutinised and, where the answer had been technically 
filled in incorrectly, e.g. two answers marked where only one answer was asked for, that question was 
marked as spoilt and not analysed further. 
Results were entered onto an ISM compatible personal computer, using DBase IV and Harvard Graphics 




* Minimal Pre-operative Haemoglobin 
* Maximum Pre-operative Haemoglobin 
4 Pre-operative Assessment 
MINIMAL ACCEPTABLE PRE-OPERATIVE HAEMOGLOBIN LEVELS 
Survey Question 
For a non-emergency, asymptomatic patient on average, what is your m1mmum pre-operative 
haemoglobin level which you consider to be adequate for elective minor surgery? 
a) No requirement if blood volume considered normal 
b) 8g/100ml 
c) 10g/100ml 







Answer IJ.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 







9 6 3 6 
56 37 23 43 




Note_ that 63% (208) anaesthetists would not accept a lower 
haemoglobin than 10mgjdl for an asymptomatic patient 
booked for an elective minor operation. 
5 2 
1 
4 8 3 11 17 5 
2 8 5 39 7 21 2 8 100 30 











<6 <20 >20 
- NIL - 8 Gm CIJ 10 Gm ~ 12 Gm 
Note that percentage-wise more anaesthetists who had been in 
in practice less than six years and more than 20 years chose 
10gmjdl as compared to Sgmjdl. Those 
anaesthetists in practice between 6 and 20 years 
were equally divided as to choosing 8 or 10mgjdl. 
Answer 1-5 6-20 >20 







2 12 11 3 10 
44 23 48 43 24 
143 75 49 43 17 56 
2 2 
Note that when analysed according to area, with Natal and 
Western Cape designated as sea level and the Orange Free 
State (OFS) and the Transvaal as altitude, a greater percentage 
of those practising at higher altitudes used 10gmjdl as their 
lower pre-operative haemoglobin limit. 
5 Pre-operative Assessment 
MINIMUM HB. 
REPLIES BY ALTITUDE 
PERCENTAGE OF REPLIES 
100 
NIL 8 GM 10 GM 
-SEA LEVEL ~ REEF/OFS 
6 Pre-operative Assessment 
The figure of 10gm/dl as a minimal pre-operative acceptable haemoglobin was partially confirmed 
by question 4c: 
What course of action would you take in the following cases: 
30 year-old female with menorrhagia for a 
D & C, haemoglobin 8,5g/100ml 
Female 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No % 
N/A 
Spoilt 
Transfuse 71 22 2 12 
GA 39 14 3 5 
X match 32 14 6 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
Spoilt 
Transfuse 87 47 39 46 18 69 
GA 42 23 40 37 4 15 
X match 52 28 26 24 3 12 
Administer Require 
Transfuse General Blood Cross 
Pre-op Anaesthetic Matched 
D D D 
Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
15 
7 2 











7 8 86 










Note that 45% (144) of respondents would transfuse 
pre-operatively a 30-year-old female with menorrhagia for a D & 
C with a haemoglobin of S,Sgm/dl and 26% (81) would ask for 
blood to be cross-matched. 
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DISCUSSION 
In the past surgical anaesthetic practice has been guided by the belief that a minimum acceptible 
haemoglobin level of 10g per 100ml was important in providing safe anaesthesia (Gillies 1974, 
Rawstron 1970). Less than the "magic 10g" or a haematocrit of less than 30% was taken as indicating 
the need for red blood cell transfusion. This concept was based on calculations which suggest oxygen 
availability to the tissues and organs might be impaired when haemoglobin values are less. However, 
these calculations did not include: appropriate corrections for cardiac output; oxygen extraction; or 
alterations in the haemoglobin affinity for oxygen by physiological adaptations such as a rise in 2, 3 
diphosphoglycerate (2, 3 DPG), which shifts the oxygen haemoglobin dissociation curve to the right. 
Evidence suggests that the haemoglobin level a given person will tolerate before becoming symptomatic 
depends on many factors. Cardiac output does not increase dramatically in healthy humans until the 
haemoglobin decreases to 7g% and then there is a linear increase as the haemoglobin falls further to 
2g% (Varat et al1972), as long as the fall in haemoglobin is slow enough to allow the blood volume to 
remain normal. However~ an acute loss of only 30% red cell mass will result in hypovolaemic shock 
(Unman, 1968) and hypovolaemia on its own is deliterious to tissue perfusion both in patients with 
normal haemoglobin levels and in those with anaemia. Thus, acute anaemia due to blood loss needs to 
be treated aggressively with intensive monitoring and a low haemoglobin in these patients should be 
assessed differently from those patients who present with a chronic anaemia and presumed normal 
blood volume. 
Chronic Anaemia 
Most patients who are anaemic on presentation for elective surgery have a chronic anaemia, generally 
caused by nutritional deficiency, chronic bleeding disorders, chronic illness or the cause may be 
multifactorial. Various compensations for the decreased oxygen carrying capacity associated with 
chronic anaemia include: 
1. Vasodilation of tissue vessels 
Vasodilation is thought to be due to the decreased viscosity because of the lowered haematocrit 
and not due to the decreased oxygen carrying capacity. This may increase tissue oxygenation of 
the organs. The decrease in after load due to the vasodilation also causes an increase in cardiac 
output when the haemoglobin is reduced to less than 7g%. This was shown by Murray & Escolar 
(1968) who replaced a fraction of the normal haemoglobin with methaemoglobin and noted that 
the cardiac output remained the same. However, when red blood cells were withdrawn and 
replaced with plasma giving an oxygen carrying capacity equivalent to the met haemoglobin 
model but with a decrease in the hematocrit and viscosity, cardiac output increased considerably. 
2. 2. 3 Diohosphoglycerate (2. 3 DPG) Levels 
The level of 2,3 DPG in the red blood cells is increased considerably in anaemia shifting the 
oxygen haemoglobin dissociation curve to the right. Thus a 50% reduction of circulating 
haemoglobin only results in a 27% decrease of oxygen availability at tissue level. This is due to a 
direct effect on oxygen binding to deoxyhaemoglobin and an indirect effect secondary to a 
decrease of intracellular pH (Benesch & Benesch 1967). 
3. Increased organ blood flow 
The blood flow to individual organs is increased by varying degrees. In the heart ~s long as the 
coronaries are healthy the increase is proportional to the elevation of cardiac output. Early studies 
in chronically anaemic dogs and humans showed additional coronary vessels and collaterals may 
form over a period of weeks (Eckstein 1955, Zoll et al1951). 
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Cerebral blood flow is increased although oxygen delivery to the brain is slightly decreased. This 
is associated with a small but significant decrease in brain oxygen consumption (Varat et al, 
1972). 
Hepatic and renal blood flow are both increased in anaemia provided the circulating blood volume 
and cardiac output is increased (Varat et al, 1972). 
Symptoms of anaemia 
In an otherwise healthy patient as anaemia becomes more severe, symptoms become more marked 
(Linman, 1968). Mild anaemia (9-11 %) may cause only pallor and tachycardia. With a further fall to 7 or 
8g% dyspnoea of exertion occurs. At a haemoglobin of· 6g% most patients complain of weakness. A 
haemoglobin of 3g% causes the patient to complain of dysnoea at rest and at a haemoglobin of 2-2,5g% 
congestive cardiac failure frequently occurs. Symptoms of anaemia occuring at higher haemoglobin 
levels should be treated vigorously as it indicates cardiac problems e.g. ischaemic heart disease, 
shunting in the lungs or heart or a hyperdynamic circulation e.g. in thryotoxicosis. 
In cigarette smokers, in whom a significant fraction of haemoglobin is combined with carbon monoxide, 
a haemoglobin level of 8,6g% was necessary to prevent symptoms at rest and 10,7g% was needed for 
strenuous exercise. This was contrasted to healthy non-smokers in whom the critical symptomatic levels 
were 7,5g% and 9,5g% respectively (Scott 1975). 
Age also affects the level of haemoglobin fall necessary to cause symptoms. Children appear to be 
remarkably resistant to the effects of anaemia, whereas the elderly may not tolerate even minor 
reductions in haemoglobin level (Varat et al, 1972). · 
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Diagnosis of the Anaemia 
Grindon et al (1985) suggest that patients with a haemoglobin of less than 8g% without symptoms of 
hypovolaemia or hypoxia should be investigated for a nutritional reason for their anaemia, such as iron 
deficiency, pernicious anaemia, intestinal malabsorption or hereditary haemolytic anaemia. 





MCH low < 17pc 












































However the cause of the anaemia may be multifactorial and the response to therapy may need to be 
assessed prior to a final diagnosis. Inappropriate blood transfusion is not only hazardous but may delay 
response to definitive therapy by suppressing the bone marrow response. 
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Anaesthetic Implications 
The cause of the anaemia should have more than a passing, academic interest to the anaesthetist due to 
other organ systems which may be affected, for example, liver impairment due to malnutrition. The fact 
that many other systems including the immune system are affected by iron deficiency may delay or 
compromise recovery. Also liver, renal or thyroid disease can have a profound effect on the anaesthesia 
if these disorders are unrecognised in the pre-operative assessment. 
If the cause of the anaemia is an infective process, sub acute bacterial endocarditis should be excluded, 
as in these patients all but the most urgent of surgical procedures must be postponed because of the 
high peri-operative morbidity and mortality risk. 
Therapy of Nutritional Anaemias (Isbister & Pittiglio, 1988) 
If the anaemia is due to malnutrition and the operation can safely be postponed it is safer to treat the 
anaemia and operate with the anaemia corrected. 
Iron Deficiency 
The treatment of iron deficiency requires the regular delivery of iron to the upper small bowel until the 
haemoglobin level is normal. Following this, a longer period of less intense iron therapy is necessary tQ 
replete the body's iron stores. 
The rate of erythropoiesis is intimately connected to the stimulus for red cell production i.e. degrees of 
anaemia and the presence of other nutritional or suppressive factors which may impair the response. 
Normal bone marrow has the potential to produce at six times the normal rate and thus utilize as much 
as 120mg of iron a day. Thus, if the patient can tolerate a high iron intake (4-5mgjKgjday of elemental 
iron) three times a day, a maximal response of approximately 1 OOml of new red cells each day results in 
a haemoglobin rise of 1-2gjweek. Because of gastrointestinal intolerance it is wise to build up to this 
dose gradually. However the marrow of a patient with severe iron deficiency anaemia needs time to 
"wind-up" and produce red blood cells. So a delay of up to 7-10 days may occur before a rise in 
haemoglobin is noted. 
It is unusual to see a reticulocyte count of more than 12% in a resolving iron deficiency anaemia, in 
contrast to a severe megaloblastic anaemia where responses as high as 60% may be observed. 




Continued blood loss 
Inappropriate iron therapy e.g. single dose or delayed release 
Gastrointestinal malabsorption 
Suppressive effects on bone marrow response and iron absorption by initial blood transfusion. 
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Pre-operative transfusion and oxygen carrying capacity 
If pre-operative transfusion is ·believed necessary, ideally one to two days should be allowed for the 
volume shifts to normalise and the transfused blood to regain normal 2, 3 DPG levels and restore the 
oxygen release to normal (Allen & Allen). However with the introduction of ADSOL (Mannitol, 
750mg/100ml; glucose 2000mg/100ml; adenine 27mg/100ml and NaCI 900mgj100ml) to packed red 
blood cells 2, 3 DPG is better preserved and within several hours after transfusion the haemoglobin 
oxygen carrying capability will have normalised. It has been reported that ADSOL; (a) maintains at least 
50% of original ATP values by day 35 or beyond; (b) minimises haemolysls to less than 0,5% at day 35 or 
beyond; (c) provides at least 75% post transfusion recovery of red cells and (d) allows for relatively 
simple manufacturing methods while providing a stable solution under current standard storage practice 
(Heaton et al, 1984). Blood transfusions should be given slowly especially in patients with cardiac 
insufficiency. If there is a risk of cardiopulmonary embarrassment a diuretic may be given concurrently 
with the transfusion. 
Effects of anaesthesia and oxygen carriage 
Anaesthesia may increase shunting in the lung due to vasodilation of hypoxically restricted pulmonary 
vessels thus diminishing total oxygen uptake. In clinical practice, however, patients are given high 
inspiratory oxygen concentrations. This, together with the fact that General Anaesthesia reduces the 
oxygen requirements of the body as a whole, and specifically those of the heart (Theye & Michenfelder, 
1975), means that most adequately ventilated patients have arterial oxygen tensions far greater than 
when they are awake and breathing room air. 
Morbidity of anaemia in the peri-operative period 
Mild . anaemia, itself, is not associated with peri-operative morbidity or poorer surgical healing. The 
frequency and severity of post-operative infections is also not increased in anaemia (Consensus 
Statement on Peri-operative Red Cell Transfusion, 1989). Similarly, in non-uraemic patients no 
relationship has been demonstrated between anaemia and increased bleeding times. However there are 
no controlled studies on the relationship of anaemia to delayed recuperation or Increased hospital stay. 
Optimal haematocrit values 
The haematocrit value at which peak oxygen transport occurs has been reported to be as low as 30% in 
a theoretical study on dogs and as high as 40-45% in other studies on dogs (Richardson & Guyton, 
1959, Hint 1968}. However a study of critically ill post-operative patients (Czer & Shoemaker, 1978} 
found a maximum survival rate in those patients who had a haematocrit between 27 and 33%. They· 
suggested the optimum haematocrit level was in the peri-operative period about 33%. 
Optimal pre-operative haemoglobin levels 
It would seem reasonable that evolution would select the haemoglobin level that would allow an animal 
the greatest chance of survival following injury. However, the decision to transfuse patients should not 
be made on laboratory values alone but must take into account various clinical factors including: the 
patient's symptoms; the duration of anaemia; level of the anaemia; the intravascular volume; the extent 
of the operation; the ability of the surgeon and the probability of surgery causing significant blood loss; 
the presence of co-existing conditions such as impaired lung function, impaired cardiac output, 
myocardial ischaemia and cerebrovascular or peripheral circulatory disease; and the possibility of the 
formation of HLA cytoxic antibodies. The latter is important in terminal renal failure where the presence 
of antibodies will make a suitable donor more difficult to find. 
12 Pre-operative Assessment 
The optimal haemoglobin level will be different for each pati~nt. No single measure can replace good 
clinical judgment. However, current internationally reported experience suggests that healthy patients 
with haemoglobin levels of 10/dl or greater seldom require peri-operative transfusions. Whereas.those 
with acute anaemias and haemoglobins of less than 7gjdl will frequently require transfusions 
(Consensus Conference on Peri-operative Red Cell Transfusion, 1989). During the pre-operative 
visit by the anaesthetist an acceptable haemoglobin level for the patient should be ~lculated based on 
the abovementioned clinical factors. This should be the level which one allows the patient to bleed down 
to in the peri-operative period whilst replacing blood with clear fluids (crystalloids or colloids). 
A postal survey by Stehling et al (1987) of transfusion practices amongst anaesthesiologists In the USA 
showed similar trends to those found in the present survey. 65% of respondents required patients to 
have a pre-operative haemoglobin of 1 Ogmjdl for elective surgery (63% in South African survey). This is 
similar to a survey by Kowalyshyn et al (1972) in which 88,1% of anaesthetists at 1,249 institutions 
required a haemoglobin greater than 9,0gmjdl and 43,9% required that the level be higher than 1 Ogm/dl. 
CONCLUSION 
The survey suggests that fixed haemoglobin levels are used as cut offs for pre-operative acceptance of 
the patient's fitness for anaesthesia amongst the majority of South African anaesthetists surveyed. Whilst 
the actual acceptable haemoglobin pre-operatively will vary from different areas and with different 
patients, a more critical look should be taken at pre-operative haemoglobin levels. To transfuse 
unnecessarily based on fixed cut off levels without cognizance of the cause, symptoms, or typ~ of 
surgery contemplated is expensive at best and at worst may cause serious harm to the patient. An 
important clinical role the anaesthetist has to be able to fulfill is to assess if a proper work up of the_ 
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MAXIMUM PRE-OPERATIVE HAEMOGLOBIN LEVELS 
Survey Question 
For a non-emergency case, on average, what is the maximum pre-oper
ative haemoglobin level above 
which you would sugge~t postponing the operation? 
a) No maximum requirement CJ 
b) 17-18g/100ml D 
c) 18g-19g/100ml D 
d) 19-20gj100ml D 
RESULTS 
Maximum Haemoglobin 
Answer W.Cape Natal NTvl STvl OFS Pretoria M
edunsa JHB Baragwanath Total % 
No •% No % No No No % No % No % N





Nil 24 16 15 28 1 . 10 40 11 40 
8 8 31 5 20 76 23 
17-18gm 38 25 13 25 2 3 12 3 11 
8 5 19 9 36 74 23 
18-19gm 63 41 14 26 9 36 4 15 5
 39 7 27 4 16 106 32 
- 19-20gm 28 18 10 19 2 2 8 9 33 
5 39 6 23 7 28 69 21 
MAX HAEMOGLOBIN 
Answer 1-5 6-20 >20 
'Ko Returns 
100 




Nil. 38 20 34 30 4 14 
17-18gm 35 19 26 23 12 42 
60 
18-19gm 68 37 30 26 9 31 




'Nil 17-18 G1n11 18-19 Gms 19-20 Gms 
Note that 23% (74) of respondents stated their maximum 










PERCENTAGE BY AGE GROUP 
<6 
-NIL I 
CIJ 18-19 Gm 
<20 
1.\\\\ll 17-18 Gm 
~ 19-20 Gm 
12 
>20 
Note that a higher percentage (42%) of those with more than 20 
years anaesthetic experience would suggest postponing a case 
when the haemoglobin was 17-18 gm than those with less than 









REPLIES BY ALTITUDE 
PERCENTAGE OF AREA 
NIL 17-18 GMS 18-19 GMS 19-20 GMS 
- SEA LEVEL ~ REEF\OFS 
Note that there is no statistical difference between the 
percentage of respondents at either sea level or at altitude 
(Reef & OFS) choosing each of the maximum haemoglobin 
levels. 
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DISCUSSION 
There is continued debate in relation to the upper reference range for the haemoglobin level. There 
does, howe~er, appear to be agreement that a haemoglobin above 17gjdl in a male and 16g/dl in a 
female reqUires an explanation and should be considered as a significant risk factor for vascular disease 
(lsiblster, 1986). 
The polycythaemias can be divided into three groups (lsibister, 1986}: 
1) Polycythaemia Rubra Vera or primary polycythaemia: a stem cell disease of clonal origin 
characterised by an increased production not only of ABC's but also of granulocytes and platelets. 
2) Secondary Polycythaemia: a complication of a variety of disorders in which an increased 
production of erythropoietin leads to an increased ABC mass. 
3) Relative Polycythaemia (stress polycythaemia, spurious polycythaemla) due to plasma volume 
contraction. 
Polvcvthaemia Rubra Vera (PRYl 
This is a myeloproliferative disease in which there is increased activity of erythropoiesis with varying 
degrees of granulopoietic and megakaryocytic proliferation. The disease gradually progresses to a 
"spent" phase with myelofibrosis and myeloid metaplasia in the majority of patients. The disease is 
clonal in nature and has the potential for acute leukaemic transformation in as many as 25% of patients. 
Clinical Features: 
Historv: 
PRV typically occurs in patients over the age of 40 years. Clinical features include hyperviscosity and 
hypervolemia, haemostatic impairment (epistaxis, GIT haemorrhage), pruritus (especially after heat 
exposure), thrombotic events, gout and peripheral vascular insufficiency. 
Examination: 
Patients are typically plethoric with signs of hyperviscosity, hypertension (30%), splenomegaly (75%) and 
hepatomegaly (35%). 
Laboratory Features: 
Full Blood Examination: 
Usually polycythaemia Is present with normocytic normochromic red cells unless iron deficiency has 
supervened; leukocytosis In 75% of cases; thrombocytosis in 50% and a reduced ESR. 
Bone Marrow: 
Bone marrow aspirate and biopsy may help by demonstrating hypercellularity with panhyperplasia, 
reduced iron stores and Increased reticulin. 
Other Haematologlcallnvestigations: . 
Leukocyte alkaline phosphatase score (LAP), vitamin B12 and B12 binding proteins are elevated, ferritin 
and folate are commonly low. Abnormal platelet function may be found. 
Biochemistry: 
Hyperuricaemia Is common and LDH may be elevated due to ineffective erythyropoiesis. 
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Management: 
With treatment, the mean survival of patients with polycythaemia is 10 to 15 years. ·In the past the 
majority of patients died from thrombotic events secondary to the hyperviscosity and factors inducing 
hypercoagulability. Initial treatment must be directed towards correcting hyperviscosity followed by a 
programme for long-term control of the disease. Therapy must be individualised as some patients can 
be controlled with minimal therapy whereas others require more definitive, regular marrow suppressive 
medications. 
Initial Control of Hyperviscosity: 
Phlebotomy has always been the mainstay of therapy. As the red cell mass may be markedly increased, 
large volumes of blood may need to be removed before the haematocrit is reduced to an acceptable 
level. The importance of adequate intravascular volume replacement to maintain normovolaemia, 
especially in elderly patients, is crucial. Any sudden reduction in perfusion pressure may have additional 
detrimental effects on microcirculatory flow which is compounded by hyperviscosity or large vessel 
stenosis. If only a single unit of blood is being removed at any one time crystalloid is usually adequate 
for volume replacement; but if larger volumes are being removed colloid replacement is desirable. The 
use of low molecular weight dextran is commonly advocated because of its rheological effects in 
improving microcirculatory flow. 
Thrombocytosis commonly occurs following venesection and this may arouse considerable alarm. ·It is 
unlikely that this is a reactive thrombocytosis as the disease process is autonomous. It is more likely that 
the increase in circulating platelets is an indication of platelet mobilization from the microcirculation as 
sludging is relieved by the haemodilution. Antiplatelet therapy is desirable if the platelet count is elevated 
(aspirin and dipyridamole). However, if the platelet levels are markedly elevated specific suppressive 
therapy is necessary (busulphan or radioactive phosphorous). 
Long-term Therapy: 
Over 10% of patients with polycythaemia vera may suddenly develop acute non-lymphocytic leukaemia. 
The interval until onset of acute leukaemia is usually less than 5 years for patients developing acute 
leukaemia after chlorambucil and 6 to 10 years for patients developing acute leukaemia after radio active 
phosphorus. 
Failure to treat patients with polycythaemia vera results in a median survival of less than 2 years, 
primarily because of fatal thrombosis or haemorrhage. Cumulative survival does not differ significantly 
for patients treated only with repeated phlebotomy or patients treated with radio active phosphorus. 
The decision whether or not to manage a patient with phlebotomy alone or phlebotomy followed by a 
myelosuppressive agent depends on assessment of a patient's risk for an early thrombotic event. One 
approach to treatment may be summarised as follows: 
1) Initial isovolaemic phlebotomies at 2- to 3-day intervals to reduce RBC mass. 
2) Management by continued phlebotomy alone in the patient under the age of 50 years unless 
findings arousing concern of incipient thrombosis are present - platelet count over 700,000 per J,£L 
plus a history of an earlier thrombotic event, angina, or neurologic symptoms suggestive of 
transient episodes of cerebral ischaemia. If myelosuppression is needed, hydroxyurea, which is 
an antimetabolite and therefore may have less risk for inducing secondary leukaemia than an 
alkalating agent or 32p, may be the best agent to use (lsibister, 1986). 
3) Myelosuppressive therapy with hydroxyurea or with 32p (whose long-term effects are known and a 
single intravenous injection may control the disease for months) in the patient between the ages of 
50 and 80 years if one believes that the likelihood of a thrombotic episode within the ensuing 5 
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4) Administration of 32P after initial phlebotomies to most patients over age 70, because of the known 
increased risk for arterial thrombotic disease in the elderly. 
Anaesthetic Implications of PRV: 
Spontaneous thrombotic and haemorrhagic complications can occur even without surgery. These 
events increase precipitously when the haematocrit is more than 54%. Wasserman and Gilbert (1964) 
reported on a series of 68 patients who had primary polycythaemia vera who underwent 81 operations. 
Twenty-eight operations were performed on uncontrolled polycythaemic patients (haemoglobin more 
than 16g% or haematocrit values more than 52%). These patients had a complication rate of 79% with a 
43% morbidity and 36% mortality. By comparison, 53 operations performed on controlled (haemoglobin 
less than 16g%, haematocrit less than 52%) polycythaemic patients had a 23% complication rate with 
only 5% being fatal. Those patients who had been controlled and had a normal blood count for more 
than four months had a complication rate of only 5% with no deaths, in contrast to those who had a short 
(1 week to 4 months) or immediate (0-7 days) control. These latter groups had a complication rate of 
45% and 42% respectively with a 15% mortality. 
Sixty-five percent of the complications consisted of haemorrhage leading to 69% of the deaths. 
Thirty-seven percent of these bleeds were in the late (more than 48 hours) post-operative period. 
Thrombosis caused 32% morbidity and was associated with haemorrhage in 15%. The authors 
recommended effective and long term control of polythaemic vera patients where possible, prior to any 
elective procedure. 
Secondary Polycvthaemias: 
Polycvthaemia Secondary to Hypoxaemia: 
Any condition causing intermittent or chronic reduction in arterial oxygen saturation will stimulate the 
erythropoietin system, resulting in a reactive erythroid hyperplasia in the bone marrow. It is not essential 
to demonstrate hypoxaemia on a random blood sample to suspect this type of secondary 
polycythaemia. The maximum hypoxic stimulus may occur at other times, especially at night and sleep 
studies may be necessary. The possible causes of hypoxaemia causing polycythaemia are: 
1) Low barometric pressure (altitude dwellers) 
2) Cyanotic heart disease and other right-to-left shunts 
3) Pulmonary disease 
4) Hypoventilation syndromes 
5) Sleep apnoea. 
Polycvthaemia Secondary to Tissue Hypoxia: 
There are several conditions where there is defective release of oxygen to the tissues. This stimulates 
erythropoietin production. This can occur in chronic carbon monoxide poisoning either from smoking or 
environmental exposure. Not only does carbon monoxide make some haemoglobin unavailable for 
oxygen transport, but the remaining functional haemoglobin has an increased oxygen affinity. 
Carboxyhaemoglobin measurements should be made at the times of peak exposure. An uncommon 
cause of secondary polycythaemia is seen in families with congenitally abnormal high affinity 
haemoglobins where the haemoglobin dissociation curve can be shifted markedly to the left. These are 
sometimes called "Uama" haemoglobins as their oxygen dissociation curve is similar to that of 
high-altitude-dwelling mammals. 
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Polycvthaemia Secondary to Inappropriate Ervthropoietin Production: 
On rare. ?ccasions polycythaemia may be the presenting symptom of an underlying 
erythroporetrn-produced tumour or of renal pathology. Renal ischaemia, cysts and hydronephrosis as 
well as hypernephroma may be responsible. Other non-renal erythropoietin-producing tumours include: 
hepatomas, uterine myomas and cerebellar haemangiomas. Certain endocrine diseases, such as 
Cushing's syndrome, phaeochromocytoma and androgenizing states, may also be associated with 
polycythaemia. A condition of over-production of erythropoietin has also been identified, explaining 
some cases of "idiopathic erythrocytosis". 
Anaesthetic Implications: 
Secondary polycythaemia that is due to a physiologically appropriate response, i.e. a response to tissue 
hypoxia does not appear to be associated with an increased thrombotic element. However the primary 
disease causing the polycythaemic response needs to be assessed carefully from the anaesthetic risk 
point of view e.g. chronic obstructive airways disease. The physiologically inappropriate response e.g. 
secondary to a neoplasm, cerebellar haemangioma, polycystic kidneys or phaeochromocytoma carries 
an increased anaesthetic risk if the pathology is not recognised. This is especially true with 
phaeochromocytomas. 
Polycvthaemia due to Plasma volume contraction : Relative polycvthaemia: 
It is becoming increasingly recognised that In the majority of patients with mild polycythaemia the 
underlying mechanism is a contraction of the plasma volume. This is due either to a salt and water 
deficit, capillary leak of protein-rich fluid or a contraction of the venous capacitance volume. This causes 
compensatory reduction in plasma volume to maintain normal central cardiac filling pressures and 
volumes. 
Dehydration and Salt Deficit: 
Plasma volume contraction secondary to water andjor salt depletion is usually due to excessive losses 
with inadequate intake, but disorders of thirst control may be responsible. Therapeutic dehydration is 
commonly used in order to treat or prevent oedema formation in vital organs, especially the central 
nervous system and lung. Over zealous therapy will severely contract the plasma volume and 
haemoconcentrate the blood with detrimental effects~ Constant maintenance of adequate peripheral 
perfusion pressure is essential in the presence of severe haemoconcentration. 
Chronic Disorders of Osmoregulation: 
Disorders of osmoregulation and the thirst mechanism may cause severe dehydration, plasma volume 
contraction and polycythaemia. The syndrome particularly occurs in elderly patients who may or may 
not have recognisable neurological disease resulting in chronic hypodypsia and dehydration. These 
patients have intact osmoreceptors and appropriate vasopressin responses, but the message is not 
communicated to the thirst centre, so the patients will unknowingly allow themselves to become 
dehydrated despite the ready availability of water. 
Diuretics: 
Acute and chronic diuretic therapy may both cause plasma volume contraction and polycythaemia. The 
administration of diuretics to patients for the first time is particularly likely to result in sudden plasma 
volume reduction and associated haemodynamic consequences. 
Hypoxic States: 
Rapid ascent to high altitude may be associated with the development of a syndrome of headache, 
insomnia, nausea, irritability, oliguria and sometimes life-threatening pulmonary oedema and coma. This 
acute mountain sickness, although initiated by a low inspired oxygen tension, has a complex 
pathophysiology of which an important component Is polycythaemia with hyperviscosity and 
microcirculatory failure. Maintenance of hydration is of crucial importance. This is well known to 
climbers who drink copious amounts to achieve "gin clear'' urine. 
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Stress Polycvthaemia (Gaisbock's Syndrome): 
It is not strictly correct to give this syndrome the status of a disease as many different disorders have 
been included under a multitude of different synonyms. Gaisbock originally described a group of 
patients with polycythaemia and hypertension (polycythaemia hypertonica) with splenomegaly. Some of 
these patients may have had polycythaemia rubra vera. With the introduction of red cell mass and 
plasma volume measurements it became clear that there were patients with relative polycythaemia due 
to plasma volume contraction and various terms were introduced to cover this entity, including chronic 
relative erythrocytosis, benign erythrocytosis, spurious polycythaemia, pseudopolycythaemia and stress 
polycythaemia. As well as psychological stress and hypertension other causes include obesity, vascular 
occlusive disease, excess alcohol intake and cigarette smoking. Several theories have been proposed 
relating polycythaemia to stress and the most tenable one at present is the increased venous tone 
theory. This theory suggests chronically raised catecholamine levels which cause venoconstriction and 
centralise the blood volume. In order to maintain normal cardiac filling pressures and volumes the 
plasma volume contracts. 
Cigarette Smoking: 
The association between smoking and polycythaemia has been recognised for many years, but it is only 
in the last decade that there has been a clearer understanding of the pathophysiology. Until recently it 
was assumed that pulmonary disease with arterial hypoxia was necessary for polycythaemia to develop. 
However it has been found that most heavy smokers with polycythaemia have normal arterial oxygen 
tension. Red cell mass and plasma volume studies have revealed several different patterns. Some 
patients have clearly elevated total red cell mass, but the majority have a significant plasma volume 
contraction with minimal or no increase in red cell mass. In some patients both parameters are within 
the normal range, but the plasma volume is at the lower limit and the red cell mass is at the upper limit. 
When plasma volume contraction is present, the effects of smoking on the haematocrit are relatively 
quickly reversible. Cessation of smoking may lead to the haemoglobin falling 1 gfdl or more in a matter 
of 24 hours. It is a common observation in the coronary care unit that many patients are mildly 
polycythaemic on admission with the haematocrit returning to normal in the days following admission to 
the unit. This is commoner in smokers, but recent diuretic therapy, dehydration or stress may also be 
incriminated. 
Anaesthetic Implications: 
The increased viscosity which occurs in association with plasma volume contractions is not only likely to 
impair oxygen transport to the tissues, but may set up a series of viscous cycles in the microcirculation 
ultimately culminating in thrombosis. Thrombosis may also occur at other sites of vascular narrowing 
(e.g. atheroma or spasm). Thus the patient is more at risk of a coronary thrombosis or cerebral vascular 
accident especially if blood flow is further compromised by a fall in blood pressure. Hypotension is 
unfortunately a common occurence when anaesthesia is induced in the presence of unexpected plasma 
volume depletion. Thus intravenous fluids should probably be 'up and running' in any patient suggestive 
of secondary polycythaemia prior to the induction of anaesthesia. i 
Diagnostic Approach: 
The evaluation of a patient with an elevated haemoglobin and haematocrit may be simplified by focusing 
initial attention on two questions: 
1) Is there an obvious chronic hypoxia, for example, chronic obstructive pulmonary disease? If so, 
further haematologic study is rarely indicated. 
2) Is there evidence suggestive of proliferation of other cell lines besides the RBCs, for example: 
a) An enlarged spleen on physical examination. 
b) A high WBC and platelet count. If so, the patient possibly has polycythaemia vera and further 
work up is directed toward confirming that diagnosis prior to any anaesthetic because of the 
increased risks involved for any operation. 
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If both of these questions are answered negatively, the haematocrit is between 54% and 60%, and the 
patient smokes, ideally one should try to convince the patient to stop smoking and observe the 
haematocrit over the next few weeks. If the value falls to normal, the diagnosis of polycythaemia 
secondary to smoking is established. If an elevated haematocrit persists, RBC mass, plasma volume 
and arterial oxygen saturation should be measured. 
If the RBC mass is elevated and arterial oxygen saturation is reduced, one's attention turns to tracking a 
less obvious cause for arterial hypoxaemia. If RBC mass is elevated but arterial oxygen saturation is not 
reduced, one needs to: 
1) Rule out a cause for intermittent arterial hypoxaemia (e.g. sleep apnoea). 
2) Measure p50 to screen for impaired oxygen release from haemoglobin. 
3) Perform an ultrasound examination of the kidneys to look for evidence of an 
erythropoietin-producing renal lesion (e.g. a renal tumour or renal cysts). 
4) Measure the metabolic breakdown products of catecholamine release e.g. VMA to rule out 
phaeochromocytoma. 
5) Consider the possibility of an unusual presentation of polycythaemia rubra vera without evidence 
in the peripheral blood of increased proliferation of granulocytic or megakarycocytic cell lines. 
Measuring plasma erythropoietin by radioimmunoassay will distinguish a patient in whom the level 
is not elevated from a patient with secondary polycythaemia in whom the level is elevated. 
Unfortunately, this assay is still not generally available, and one is usually limited to looking further 
for evidence of granulocytic and megakaryocytic hyperplasia by: 
a) Examining a histology section of the bone marrow for evidence of increased myeloid activity 
and megakaryocytic hyperplasia. 
b) Measuring serum vitamin B12 and unsaturated B12 binding capacity. 
Other surveys of Maximal Pre-operative Haemoglobin Levels: 
Kowalyshyn et al (1972) conducted a postal survey on the maximal acceptable pre-operative 
haemoglobin levels of 1903 Anaesthetic Departments in the USA. There was a 66% return (1249 replies). 
The survey revealed that 39,9% (499) of the institutions had no maximum requirement; 0,1% (12) stated 
less than 17gmjdl; and 8% (92) stated 19-20gmjdl. This survey was conducted amongst Anaesthetic 
Departments and not individual anaesthetists as was the present South African survey. This included a 
lack of awareness in the increased risk of peri-operative morbidity of the polycythaemic patient. 
CONCLUSION 
Only 23% (74) of South African respondents implied they would be concerned by pre-operative 
haemoglobin levels above 18gm/dl. This indicates a lack of awareness that polycythaemia may 
significantly affect the peri-operative morbidity and mortality. Polycythaemia is particularly relevant 
where there is no obvious physiological cause such as chronic hypoxia. The affect of altitude on the 





PRE-OPERATIVE BLOOD ORDERING 
Cross Matching 
Maximum Surgical Blood Ordering Schedules 
Practical Examples: 
Baby for hernia repair 
Sickle Cell patient for arthroscopy 
Chronic renal failure patient for AV fistula 
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PRE-OPERATIVE ORDERING : CROSS MATCHING 
Survev Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Abdominal aneurysm resection 
RESULTS 
X match Abdominal Aneurysm 
Answer W.Cape Natal NTvl STvl OFS 
No " No " No No No " 
N/A 
G & H 4 
1 units 1 
2 units 9 6 2 4 12 46 
4 units 79 52 43 14 3 6 23 
> 4 units 64 42 26 49 2 8 
Spoilt 
*Group & 
Hold 1 Unit 
D D 
Pretoria Medunsa 
No " No " 
9 33 2 15 
16 59 10 77 
2 7 8 
D D 
JHB Baragwanath 
No " No " 
2 7 
12 44 13 54 



















The GSH recommended MSBOS advises five units to be Note that 86% (280) of respondents would cross-matci'l four or 
cross-matched. more units for an abdominal aneurysm resection 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Total hip replacement 
RESULTS 
X match Hip replacement 
Answer W.Cape Natal NTvl STvl 
No % No % No No 
N/A 
G & H 3 2 5 10 
1 units 2 1 
2 units 112 73 28 53 4 
4 units 34 22 18 34 
4 units 2 2 
Spoilt 
Answer 1-5 6-20 >20 
No " No % No " 
N/A 
G & H 6 3 5 4 2 7 
1 unit 2 1 3 
2 units 133 71 73 64 18 62 
4 units 40 21 33 29 7 24 
> 4 units 4 2 3 
Spoilt 
*Group & 
Hold 1 Unit 
More than 
4 Units 




% No % No % No % No % 
3 
4 4 8 4 4 ~3 4H 
4 3 1 
81 22 82 10 77 10 37 16 67 ' 224 68 
12 4 15 2 15 11 41 7 29 80 24 







G.& H. 1 Unit 2 Units 4 Units >4 Units 
-All Areas 
Note that 68% (224) of respondents would cross-match two units for a 
total hip replacement. 
The MSBOS recommendation of GSH advises Group & Screen only. 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Nephrectomy 
RESULTS 
X match Nephrectomy 
Answer. \/.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
G & H 72 48 14 27 3 10 
1 unit 4 3 2 
2 units 64 44 34 65 2 
4 units 5 3 3 6 2 
> 4 units 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
G & H 54 29 55 51 16 62 
1 unit 8 4 1 4 
2 units 108 58 so 46 9 35 •, 
4 units 12 6 2 2 
> 4 units 1 
Spoilt 
*Group & More than 
Hold 1 Unit 2 Units 4 Units 4 Units 
D D D D D 
Pretoria Medunsa JHB Baragwanath Total % 
% No % No % No % No % 
11 
42 8 30 3 23 8 32 6 25 125 39 
8 2 7 1 7 1 4 10 3 
40 8 33 16 60 7 54 17 68 167 52 











G.& h. 1 Unit 2 Units 4 Units >4 Units 
-All Areas 
Note that: 52% (167) of respondents would cross-match two units for a 
nephrectomy. 
The MSBOS recommendations of GSH advises two units be 
cross-matched. 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Hysterectomy (Vaginal, Abdominal) 
RESULTS 
X match Hysterectomy 
Answer w.cape Natal NTvl STvl 
No % No % No No No 
N/A 
G & H 125 85 35 67 4 20 
1 unit 4 3 1 2 2 
2 units 14 10 14 237 
4 units 1 2 
> 4 units 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
G & H 138 75 91 85 15 63 
1 unit 6 3 2 2 
2 units 37 20 11 10 8 33 
4 units 1 







*Group& More than 












D D D D 
Medunsa JHB Baragwanath Total 
No % No % No % 
17 
6 46 17 71 12 so 243 
1 4 8 










Note that 77% (243) of respondents would Group and Hold blood for an 
elective hysterectomy. 
The MSBOS recommendations of GSH advises Group & Hold only. 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Thryoidectomy 
RESULTS 
X match Thvroidectomy 
Answer W.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
G & H 123 87 45 88 5 22 
1 unit 3 2 1 2 
2 units 11 8 5 10 
4 units 
> 4 units 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
G & H 151 83 94 93 17 77 
1 unit 7 4 1 1 3 14 
2 units 19 11 3 3 5 
4 units 1 





















D D D D 
Medunsa JHB Baragwanath Total 
No % No % No % 
29 
10 83 19 83 16 70 263 
4 4 17 11 






G.& H. 1 Unit 2 Units 4 Units >4 Units 
-All Areas 
Note that 87% (263) of respondents would Group and Hold blood tor an 
elective thyroidectomy. 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Cholecystectomy 
RESULTS 
X match Cholestectomy 
Answer W.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
G & H 129 91 41 82 5 22 
1 unit 2 1 
2 units 7 5 9 18 
4 units 
> 4 units 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
G & H 154 85 92 91 19 86 
1 unit 5 3 1 5 
2 units 21 12 6 6 5 
4 units 





















D D D D 
Medunsa JHB Baragwanath Total 
No % No % No % 
29 
9 75 19 83 16 70 265 
1 8 1 4 6 





G.& H. 1 Unit 2 Units 4 Units •4 Units 
-All Areas 
Note that 87% (265) of respondents would Group and Hold blood for an 
elective cholecystectomy. 
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Survey Question 
An average of how many units of blood would you cross-match for the following procedures? 
Assume it Is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
Colon resection 
RESULTS 
X match Colon .resection 
Answer II.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
G & H 70 48 25 50 5 18 
1 unit 4 3 1 2 
2 units 66 45 19 38 8 
4 units 5 3 3 6 
> 4 units 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
G & H 91 50 52 48 9 36 
1 unit 7 4 1 1 4 
2 units 77 42 48 44 12 48 
4 units 5 3 6 6 2 8 






Hold 1 Unit 
More than 
4 Units 
D D D D D 
Pretoria Med~.nsa JHB Baragwanath Total 
No % No % No % No % 
17 
13 48 6 46 7 29 7 30 152 
2 7 1 4 4 9 
10 37 7 54 13 54 14 61 137 

















48% {152) amd 43% {137) would. Group and Hold or 
cross-match two units respectively for an elective colon 
resection. 
The MSBOS recommendations of GSH advises three units to 
be cross-matched. 
28 Pre-operative Blood Ordering 
DISCUSSION 
PERI-OPERATIVE CROSS MATCHING 
Peri-operative transfusion ordering policies are littered with personal, often· unsubstantiated practices. 
These have resulted in (1) excessive blood requests (RouauH & Gruenhagen 1978, Lee & Lachance 
1980, Friedman 1979, Mintz et al, 1976). 2) Over transfusion. This has been defined as transfusions 
resulting in a pre-operative haematocrit exceeding 36% or an intra-operative or post-operative 
haematocrit exceeding 33% (Tartter & Barron, 1985). 3) The reconstitution of whole blood (i.e. the 
concomitant transfusion of red blood cells and FFPs) (Blumberg et al, 1986) and 4) The under use of 
autologous blood (Toy et al, 1987). 
Ideally the ratio of cross-matched to transfusion ratio (C:T ratio) should be 2,5-1 or less in hospitals with 
a full range of clinical services (Friedman, 1979). A high C:T ratio indicates a large number of units are 
cross-matched but are never used. This means that more units have to be kept and more units become 
out-dated. The cost of a cancelled cross-match is also significant (W.P.B.S. charge 1989 R52-00 per 
unit). To achieve low C:T levels many institutions in the USA have employed maximum surgical blood 
ordering schedules and type and screen procedures. As a result of instituting these measures Lee & 
Lechancel (1980) reported a decrease of 49% in cross-matches for surgical procedures and a reduction 
of C:T ratio from 6,5 to 3,2 within one year. Within six months of implementing type and screen 
procedures at Los Angeles County Hospital, the number of cross-matches decreased by 33% and daily 
blood inventories were cut from the 450-500 unit range to 300-350 units (RouauH & Gruenhagen, 1978). 
Routine Blood Transfusion Procedure: 
Although 21 different blood group systems have been identified on the ABC membrane, the antigens of 
only two of these blood group systems - the ABO system and the Rh system - are typed prior to a blood 
transfusion. The ABO system is typed because each person has naturally occurring plasma antibodies 
to antigens of the ABO system that he or she does not possess. The Rh system is typed to determine 
the presence (Rh positive) or absence (Rh-negative) of the D antigen, which is highly immunogenic. 
Donor and recipient RBCs should be of the same type in these two systems. 
The antigen composition of the other, less immunogenic blood group systems is not routinely 
determined, since this would involve an impossible commitment of time, personnel, and scarce reagents. 
Instead, one establishes that the recipient's serum contains no antibodies that react in vitro with antigens 
on the donor RBCs. Although this protects against an acute haemolytic transfusion reaction, it does not 
prevent immunization of occasional patients to foreign antigens on donor cells, with formation of serum 
antibodies that then increase the difficulty of obtaining compatible blood for later transfusion. 
Group and Hold (Group & Screen) 
This consists of ABO and Rhesus typing by conventional methods plus a screen for unexpected 
antibodies. This latter test is performed by mixing a pure suspension of selected red blood cells 
possessing the most common blood group factors with the potential recipient's serum. It takes the same 
time (± 1 hour) as a major cross-match. If an antibody is detected during the screen it Is further 
identified by testing with commercial reagent erythrocytes. Donor units are also screened against the 
recipient's blpod. 
Blood administration following a negative antibody screen is 99,99% safe as regards having an 
incompatible transfusion (Boral & Henry 1977, Boral et al 1979). Boral and Henry (1977) estimated 
that the chance of having haemolytic reaction following the administration of typed but 
uncrossed-matched blood with a non-reactive screen was 1 in 12,500,000 units. 
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Technique of performing a cross-match and antibody screen: 
The crossmatch and antibody screen must be carried out under conditions that will detect 1 gM 
antibodies, 1 gG antibodies, and cell bound complement components. The tests are carried out as 
follows: 
1) An approximately 5% suspension of RBCs in saline is incubated with serum at both room 
temperature and 37<lC and examined for agglutination. Agglutination means that an 1 gM antibody 
has reacted with the RBCs. This may occur if: 
a) An error of ABO typing has been made. 
b) The serum contains a cold agglutinin with a thermal amplitude that extends to 
temperatures of clinical significance. 
2) The above incubations are repeated but with the addition of two drops of a concentrated albumin 
solution to the mixtures. The Increased protein concentration reduces the electrostatic forces 
separating the RBCs, which facilitates the agglutination of RBCs that have become coated with an 
lgG antibody. 
3) An indirect anti-human globulin (Coombs') test is performed. A 5% suspension of RBCs is 
incubated with the serum, separated by centrifugation, washed thoroughly, and then reacted with 
a "broad-spectrum" anti-human globulin (Coomb's) serum. The anti-human globulin serum will 
agglutinate the RBCs if .lgG, complement, or both have bound to the RBCs during their initial 
Incubation with the serum. 
Group and Hold techniques are not a substitute for cross-matching (Stehling, 1982) but should rather 
be used when the probability that the patient may require blood during the operation Is remote. If a 
Group and Hold has to be converted to a cross-match urgently during surgery, the first portion of a full 
cross-match, taking 3 minutes, is completed and the required number of units is rushed to theatre. If 
there is less urgency a full cross-match taking one hour should be performed. 
CONCLUSION 
The present survey indicates that there is a large degree of consent as to blood ordering practices for 
relatively common 'cold' procedures. There will obviously be regional variations dependent principally 
on the surgical skills available. 
Stehling et al (1987) conducted a postal survey of 389 anaesthetists in the USA asking the same 
questions regarding cross matching. 
USA Survey Present SA Survey 
No. of Units No. of Units 
Mean± SEM Mean 
Abdominal aneurysm 4,5 ± 0,13 4,5 
Total Hip replacement 2,9 ± 0,06 2,55 
Nephrectomy 2,2 ± 0,06 1,31 
Hysterectomy 1,3 ± 0,05 0,41 
Thryoidectomy 97 ± 0,05 0,20 
Cholecystectomy 0,7 ± 0,04 0,21 
As can be seen from the above comparison the South African respondents were more reticent about 
cross matching blood for most of the listed procedures. However details of the cross match to 
transfusion ratios of the blood banks need to be examined before one can infer the smaller number of 
units cross matched by the present respondents are optimum or not. 
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PRE-OPERATIVE BLOOD ORDERING : MAXIMUM SURGICAL BLOOD ORDERING 
SCHEDULES (MSBOSl 
Survey Question 
Does your hospital have a Maximum Surgical Blood Order Schedule? (i.e. recommendations for 






Yes 22 14 
No 87 57 





Yes 52 28 
No 53 28 
Not know 82 44 
Spoilt 
Yes 
Natal NTvl STvl OFS 
No % No No No % 
27 54 16 64 
4 8 
19 38 5 9 36 
6-20 >20 
No % No % 
47 42 16 59 
37 33 6 22 
24 22 4 15 
No Don't know 
Pretoria Medunsa JHB Baragwanath Total 
No % No % No % No % 
8 
14 52 7 54 18 69 9 38 114 35 
1 4 2 15 2 8 4 97 30 










YES NO NOT KNOW 
-All Areas 
Note that 34% (110) of respondents did not know if the hospital 
had a MSBOS. 
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DISCUSSION 
Optimum blood ordering 
Maximum Surgical Blood Ordering Schedules (MSBOS) consist of a list of the recommended maximum 
number of units of blood which should be cross-matched pre-operatively for most commonly performed 
surgical procedures. Although guidelines differ slightly between institutions, the recommendations of 
several groups are very similar (Stehling 1982, Rouault & Gruenhagen 1978, Friedman 1979). The 
Groote Schuur Hospital group MSBOS is included in the appendix. If more blood than recommended is 
ordered there should be a system whereby the Blood Bank contacts the doctor Involved for the reason 
for the abnormal request. 
Employing an MSBOS effectively has been recommended to reduce the following: Total blood 
Inventory, total number of cross-match procedures, out-dating of blood, laboratory expenses, expense 
to patients, and clerical and technical errors. 
In order for such a system to run effectively it is recommended that a hospital transfusion committee be 
set up (Stehling 1978, Grindon et al1985, Glovenettl et al1988). This committee should be made up 
of all major departments utilising blood products. They should set standards of transfusion practices 
and review cases where pre-operative orders do not agree with the recommended schedule. These 
standards should be reviewed periodically as new information becomes available. The committee 
should have several functions: 
1. To assess the adequacy of blood supply and be able to institute corrective action for serious 
deficiencies. 
2. To compare actual transfusion practices to the recommended standards and where they are 
different to assess whether they are due to the practices of a Department, group of physicians or 
even one physician. Corrective methods will, obviously, differ in each case, but education should 
be the principle method of change. 
3. To review the frequency of transfusion transmitted diseases. 
4. To review the efficacy of blood and component therapy e.g. by haematocrit or post-transfusion 
platelet counts. 
CONCLUSION 
Over one third of anaesthetists did not know whether or not their Department had recommended 
MSBOS's. Even many of those who answered that their area had or had not recommendations were 
incorrect, for example only 14% of the Western Cape area which has MSBOS's knew they did; 57% 
thought they did not. 
This indicates a lack of Departmental communication where blood transfusion guidelines are concerned. 
This is a fundamental educational question which needs to be urgently addressed by Individual 
Departments. 
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PRE-OPERATIVE BLOOD ORDERING PRACTICAL EXAMPLES 
Survey Question 
What course of action would you take in the following cases: 














Answer w.cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total " 
No " No % No No No % No " No % No " No % 
N/A 
Spoilt 7 2 
Transfuse 9 3 3 6 4 2 3 30 9 
GA 123 43 4 13 14 6 21 20 245 
X match 21 4 8 7 2 5 2 8 15 
INFANT 
HERNIA REPAIR 
Answer 1-5 6-20 >20 
%Returns 
No " No " No % 100 
N/A •••••••••••••••••••••••••••••••••••••••••••••••245m ····················-···· 
. Spoilt 80 
Transfuse 24 13 4 4 2 7 
GA 126 66 99 87 21 75 




Transfuse G.A. Cross Match 
-All Areas 
NUMBER-TOTAL REPLIEB 
Note that 9% (30) of respondents would transfuse the baby 
pre-operatively and 15% (49) would have blood matched. 
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DISCUSSION 
A term infant has a mean cord haemoglobin of 16,5g/dl and a few hours after birth a mean venous 
haemoglobin concentration of 19g/dl due to loss of plasma volume. Erythropoeisis almost stops for 
several weeks after birth and the haemoglobin level may fall to about 9.5g/dl at nine weeks of age in a 
full-term infant. It then rises gradually to 11-12g/dl at the first year of life. In premature infants the 
haemoglobin may fall even lower with means of 9.4gfdl ± 1,0 at 10 weeks (Gorton & Cross, 1964(. 
Oski & Stockman, 1974 state that apparently healthy premature infants weighing 1,2Kg or less show 
average haemoglobin levels of 8,9g/dl between six and eight weeks. Values of 7g/dl are frequently seen 
without recognisable haematological or other disease. 
Thus the three-month-old baby with a haemoglobin of 9,2g/dl has a normal haemoglobin for its age. 
The procedure of hernia repair does not usually require blood and so both cross-matching and 
transfusion are unnecessary. 
Although 24% of respondents stated they would transfuse (9%) or cross-matched (15%) this may have 
been due In part to inexperience. Twenty-four out of 30 who would transfuse and 35 out of 49 who 
would cross-match had been in anaesthetic practice less than six years and may not have had exposure 
to paediatric anaesthesia. 
Stehling et al {1987) in their postal survey of 389 anaesthetists in the USA found 2,6% would transfuse 
pre-operatively, 91,7% would administer a GA and 21,7% would require blood to be cross-matched. 
These results are similar to the South African findings remembering that a postal survey allows 
references to be consulted regarding the normal haemoglobin for a three-month-old baby. 
CONCLUSION 
With the exception of some of the less experienced anaesthetists the use of blood components as 
investigated by this question was satisfactory. 
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Survev Question 
What course of action would you take in the following cases: 
Administer Require 
Transfuse General Blood Cross 
Pre-op Anaesthetic Matched 
15 year-old male with sickle cell anaemia for 
arthroscopy of the knee, haemoglobin 7,5g/1 OOml 
D D D 
RESULTS 
Sickle Cell 
Answer W.Cape Natal NTvl STvl 
No % No " No No No 
N/A 
Spoilt 
Transfuse 71 22 2 12 
GA 39 14 3 5 
X match 32 14 6 
Answer 1-5 6-20 >20 
No " No " No " 
N/A 
Spoilt 
Transfuse 87 47 39 36 18 69 
GA 42 23 40 37 4 15 
X match 52 28 26 24 3 12 
OFS 
% 
Pretoria Medunsa JHB Baragwanath Total " 
No % No % No " No " 
15 
7 2 
14 4 13 5 144 45 
5 5 7 8 86 27 









Transfuse G. A. Cross Match 
-All Areas 
Note that 45% (144) would transfuse pre-operatively 27% (86) 
would administer a GA and 26% (81) would require blood to be 
cross-matched. 
35 Pre-operative Blood Ordering 
DISCUSSION 
Sickle Cell Disease 
Sickle cell disease represents an inherited group of disorders ranging in severity from the usual benign 
sickle cell trait to the debilitating and often fatal sickle cell anaemia (Lessin & Jensen, 1974). All the 
varients of sickle cell disease have various qualities of haemoglobin S. Haemoglobin S differs from 
normal adult haemoglobin A by the substitution of valine for glutamic acid at the sixth position on the 
Beta chain of the haemoglobin molecule. Confirmation of the presence of haemoglobin S depends on 
electro-phoretic studies. 
Sickle cell anaemia is present when patients are homozygous for haemoglobin S. Approximately 0,3% to 
1% of the Black population of the United States are homozygous for haemoglobin S, with a further 8-14% 
having the sickle cell trait which may cause sickling with hypoxia. 
The presence of hypoxia results in the deformation of the erythrocytes into sickle shapes which form 
long aggregates causing infarctive areas. In addition the sickle shape damages the erythrocyte 
membrane leading to their rupture and chronic haemolytic anaemia. In the steady state haemoglobin 
concentrations are 5g/dl to 10g/dl. Thus the sickle cell patient in the question has an acceptable 
haemoglobin (7,5g/dl) for this disease. 
The need for pre-operative transfusion is determined by the severity of co-existing anaemia and the 
magnitude of the proposed operation. The goal of pre-operative infusion of erythrocytes is to increase 
the concentration of haemoglobin A to at least 40%. The hazards of transfusion include depression of 
the hyperactive bone marrow and increased blood viscosity. 
Goals in the management of anaesthesia include: 
1) Avoidance of acidosis due to hypoventilation 
2) Maintenance of optimal oxygenation including supplementary oxygen if a regional technique Is 
employed 
3) Prevention of circulatory stasis due to improper body positioning or the use of a tourniquet 
4) Anticipation and rapid correction of hypotension 
5) Maintenance of intravascular volume by intravenous infusion of crystalloid solutions 
6) Maintenance of normal body temperature to prevent vasoconstriction and stasis of blood flow. 
Thus, the correction of a mild to moderate anaemia for an arthroscopy is less Important ~han being 
aware of the above goals of anaesthesia. Anthroscopy without a tourniquet has been shown to be 
surgically as equally as effective (Stein & Urbaniak, 1980). 
Stein & Urbaniak {1980) undertook a 17 year review of tourniquet procedures involving 29 tourniquet 
applications to 21 patients with sickle cell disease. They found no differences between the incidence of 
complications of sickle cell patients and that in a randomly selected control population. They concluded 
that the use of a tourniquet was not contra-indicated in sickle cell patients. However if a tourniquet is 
used, it would be prudent to exsanguate the limb carefully. -
There does not appear to be statistics regarding the incidence of sickle cell anaemia in South Africa. 
However on personal questioning, most anaesthetists have never anaesthetised a case, so the incidence 
must be very infrequent. This probably accounts for the low pro~-of anaesthetist& (2.7%) who 
answered the question correctly i.e. proceed with a general anaesthetic. 
Stehling et al (1987) in their survey in the USA, where the incidence is 0.3-1% for the black population, 
showed only 60,5% would administer a GA whereas 40,8% would transfuse pre-operatively (compared to 
45% S. Africa) and 44,4% would require blood to be cross-matched (compared to 26% S. Africa). This 
was a postal survey where the respondents had the advantage of being able to refer to text books. 
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CONCLUSION 
The knowledge of the normal haemoglobin for a person suffering from sickle cell anaemia is, not 
surprisingly, poor amongst South African Anaesthetists. However, it also may indicate either poor logical 
thought procedures when considering a patient with a chronic anaemia of known aetiology for an 
operation where there is no blood loss, or it confirms that most South African Anaesthetists have a firm 
cut off figure for the lower limit of haemoglobin before elective minor surgery. 
--.- ~ ~ 
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Survey Question 
What course of action could you take in the following cases: 
45 year-old male with end stage renal disease 














Answer W.Cape Natal NTvl STvl 
No " No % No No 
N/A 
Spoilt 
Transfuse 16 2 
GA 99 40 2 
X match 9 3 
Answer 1-5 6-20 >20 
No " No " No " 
N/A 
Spoilt 
Transfuse 17 9 4 4 5 20 
GA 116 63 90 80 15 58 






Pretoria Medunsa JHB Baragwanath Total 
No " No " No " . No " 
12 
8 3 
3 2 1 26 8 
16 6 20 17 220 69 
8 2 6 5 67 21 








Transfuse G. A. Cross Match 
-All Areas 
Note that only 8% (26) of respondents would transfuse 
pre-operatively and 21% (67) would require blood to be 
cross-matched. 
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DISCUSSION 
Chronic Renal Failure 
Normochromic, normocytic anaemia occurs in almost all patients with chronic renal failure who have 
plasma creatinine concentrations greater than 3,5mg.dl·1. The degree of anaemia often parallels the 
degree of chronic renal dysfunction but remains relatively constant after end-stage renal failure has 
occurred. 
Haemoglobin concentrations in the range of 5g.dl·1 to 8g.dl·1 are hallmarks of chronic renal failure. 
Decreased erythropoietin production in the presence of elevated blood urea nitrogen levels is the most 
likely explanation. Also survival time for erythrocytes is shortened about 50% in the presence of chronic 
anaemia reflecting an increased erythrocyte membrane fragility. These two factors together with an 
increased tendency for menorrhagia and gastrointestinal bleeding cause anaemia. 
The anaemia is well tolerated because of its slow onset and pre-operative transfusions are not routinely 
indicated. The decreased oxygen carrying capacity is compensated for by increased tissue blood flow, 
and a right shift of the oxygen haemoglobin curve, resulting in increased release of oxygen due to 
increased 2:3 Di-phosphoglycerate and metabolic acidosis. Because of the risk of creating HLA 
antibodies which makes tissue compatability matching for a suitable donor harder, most anaesthetists 
would accept a much lower haemoglobin in these patients before transfusing. 
The postal survey by Stehling et al ( 1987) revealed a poorer knowledge of the use blood products in the 
patient suffering from chronic renal failure, when compared to the present survey. The same question 
was answered; transfuse pre-operatively 20,2% (compared with 8% S. Africa) administer general 
anaesthetic 54,5% (compared with 69% S. Africa) and cross-match 61,5% (compared with 21% S. Africa). 
CONCLUSION 
Most respondents accept a low haemoglobin level (6gmjdl) in a patient with end stage renal failure. This 
is at variance with the previous questions relating to pre-operative acceptable minimal haemoglobin 
levels where most anaesthetists used 1 Ogmjdl as their lower level. This must add further to the debate 
regarding safe minimal haemoglobin levels. 
Cross-matching for a relatively bloodless procedure was again excessive (21%), although 47 out of 67 
respondents had less than six years anaesthetic experience and so inexperience may be a factor. 
) 
CHAPTER THREE 
BLOOD TRANSFUSION DURING OPERATION 
* Assessment of Blood Loss 
* Replacement of Blood Loss 
* Incorrectly Labelled Blood 
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BLOOD REPLACEMENT : ASSESSMENT OF LOSS 
Survey Question 
Which methods of blood loss assessment do you usually employ during major abdominal surgery? 
Visual estimation D 
RESULTS 
Blood loss visual 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total 
No " No " No No No " No " No " No " No " 
N/A 2 
No 4 3 12 23 4 15 3 11 1 8 25 
Yes 150 97 41 77 5 22 85 24 89 12 92 28 100 24 100 306 




No " No 
12 6 10 9 














Note that 92% (306) of respondents visually assess blood loss. 
8 
92 
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Survev Question 
Which methcx:ls of blocx:l loss assessment dp you usually employ during major abdominal 
surgery? 
Measuring suction bottles D 
RESULTS 
Blood loss Suction 








No X No X No 
9 6 4 8 
145 94 49 92 
1·5 6-20 
No X No X 
11 6 6 5 










No X No 
2 8 2 
24 92 25 
X No X No X No X 
2 
7 3 13 21 
93 13 100 28 100 21 88 310 




Note that 98% (310) of respondents do take note of suction 
bottle measurement in estimation of blood loss. 
6 
94 
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Survey Question 
Which methods of blood loss assessment do you usually employ during major atx:lominal surgery? 
Weighing swabs 
RESULTS 
Blood loss weighing 
Answer W.Cape Natal NTvl STvl 
No " No " No No 
N/A 
No 114 74 12 23 4 
Yes 39 25 41 n 1 
Spoilt 
Answer 1·5 6·20 >20 
No " No " No " 
N/A 
No 126 67 57 50 15 52 











" No " No " No " 
2 
52 7 54 12 43 24 100 198 60 
48 6 46 16 57 132 40 
1 










Note that 60% (198) of respondents do not weigh swabs to 
estimate blood loss. 
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Survey Question 
Which methods of blood loss assessment do you usually employ during major abdominal 
surgery? 
Serial haemoglobin estimation 
RESULTS 
Blood loss serial Hb 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No % 
N/A 
No 97 63 37 60 11 42 
Yes 55 36 16 30 4 15 58 
Spoilt 
Answer 1-5 6-20 >20 
No " No % No % 
N/A 
No 118 63 73 64 21 72 
Yes 69 37 40 35 7 24 
Spoilt 
D 
Pretoria Hedunsa JHB Baragwanath Total % 
No " No % No % No % 
2 
25 93 11 85 19 68 12 so 213 64 
2 7 1 8 9 32 12 so 115 35 
2 










Note that 64% (213) of respondents do not use Intra-operative 
haemoglobin measurements when estimating blood loss. 
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Survey Question 
Which methods of blood loss assessment do you usually employ during major abdominal 
surgery? 
Serial haematocrit (PCV) estimation 
RESULTS 
Blood loss Serial HCt 
Answer W.Cape Natal NTvl STvl OFS 
No X No % No No No 
N/A 
No 34 22 15 28 5 11 
Yes 118 n 38 72 15 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
No 47 25 44 39 14 48 






Pretoria Medunsa JHB Baragwanath Total X 
No 
27 
% No % No % No X 
2 
16 57 22 92 103 31 
100 12 92 12 43 2 8 225 68 










Note that 68% (225) of respondents do use serial haematocrit 
estimations when calculating intra-operative blood loss. 
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DISCUSSION 
The assessment of blood loss during major surgery involves the use of all the anaesthetists experience 
and perceptions. Thus he should look at the swabs, the drapes, any blood spillage onto the floor and 
bleeding into the operation site. In the survey 92% of respondents stated they did so. The suction 
bottles should be marked with graduations so that blood collected in them can be estimated with 
allowance made for any washings. In the survey 94% of respondents stated they did so. Weighing the 
swabs may be misleading if dampened swabs are used (common in abdominal surgery) and weighing 
the drapes can only occur when the operation is over. Thus weighing of swabs if often only done where 
even a small amount of blood loss is significant, such as in paediatric surgery. In the survey only 40% of 
respondents indicated they weighed swabs. There was no allowance made for paediatric and 
non-paediatric anaesthetists in the Questionnaire. 
A similar question was asked by Stehling et al (1987) in their survey or 389 anesthesiologists in the USA. 
87,9% used visual estimation (S.A. survey 92%) 94,6% measured contents of the suction bottle (S.A. 
survey 98%) 48,3% weighed sponges (S.A. survey 40%) 45,2% used serial haemoglobinjhaematocrit 
(S.A. survey 35-68%). 
Serial_ haematocrit even more so than serial haemoglobin estimations, are extremely important in 
accurately following the blood loss during the operation. It was therefore disappointing that 32% and 
64% of respondents neither used serial haematocrit nor haemoglobin estimations respectively. The 
inference must be they use a fixed volume loss for their indications for blood transfusion. This 
hypothesis was investigated in the following survey question. 
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BLOOD TRANSFUSION REPLACEMENT OF BLOOD LOSS 
Survey Question 
During an operation NOT normally requiring blood replacement which of the following best describes 
your approach? (Tick only one) 
a) Replace when blood loss Is, or will be, by the 
end of the procedure 1 0% of estimated blood 
volume: 
b) Replace when blood loss Is, or will be, by the end of 
the procedure, 20% of estimated blood volume 
c) Allow the patient to bleed to a haematocrit of 30% before transfusing: 
d) In adults administer blood only If more than one unit is required 
e) Administer blood only If vital signs change e.g. blood 
pressure drops or pulse rate increases significantly 
RESULTS 
Blood Replacement 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa 
No " No " No No No " No % No " 
N/A 
10% 11 7 4 7 4 15 3 
20% 56 36 24 44 4 11 42 7 26 4 31 
HCt 30 44 29 12 22 3 12 11 41 5 39 
>1 unit 25 16 7 13 3 11 3 23 










% No % 
11 2 8 
32 13 54 
7 3 13 























Blood Replacement <contd.): 
Answer 1-5 6-20 >20 
No X No X No 
N/A 21 11 4 7 
10X 76 40 48 42 6 
20X 49 26 27 24 4 
HCt 30 15 8 18 16 11 












- 10'1o LOSS 
~ •1UNIT 
<20 >20 






Note that percentage-wise more experienced anaesthetists, 
(>20 years) used more than one unit loss as their main 
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BLD REPLACEMENT 
%RETURNS 
10'1o 20'1o HCT 30'1o •1 Unit VItal Signa 
-All Areas 
Note that only 24% (81) of respondents replied 
that they would use a haematocrit of 30%. 
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DISCUSSION 
Most healthy patients can sustain acute blood losses of 30% of their blood volume and require 
replacement only with clear fluids (Stoelting et al, 1988). Czer and Shoemaker (1978) reported that 
· the maximal survival rate In critically ill patients occurred at a haematocrit of between 27 and 33%. 
Because of differences in pre-operative haemoglobin levels and physical status it would seem logical to 
have a policy of blood transfusion based on a measured value as opposed to a fixed volume loss which 
may be difficult to measure accurately. The simplest and most accurate theatre test at present available 
which can be applied in the theatre is the measurement of haematocrit. Using serial haematocrit 
. estimations with an end point before transfusing of 30% {haemoglobin of 1 Ogjdl) as long as there is no 
clinical contraindications, is a logical method of assessing when to start blood replacement. At a 
haematocrit of 30% there is favourable rheological blood flow properties and oxygen transport to the 
tissues is not compromised. Vital signs changing can be caused by many factors, not only blood loss, 
such as drugs given, surgical interference with venous return and myocardial depression. 
CONCLUSION 
The majority of anaesthetists surveyed {63%) used a blood volume loss of 10-20% as their indication for 
blood replacement. Translated Into practical terms this must result in a major cause of over-transfusion 
of blood. Serial haematocrlt estimations should be used routinely to assess the need for blood 
replacement. 
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BLOOD TRANSFUSION INCORRECTLY LABELLED BLOOD 
Survey Question 
Within the last five years have you ever received incorrectly labelled blood (wrong patient or 
wrong folder number)? 
If Yes - how many times over the last 5 years? 
Once D <than 3 D 3-9times D more than 9 times 0 
RESULTS 
Wrong Transfusion 
Answer W.Cape Natal NTvl STvl 
No .l No % No No 
N/A 
Never 105 68 20 37 
Once 23 15 13 24 
1-3 18 12 14 26 2 
3-9 7 5 4 7 2 
>9 
Spoilt 
Answer 1-5 6-20 >20 
No l No l No " 
N/A 
Never 92 49 48 42 19 66 
Once 34 18 16 14 4 14 
' 1-3 47 25 29 25 2 7 




















% No % No % No l 
2 
30 6 46 5 18 6 25 160 
26 2 15 1 4 53 
41 4 31 9 32 13 54 78 
4 8 13 46 5 21 36 
4 
TRANS. MISSMATCH 
INCORRECT LABEL \PATIENT 
~RETURNS 
160 






Note that 51% (168) of the respondents had received at least 
one unit of incorrectly labelled blood within the last five years. 
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DISCUSSION 
Incorrectly labelled blood 
Blood Transfusion during op. 
TRANS.MISSMATCH 
INCORRECT LABELS\PATIENT 









<6 <20 >20 
-NEVER ~ONCE CJ <3 TIMES 
~ 3-9 TIMES !TimJ •9 TIMES. 
Note that there appears to be no significant increase in the 
percentage of transfusion mismatches received and length of 
anaesthetic experience. 
Myhre (1980) reported on fatalities associated with blood transfusion in the USA between 1976 and 
1979. There were 113 reported fatalaties out of 11,8 million units of blood transfused (a fatality rate of 
0,00023% or approximately 1 in 100,000). 
In forty-seven cases clerical error was at fault due to mislabelling of blood samples or cross-match 
·records interchanged in the laboratory. Koepke (1971) looking at transcribing errors reported a rate of 
4,6% when blood bank technologists were asked to copy eleven digit numbers from one side of a survey 
report to another. In thirty-one fatal cases the wrong unit of blood was given to the patient. Thus 
sixty-five percent of fatalities were due to misidentification of the patient, sample, or unit of blood. 
Laboratory errors were eight and included incorrect typing of the blood or undetected antibodies. 
CONCLUSION 
There was an alarmingly high percentage (51%) of anaesthetists surveyed who had incorrectly labelled 
blood, either wrong patient or wrong folder number, within the last fiVe years. This makes it vitally 
important that no matter what the urgency the blood is checked carefully before being transfused. 
CHAPTER FOUR 
BLOOD PRODUCT KNOWLEDGE 
* Basic Knowledge, Haemoglobin Elevation by Transfusion 
* Haemophilia 
* Transmission of infection 
* Suppression of immunity 
* Costs 









d) Don't know 
RESULTS 
Raise Haemoalobin 
Answer W.Cape Natal NTvl STvl 
No X No X No No No 
N/A 
o,5· 12 8 5 9 3 
1gri'l 84 55 26 50 7 
1,5 54 35 22 42 5 16 
Not know 1 
Spoilt 
Answer 1·5 6·20 >20 
No X No X No X 
N/A 
0,5gm 17 9 8 7 
1gm n 38 67 59 18 62 
1,5gm 96 51 38 33 10 35 
Not know 
Spoilt 
Note that 48% (159) replied that one unit of blood raised 





OFS Pretoria Medunsa JHB Baragwanath Total 
X No X No X No X No X 
2 
12 4 - 15 4 25 8 
27 13 49 4 31 15 54 10 48 159 48 













0.5 Gm 1 Gm 1.5 Gm NOT KNOW 
-All areas 
51 Blood Product Knowledge 
DISCUSSION 
One unit of whole blood contains approximately 450ml of blood and 63ml of preservative, 6mljKg body 
weight of whole blood will raise the haemoglobin concentration by 1gjdl (Mollison, 1972). In the text 
books by Dripps et al {1988) and Scurr and Feldman {1982) it is stated that one unit of whole blood or 
packed cells increases the haemoglobin level by 1 gjdl. 
CONCLUSION 
Less than 50% of respondents were aware of how much one unit of blood raised the haemoglobin level. 
This shows poor basic knowledge of blood transfusion. 
52 Blood Product Knowledge 
BLOOD KNOWLEDGE HAEMOPHILIA 
Survev Question 
A haemophiliac (Type A) presents for an elective dental clearance under general anaesthetic. 
What is the minimal level of Factor VIII you would consider necessary prior to operation? 
a) More than 25% D 
b) More than 50% D 
c) · More than 75% D 
d) 100% D 
RESULTS 
Haemoohllla 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total " 
No " No " No No No " No " No " No % No " 
N/A 11 
>25 45 30 13 24 3 12 9 35 1 32 5 19 8 36 85 26 
>50 58 39 27 50 3 10 39 13 50 5 42 8 30 11 50 135 42 
>75 31 21 6 11 7 27 3 12 5 42 13 48 2. 9 69 21 
>100 9 6 4 7 6 23 4 8 4 5 23 7 
Spoilt 10 
HAEMOPHILIA 
Answer 1-5 6-20 >20 
%RETURNS 
No % No " No " 
100 
10 1 
45 25 34 30 6 21 80 
8 45 43 38 11 38 
38 21 23 20 8 28 





N/A •25 >50 •75 >100 
-All Areas 
Note that 42% (135) of respondents replied that the Factor VIII 
level should be 50% or above for a dental clearance. 
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DISCUSSION 
Haemophilia 
Classical haemophilia (Type A) results from deficient synthesis of Factor VIII:C, while the Von Willebrand 
portion of the molecule Is normal. Application of recombinant DNA technology with cloning of the 
protein has shown that most patients have a parallel decrease in Factor III:C, together with its antigen, 
whereas less than 1 0% may have a biologically defective molecule, with normal antigen, but marked 
reduction in coagulant activity (Jacobs, 1989). The gene encoding the protein is carried on the X 
chromosome and all daughters of Involved males are carriers In contrast to offspring from a mother who 
carries the trait, where half the sons will have haemophilia and half the daughters will transmit the genetic 
abnormality. The incidence of Factor VIII deficiency is estimated to be 1:10,000 to 1:24,000 births 
(Ellison, 1977). 
Clinically the bleeding pattern varies widely and correlates with the level of Factor VIII coagulant activity. 
Thus, the more severe disorders where the value is less than 1% of normal, present early in life with 
spontaneous haemarthoses and deep tissue bleeding. At levels of 1-5% there is typically childhood 
bleeding associated with trauma. With values of 15-20% more substantial trauma such as minor surgery 
or dental extraction reveal abnormal bleeding. With higher levels of Factor VIII the patient remains 
asymptomatic until major trauma or surgery are followed by severe bleeding. 
When a deficient factor is infused Into a patient the volume required depends on: patient size; desired 
elevation in level of deficient factor; and preparation potency. Survival of the transfused factor In vivo 
shows a characteristic double exponential curve in which the early rapid disappearance represents 
equilibration with the extravascular space and the later slower disappearance with natural degradation, 
which is accelerated in the presence of fever or infection (Britten & Salyman, 1966). To prevent 
excessive bleeding with operations the actual replacement is calculated to accomplish minimal levels In 
excess of that needed. to permit partial saturation of the extravascular stores and to allow for 
intravascular decay with a reasonable booster schedule. 
Factor VIII:C Is usually given as cryoprecipitate or heat treated lyophilised concentrate to achieve desired 
haemostatic levels. The following equation can be used to calculate the dose required: 
Dose (units of Factor VIII:C) = (0,01) (%Factor VIII Increment) (plasma vol. of patient In mls) 
Cryprecipltate generally contains 100 unitsjbag. Commercial concentrations will carry this information 
on the label. The biological equilibration is 12 hours and therefore, after a loading infusion, a 12 hour 
replacement is adequate In the absence of inhibitors. About 1 0% of haemophiliac patients have an 
inhibitor where Factor VIII replacement fails to achieve the expected level. Haemorrhage In these 
circumstances Is life threatening and needs to be managed in association with an experienced 
haematologist (Jacobs, 1989). After transfusion the patient should have a normal activated partial 
thromboplastin time (aPTT), a measure of the intrinsic coagulation system. 
For dental extraction a single infusion to raise the Factor VIII level above 50% is required, followed by the 
fibrinolytic inhibitor epsilon aminocaproic acid, at a dose of 100mgjKg for 10 days. This will obviate the 
need for further Factor VIII replacement (Jacobs, 1989). -
For major surgery It Is common to infuse sufficient Factor VIII to raise the level to 80-100% and then give 
boosters every 12 hours to maintain levels above 50% for 10-14 days. 
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CONCLUSION 
Although 28% (92) of respondents required unnecessarily higher levels of Factor VIII pre-operatively and 
26% (85) respondents stated too low a level, most haemophiliacs in South Africa would have been 
worked up for the procedure by a haematologist. Also, being an elective case, this would have allowed 
the anaesthetist who was unsure of the required level of Factor VIII required to check It In a text book. 
The results do however point to a poor knowledge of certain blood disorders and peri-operative 
transfusion requirements. 
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BLOOD COMPONENT KNOWLEDGE INFECTION TRANSMISSION 
Survey Question 
What risk do the following blood products have of carrying transmissable disease when compared to 
one unit of whole blood? 
a) Unit of fresh frozen plasma (FFP) 
RESULTS 
FFP Risk 
Answer W.Cape Natal NTvl STvl OFS 
No " No " No No No " 
N/A 
More 26 17 16 31 2 8 
Less 22 14 6 12 5 21 
Same 99 65 28 54 4 15 63 
Not know 6 4 2 2 8 
Spoilt 
Answer 1-5 6-20 >20 
No " No " No " 
N/A 
More 27 15 23 20 3 11 
Less 44 24 11 10 7 26 
Same 106 58 76 67 13 48 








Pretoria Hedunsa JHB 
No " No " No 
2 8 8 3 
9 35 4 31 5 


















" No " 
9 
12 2 8 52 
19 10 42 62 
65 10 42 196 
4 4 2 8 
RISK 
196 







Note that 35% (126) of respondents did not know FFP carries 
the same risk of transmission of infection as blood. 
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Survey Question 
What risk do the following blood products have of carrying transmissable disease when compared to 
one unit of whole blood? 
1 Unit FFP plus 1 Unit pre-packed red 
blood cells 
RESULTS 
FFP + PRBC risk 
Answer W.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
More 82 54 27 54 2 8 
Less. 2 2 4 4 
Same 62 41 18 36 2 12 
Not know 6 4 2 4 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
More n 40 60 54 10 37 
Less 9 5 5 5 3 11 




























No % No 
2 17 10 
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% No % 
37 6 26 
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Note that 56% (179) of respondents did not know that 1 unit of 
FFP plus 1 unit of packed red blood cells carry a higher risk of 
transmission of disease than 1 unit of whole blood. This is 
because when given out by the Blood Bank these products will 
almost certainly not come from the same donor. 
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Survev Question 
What risk do the following blood products have of carrying transmissable disease when compared to 
one unit of whole blood? 
1 Unit Cryoprecipitate (AHF 500 units) 
RESULTS 
Crvo. risk 
Answer IJ.Cape Natal NTvl STvl OFS 
No X No % No No No % 
N/A 
More 81 53 28 53 3 9 35 
Less 26 17 11 21 1 6 23 
Same 29 19 3 6 9 35 
Not know 17 11 10 19 2 8 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No X 
N/A 
More 76 41 68 60 8 29 
Less 40 22 15 13 9 32 
Same 39 21 18 16 3 11 





















No % No 
3 25 14 
2 17 6 
3 25 3 

































Note that 53% (173) of respondents did not know 
cryoprecipitate (AHF 500 units) because it is a pooled product 
carries more risk of transmission of infection than one unit of 
blood. 
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Survey Question 
What risk do the following blood products have of carrying transmissable disease when compared to 
one unit of whole blood? 
1 OOml Albumin 
RESULTS 
Albumin risk 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No % 
N/A 
More 21 14 8 15 1 
Less 90 60 25 48 3 21 84 
Same 18 12 8 15 4 
Not know 20 13 9 17 3 12 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
More 16 9 20 18 4 
Less 114 63 61 55 19 68 
Same 23 13 14 13 3 11 


























Medunsa JHB Baragwanath Total 
No % No % No % 
14 
8 4 15 2 9 38 
5 42 14 54 13 59 195 
4 33 4 15 3 14 39 











Note that 49% (120) of respondents did not know that albumin 
carries less risk of infection transmission than blood. In fact 
because it is filtered fractionated and pasturised . albumin 
carries no risk of disease transmission. 
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DISCUSSION 
The possibility of transmlssable disease being carried In a unit of blood or blood product exists In all 
countries no matter how careful and stringent the precautions and testing. 
Transmission of Infection 
1) Bacterial: 
Bacterial contamination of blood products Is rare in modern blood banking practice. The greatest 
danger of bacterial contamination appears to be with platelet transfusions because of their storage 
at 20-24°C. This is the reason why platelets are not usually taken back by the blood bank once 
issued. 
2) Viral: 
Virus contamination remains today the main form of transmitted Infection. If an Infective agent Is 
present in the blood of a donor at the time of donation the consequence of transfusing that blood 
will depend on the nature of the agent. The incubation period for clinical signs and symptoms 
varies depending on the infective agent and signs and symptoms may be delayed many years. 
3) Hyman Heoatitis Virus: All blood products except albumin solution and gamma globulin can 
transmit hepatitis. Pooled plasma products have an obviously higher risk than products prepared 
from single donors. The usual incubation period for transfusion induced hepatitis Is 50 to 60 days, 
with a range of from 2 weeks to 6 months. 
At least four types of hepatitis have been recognised: type A, type B, a type referred to as Non-A, 
non-B, and the delta virus. Cytomegalovirus may also cause hepatitis (and accounts for 1-5% of 
post-transfusion hepatitis). 
Type A hepatitis is rarely transmitted by transfusion because the viraemia Is so brief that the 
chance of an asymptomatic viraemlc individual donating blood is small. 
The incidence of non-A, non-B hepatitis virus may be less high as 1 in 100 units, in the U.S.A. and 
until recently was difficult to test for. However, recent development (Time Magazine, 1989) of a 
test for non-A, non-B virus should markedly decrease this frequency if it Is brought Into 
widespread practice. Hepatitis B has been tested for since 1971 and mandatory testing has 
reduced the incidence of post-transfusion hepatitis B to about 2%. In 1988 the Western Province 
Blood Transfusion Service (WPBTS) had two reported cases of Hepatitis B and three cases of 
non-A, non-B due to blood transfusions. 
The delta virus Is a defective virus that requires the helper function of the hepatitis B virus to 
replicate. When a patient positive for hepatitis B surface antigen Is infected with delta virus, the 
superinfection can convert a previously mild hepatitis B carrier state into a severe, progressive 
hepatitis. 
Most patients developing hepatitis do not become jaundiced and escape notice unless 
transaminase values are measured so many transfusion related cases of hepatitis will go 
undetected and unreported. Nevertheless, In 20% of patients the hepatitis will progress to 
cirrhosis. 
Thus non-A, non-B hepatitis and hepatitis B viruses are a major risk of transfusion therapy. 
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4) Human Immunodeficiency virys CHIY): In the United States the estimated risk is 1 in 40 000 to 1 in 
100 000 units. However, the consequences of HIV infection may take many years before damage 
to the immune system allows opportunistic diseases to cause the extremely high mortality of Aids 
(Acquired Immune Deficiency Syndrome). As it is the antibodies to HIV which are tested for, it is 
possible that a donor, recently infected for the first time with HIV, may be in the so-called "window 
free zone" and prove negative on testing. This zone lasts until antibodies are formed some 
months or even years later. It is now known that some subjects infected with HIV never 
seroconvert and go on to develop AIDS still HIV negative. At present there is no test which can 
detect seronegative HIV carriers. Up until April, 1989 in South Africa there were ten cases of HIV 
positive cases associated with transfusions. These included nine haemophiliacs some of whom 
are thought to be HIV positive as a result of transfusions of commercial factor concentrates 
imported from the United States prior to 1985 when the routine testing for HIV antibodies was 
instituted. 
5) Human T Cell Lymphotropic VIruses CHTLV 1 and 2): Cohen et al (1989) reported that although 
the risk of HTLV 1 transmission is small, about 0,024% per unit of blood transfused, it Is still eight 
times higher than the risk of Human lmmuno Deficiency Virus (HIV) transmission. 
HTLV I and II viruses occur In a low but not negligible frequency amongst donor populations in the 
United States. HL TV 1 is a retrovirus which has been associated with tropical spastic paraparesis, 
also called HTLV-1 associated myolopathy and adult T -cell leukaemia/lymphoma. The virus may 
be dormant for 20-30 years In an affected Individual with only 1-2% develop clinical disease. 
Tropical spastic paraparesis is a slowly progressive neurological disease that causes weakness In 
the legs and lower body and leaves half its patients unable to walk. The virus Is believed to be 
passed through sexual contact, via the placenta as well as via contaminated blood products. 
HTLV-11 appears to cause a milder immunodeficiency disease than HIV-1. 
Screening tests recommended for HTLV-1 antibodies will add up to $2.80 per unit in the USA. This 
does not include the cost of confirmatory assays, discarded units, counselling donors or tracing 
recipients who may receive blood later found to be infected with HTLV I. 
6) Cvtomegalovlrus: Latent cytomegalovirus Is present in circulating WBC's of a substantial 
proportion of donors and Infection is readily transmitted by blood transfusion. Serum 
cytomegaloviral antibody titres rise at least fourfold in about 30% of post-operative patients given 
a large number of transfusions during surgery. A few patients develop an infectious 
mononucleosis-like syndrome. Immune-compromised patients may develop severe or even fatal 
post transfusion, cytomegalovirus septicaemia. 
The W.P.B.T.S. had one reported transfusion related cytomegalovirus infection in 1988. 
7) Others, Including parvovirus and Epstein Barr virus, which have been linked with the syndrome of 
Myalgic Encephalopathy (M. E.) 
Other Transfusion Transmitted Diseases; 
Malaria: 
The Plasmodium parasites have been known to remain In the body for years after the initial attack. If a 
specific diagnosis was not made, the donor is potentially dangerous. The parasite may be absent Initially 
in the peripheral blood but present In the bone marrow making detection of the potentially dangerous 
donor difficult. Plasmodium vivax does not survive longer than 96 hours in blood stored at 4°C. 
However, Plasmodium malariae and Plasmodium falciparum survive Indefinitely under the usual 
conditions of blood storage. Platelet concentrates have also been Implicated In malarial transmission. 
In 1988 one case of transfusion related malaria was reported In the W.P.B.T.S. 
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Syphilis: 
There is an extremely low incidence of transfusion-induced syphilis. This is due in part to the low 
incidence of syphilis amongst voluntary blood donors. Any donor giving a history of syphilis is rejected 
regardless of the outcome of a serological test for syphilis. Any serologically positive blood is also 
rejected. The problem lies in identifying the dangerous donor who has been exposed to syphilis but has 
not yet developed a chancre, secondary syphilitic lesions or a positive serologic reaction. However, 
treponema pallidum Is killed when blood is stored at 4°C for 96 hours or when plasma is stored and 
frozen. This is thought to eliminate much of the danger from the use of serologically negative blood 
containing organisms. 
Isolated transmission of other microorganisms are reported, brucellosis, trypanosomiasis, 
toxoplasmosis, visceralleukmanlasls, and Rocky Mountain Spotted Fever. 
Graft-versus-Host Disease: 
Graft versus host disease has been reported after blood tranfusions in children with various primary 
immunodeficiency states, after interuterine or exchange transfusions of neonates with haemolytic 
disease of the newborn and after transfusion of adult with myelosuppression and immunodeficiency 
secondary to chemotherapy for haematological malignancies. Irradiating stored blood with 1 ,500 to 
3,000 rads before administration prevents graft-versus-host disease by inactivating lymphocytes without 
impairing the function of ABC's, granulocytes or platelets. 
CONCLUSION 
Blood and blood products are not safe from the risk of disease transmission and, as knowledge of the 
slow acting viruses such as HIV and HTLV I and II increases even more circumspection needs to be 
taken before they are transfused. The fact that the respondents assessed the risk of infection 
transmission incorrectly for: FFP 35%; Albumin 49%; Cryoprecipitate 53% and for FFP plus packed red 
blood cells 56% shows a serious flaw in the education of those South African anaesthetlsts surveyed. 
Less than 50% of the respondents gave the correct responses to the risk of transmission of infection by 
blood. This shows a serious flaw in the anaesthetists' knowledge. 
62 Blood Product Knowledge 
BLOOD KNOWLEDGE IMMUNITY SUPPRESSION 
Survev Question 
Please answer the following questions True or False or Don't know: 
I True I False I Don't know 
Blood transfusions worsen the prognosis in 
certain cancers being operated upon (Colon, 




Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath 
No % No % No No 
N/A 
True 75 49 28 53 4 
False 39 26 12 23 1 
Not know 39 26 13 25 














% No % 
65 10 35 
17 13 45 
19 6 21 

















Note that the anaethetlst with the most experience ( > 20 
years) percentage-wise appeared to have the poorest 
knowledge. 
% No % No % No % No % 
72 14 52 7 64 21 75 18 78 
5 8 30 3 27 5 18 1 4 









TRUE FALSE NOT KNOW 
-All Areas 
Note that 57% (186) of respondents replied that 
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Survey Question 
Please answer the following questions True or False or Don't know: 
True I I Falsel Don't know I 
Blood transfusions improve long-term renal 
transplant survival rate D D 
RESULTS 
Renal Transplant Survival 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
True 65 43 24 45 2 14 
False 53 35 17 32 2 7 
Not know 35 23 12 23 4 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
True 71 88 65 57 8 28 
False 66 36 36 32 11 38 
Not know 48 26 13 11 10 35 
RENAL SURVIVAL 







<6 <20 >20 
- TRUE ~FALSE [JJ NOT KNOW 
Note that the most experienced anaesthetists ( > 20 years) 











Pretoria Medunsa JHB Baragwanath 
No % No % No % No % 
15 56 5 42 12 43 7 29 
8 30 3 25 13 46 10 42 
4 15 4 33 3 11 7 30 
RENAL SURVIVAL 
'Ill RETURNS 
TRUE FALSE NOT KNOW 
-All Areas 
Note that 44% (145) respondents stated that 
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Survey Question 
Please answer the following questions True or False or Don't know: 
Blood transfusions increase the post-
operative sepsis rate 
RESULTS 
Sepsis 




Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total 
No " No " No No No 
N/A 
True 40 36 14 26 2 10 
False 85 55 30 57 1 11 
Not know 29 19 9 17 2 3 
Answer 1-5 6-20 >20 
No " No " No " 
N/A 
·True 64 34 30 27 2 7 
False 95 51 62 55 22 76 
Not know 28 15 21 19 5 17 
SEPSIS 







<6 <20 >20 
-TRUE -FALSE CIJ NOT KNOW 
Note that the most experienced anaesthetists ( > 20 years) 
proportionately appeared to have the poorest knowledge. 
" No " No " No " No " 
4 
42 7 26 6 46 9 32 8 33 96 
46 17 63 7 54 17 61 11 46 180 










TRUE FALSE NOT KNOW 
-All Areas 
Note that 29% (96) replied that the sepsis rate 
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DISCUSSION 
lmmuno!oaical Effects of Blood Transfusions 
Repeated transfusion of blood or blood products lower both the helper/suppressor (T4/T8) lymphocyte 
ratio and Natural Killer activity, decreases circulating fibronectin and impairs macrophage function 
(Woodruff & van Rood, 1983). These effects on the immune system have been postulated as having an 
effect on cancer patient survival, renal transplant survival and post-operative sepsis rate. 
Effects of Blood Transfusion on cancer 
Colorectal Cancer 
Peri-operative blood transfusions have deliterious effects on the prognosis for a cure and the five year 
survival rate after surgical resection in patients with colorectal cancer (Blumberg et al 1988, Foster et al 
1985, Burrow 1982). This finding, however, was not supported by Cheslyn-Curtis et al (1990) in a 
multicentre study on 961 patients with large bowel cancer. They could find no overall differences 
between the patients who had received blood and those who had not. In particular there was no survival 
disadvantage for those patients who had received peri-operative blood transfusion. However, the study 
did strongly indicate that heterologous blood given in peri-operative period changes the site of 
metastasis formation. Liver metastases developed more frequently in the patients who were not 
transfused. They strongly recommend that heterologous blood transfusion be avoided where possible 
by improved surgical techniques and autologous blood collection. 
Lung Cancer 
Blood transfusion has been found to be significantly associated with diminished survival in patients who 
had resections for Stage I and Stage 2 lung tumours (Tartter et al 1984). Survival rates at 5 years were 
44% in those who had had no transfusions compared with 27% in those who had been transfused. There 
was no effect of transfusion found in patients who had had Stage 3 tumours resected. These authors 
retrospectively studied disease free survival rates in 165 patients with Stage I non-oat cell tumours. 
Those who had been transfused had a significantly worse disease free survival rate at 5 years when 
compared with those who had not been transfused. When those patients who had had extensive 
resections were eliminated the better survival rate for patients who had not been transfused was still 
evident but no longer statistically significant. 
Breast Cancer 
The one year disease free survival rate following mastectomy for Stage I, 2 and 3 tumours was 95% in 
those with no transfusions and 77% In those who had had blood transfusions (Tartter 1985). 
Soft Tissue Sarcomas 
The overall survival and disease free rate at 5 years was significantly lower in patients who had had 
amputation plus transfusion. The worsening of the prognosis was related to the number of units of blood 
' received (Rosenberg et al, 1985). 
Natural Killer cells play an important role in anti-tumour host defences particularly against circulating 
tumour cells. The number of circulating Natural Killer cells is reduced acutely post-operatively and this 
effect is Increased if the patient received transfusions (Lennard et al, 1985). This combination of 
transfusion and operation induced depression of Natural Killer activity might enhance the survival of 
tumour microemboll released during operation. This could account for the poorer prognosis reported In 
patients who were transfused peri-operatively. 
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Effects on Renal Transplantation 
Previous blood transfusions, if no cytotoxic antibodies against the donor are formed,appear to have a 
beneficial effect on the survival of kidney grafts (Bucin et al, 1981). Giving peri-operative transfusions to 
a patient who had not been previously transfused improved gross renal survival compared to patients 
who had never been transfused (Williams et al, 1980) but not with patients who had had pre-operative 
transfusions (Corry at al, 1980). 
The precise mechanism of action remains obscure. The main theories are: 
1. The selection theory. Broad spectrum antibodies occur in 30-50% of renal patients receiving 
blood in the pre-transplant period. This makes finding a suitable donor harder. However if an 
adequately HLA cross-matched donor is found, the results of the transplant is likely to be better 
because of the greater tissue compatability of donor to recipient. 
2. T -cell blocking theory (van Rood, 1983). The effect of a blood transfusion has two stages. 
Initially antibodies are formed to Class I HLA antigens and cytotoxic lymphocyte activation Is 
suppressed non-specifically. This Is followed by the production of specific anti-ldlotypic 
antibodies that prevent T -cell activation by Class I and 2 antigens present in donor blood. These 
antibodies may subsequently block host T-eall activation in response to the Class I antigens on 
the graft, thus decreasing the chance of transplant rejection. 
Bacteria and Sepsis 
Prospective studies have shown that patients having elective colorectal operations had significantly more 
infections if they received blood transfusions (Tartter et al, 1986). 
it is suggested that prostaglandin E2 formed after blood transfusions during the phagocytosis of efete 
red blood cells Inhibits the lymphocyte response through activation of T -suppressor lymphocytes 
(Lenhard, 1985). This together with the lowering of the circulating fibronectln may Impair the 'host 
capacity for bacterial clearance (Snyder et al, 1981). 
CONCLUSION 
That. blood transfusions temporarily decrease the body's immune responses appeared to be unkown to a 
significant number of the survey's respondents. Thus 71% did not know of the increase in sepsis, 56% 
did not know the improvement of renal transplant survival and 43% didn't know transfusion worsened the 
prognosis in certain cancers treated by surgery. 
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BLOOD COMPONENT KNOWLEDGE THE COSTS 
Survey Quution 
What is the cost to the hospital of the various blood components? 
Less than 
SOR R50-75 R75-100 R10G-30Q+ R300 
Fresh Frozen Plasma 
RESULTS 
Cost FFP 
Answer W.Cape Natal NTvl STvl 
No " No " No No No 
N/A 
<50 34 24 8 20 1 14 
50-75 68 47 15 38 ' 3 4 
75-100 27 19 12 30 
100-300 12 8 3 
>300 
Spoilt 
Answer 1-5 6-20 >20 
No " No " No " 
N/A 
<50 59 35 29 32 5 23 
50-75 71 41 38 41 9 41 
75-100 23 13 20 22 4 18 
100-300 17 10 3 3 
>300 
Spoilt 
Note that 42% (120) of respondents replied that FFP cost 
between 50 and 75 Rand. The actual cost varied between 
R58 for the SABTS and R69 for the wPBTS. 
D D D D D 
OFS Pretoria Medunsa JHB Baragwanath Total 
" No " No " No " No " 
45 
70 11 44 4 36 13 62 8 36 93 
20 11 44 5 46 6 29 7 32 120 
5 2 18 5 23 47 
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Survey Question 
What is the cost to the hospital of the various blood components? 
Dried Plasma 
RESULTS 
Cost Dried Plasma 
Answer W.Cape Natal NTvl STvl 
No % No % No No· 
N/A 
<50 65 47 11 28 
50-75 44 32 17 43 4 
75-100 19 14 9 23 
100-300 3 2 
>300 3 2· 
Spoilt 
Answer 1-5 6-20 >20 
No " No % No % 
N/A 
<50 90 53 44 49 11 50 
50-75 46 27 37 41 6 27 
75-100 26 15 5 6 3 14 
100-300 3 2 1. 1 
>300 2 2 
Spoilt 
Note that 12% (34) of respondents stated that dried 
plasma cost between 75 and 100 Rand. The actual cost 
ranged from R70 (SABTS) to R85 (NBTS). 
Less than 
· 50R RSo-75 R75-100 R10G-300 ~ 
D D D D 
OFS Pretoria Meclunsa JHB Baragwanath Total 
No % No % No % No % No % 
53 
18 90 14 56 7 70 16 76 12 57 144 51 
5 9 36 2 20 4 19 7 33 89 32 
5 2 8 10 1 5 5 34 12 
5 4 4 
3 
6 








50-75 75-100 100-300 >300 
-All Areas 
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Survey Question 
What is the cost to the hospital of the various blood components? 
Whole Blood ( > 96 hours) 
RESULTS 
Cost Whole Blood > 96 hrs 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
<50 5 3 2 3 
50-75 52 36 11 26 2 15 
75-100 64 44 21 49 3 3 
100~300 23 16 7 16 
>300 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
<50 19 11 7 7 2 8 
50-75 73 42 41 42 11 46 
75-100 62 35 36 37 9 38 
100-300 19 11 12 12 
>300 
Spoilt 
Note that 36% (107) of respondents stated blood cost 
between 75 and 100 Rand and 42% (125) between 50 and 
75 Rand. The actual cost of blood >96 hours old ranged 
from R58 (SABTS) to R90-R500 (NBTS). 
Less than 
50R ~ R75-100 R100=30Q ~ 
D D D D D 
Pretoria Medunsa JHB Baragwanath Total 
% No % No % No % No % 
37 
14 8 32 2 20 5 23 3 13 27 9 
71 13 52 4 40 11 so 16 70 125 42 
14 4 16 2 20 6 27 4 17 107 36 
10 31 10 
10 1 









•50 50-75 75-100 100-300 >300 
-All Areas 
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Survey Question 
What is the cost to the hospital of the various blood components? 
Whole Blood ( < 96 hours) 
RESULTS 
Cost Whole Blood < 96 hrs 
Answer loi.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
<50 3 2 5 
50-75 16 11 3 7 9 
75-100 65 45 18 42 1 5 
100-300 55 38 17 40 2 -
>300 5 3 2 5 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No " 
N/A 
<SO 11 6 7 7 4 17 
50-75 37 21 13 14 7 30 
75-100 72 41 41 44 6 25 
100-300 47 27 30 32 5 21 
>300 6 3 2 2 
Spoilt 
Note that 41% (119) of respondents replied that the cost of 
fresh blood was 75-100 Rand. The actual cost was A78 
(SABTS); R105 (NBTS) and R1Q9.50 (WPBTS). 
Less than 
50 A R75-100 A1oo-3QO A300+ 
D D D D D 
OFS Pretoria Medunsa JHB Baragwanath Total " 
" No % No " No % No " 
42 
26 5 20 2 20 2 9 3 14 21 7 
47 9 36 3 30 9 39 7 33 57 20 
26 9 36 1 10 10 44 9 43 119 41 
2 8 3 30 2 9 2 10 83 28 
10 8 3 
4 









<50 60-76 75-100 100-300 >300 
-All Areas 
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Survey Question 
What is the cost to the hospital of the various blood components? 
Cross-match cancelled 
RESULTS 
Cost Cross Match Cancelled 
Answer W.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
<50 105 72 30 70 4 60 
50-75 28 19 11 26 1 




Answer 1-5 6-20 >20 
No % No % No % 
N/A 
<50 130 74 67 69 19 79 
50-75 34 19 24 25 2 8 




Note that 73% (214) of respondents replied that the cost of 
a cross-match was less than 50 Rand. The actual cost 




SOR R50-75 R75-100 R100=300 R300+ 
D D D D D 
Pretoria Medunsa JHB Baraglo!anath Total % 
% No % No % No % No % 
38 
76 17 68 5 so 19 86 17 n 214 73 
19 7 28 4 40 3 14 3 14 61 21 











<50 50-75 75-100 100-300 >300 
-All Areas 
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Survey Question 
What is the cost to the hospital of the various blood components? 
Megapack platelets 
RESULTS 
Cost Meaapack Platelets 
Answer W.Cape Natal NTvl STvl 
No " No " No No 
N/A 
<50 
50·75 2 2 5 
75·100 7 5 5 13 2 
100·300 57 40 21 53 
>300 74 52 9 23 2 
Spoilt 
Answer 1·5 6-20 >20 
No % No " No " 
N/A 
<50 4 2 2 2 
50·75 10 6 7 8 2 10 
75·100 25 15 6 7 3 15 
100·300 72 43 34 38 7 35 
>300 54 32 40 45 5 25 
Spoilt 
Note that only 36% (100) of respondents replied that a 
Megapack of platelets cost more than. R300. Taking a 
megapack as six random units the actual cost ranged 
from R312 (SABTS) to R353 (NBTS)- By comparison a 








SOR ~ R75-100 R100=300 R300+ 
D D D D D 
OFS Pretoria Medunsa JHB Baragwanath Total 
" No " No % No " No % 
56 
18 4 6 5 6 2 
18 8 32 1 6 2 9 19 7 
30 5 20 3 30 2 13 5 23 34 12 
24 10 40 3 30 7 44 9 41 112 40 
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DISCUSSION 
All South African blood banks publish lists of the cost of their products which are sent to all the hospitals 
they service (Table 4:1) (personal communication Dr. P. Cochlan, Medical Director, W.P.B.T.S.). Thus 
each Department should have the latest costings readily available. As blood and blood components are 
often used in the peri-operative period when anaesthetists are an important part of the Health-Care Team 
the costs should be known to him or her. 
TABLE 4:1 
1989 COSTS liN RANDS) 
WPBTS BBTS 
Fresh Frozen Plasma 69 77.80 
Dried Plasma 67 81.90· 
Whole Blood > 96 hrs 87.50 81.90 
Whole Blood < 96 hrs 109.50 106.50 
Cross Match cancelled 52.00 57.35 
Random Platelets 1 unit 66.00 73.70 
Megapack Platelets 511.00 573.00 
(single donor) 
Total Blood Products 







Western Province Blood Transfusion Service 
Border Blood Transfusion Service 
Eastern Province Blood Transfusion Service 
Natal Blood Transfusion Service 


















Note that the percentage of correct answers by area, tended to be poor especially in those areas which charged the most. 
CONCLUSION 
The fact that the majority of respondents tended to underestimate the cost of blood products must be 
another factor in the upward spiral of health care costs. This ignorance may also discourage the use of 
safer and cheaper alternatives such as the synthetic colloids (approximately one quarter the price) where 
a colloid substitute is required. Knowledge of the costs of blood and blood components should be 
included in the Anaesthetic Department's teaching curriculum. 
CHAPTER FIVE 
BLOOD TRANSFUSION ADJUVANTS 
* Intra-operative Blood Scavenging 
* Micro Aggregate Blood Filter Usage 
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AUTOLOGOUS TRANSFUSION SCAVENGING 
Survey Question 























Occasionally D Frequently D NeverD 
Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 
No % No No No % No % No % No % No % 
4 7 2 68 21 
2 2 6 2 
48 4 18 22 12 25 23 249 77 
8 
6-20 >20 
No % No % SCAVENGING 
27 24 3 11 'Ill RETURNS 
3 3 1 4 100 






OCCASIONALLY FREQUENTLY NEVER 
-All Areas 
Note that 77% (249) of respondents never use blood scavenging techniques intra-operatively. 
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DISCUSSION 
SCAVENGING TECHNIQUES 
Blundell in 1818 was the first to report on autotransfusion salvage experiments and postulate as to its 
uses in shocked states, particularly post partum haemorrhage. In three of these experiments blood was 
allowed to flow from an artery to a cup and was directly returned into the vein, using "great caution in 
removing all air". Using this method he reported "twelve pints of blood were passed through the syringe 
without serious inconvenience, although the loss of one-half a pint of blood would have destroyed a dog 
of the same size~. He also concluded from his experiments that blood from one animal species could 
not be transfused with impunity into another species. Duncan in 1886 described the first successful use 
of scavenging blood, "in all about three ounces", in a surgical amputation performed in 1885. 
The advantages for intraoperative salvage and transfusion have been described as: 
Provides Immediately available blood 
Requires minimal Initial investment of time and money 
Obviates cross-matching 
Reduces the chances of errors 
Assures immunological compatibility 
Reduces blood bank workload 
Conserves blood resources 
Is suitable for elective or emergency surgery 
Is acceptable by some Jehovah's Witnesses 
Does not transmit hepatitis or other infectious diseases into a new host 
May preserve essential opsonins 
Relative safety with fewer haemolytic, febrile or allergic reactions 
Autotransfused blood is already warm 
Hyperkalaemia, hypocalcaemia and acidosis is avoided. 
Eguioment: 
The properties of the ideal transfusion device should be: 
Rapid assembly 
Low cost 
Ease of operation 
I nline filtration system 
Minimised air /blood interface 
Simplified anticoagulation 
Safety from air embolism and coagulopathy. 
The commonest type at present in South Africa appears to be the Sorenson Autotransfusion System. 
This autotransfusion system uses a special suction tip that mixes aspirated blood with 
citrate-phosphate-dextrose (CPO) anticoagulant in a minimum ratio of 7:1. All components are 
disposable, except the receptal cannister and the regulator which controls the pressure from the vacuum 
source. The collection bag has a 1,900ml capacity and a 170-/1 screen filter. When full, the bag is 
disconnected from the suction and the rigid cannister and a new bag Is inserted. A standard blood 
administration set Is inserted into the filled collection bag and the bag is inverted for conventional 
transfusion. A pressure cuff, although somewhat awkward, may be used to accelerate the infusion rate. 
The risk of air embolism Is minimal as the system transfuses blood either by gravity or pressure cuff and 
not by pressure transfusion through the system (contrast the Bentley Autotransfusion System ATS-100 
now off the market). 
76 Autologous Transfusion 
Other types include: 
Haemonetlcs Cell Saver 1. This utilises wall suction and consists of four components: (1) The heart of 
the system Is a continuous-flow, disposable washing bowl which is driven by a compact, simple, 
centrifuge. The bowl may be used to process multiple units for a transfusion in an individual patient. The 
blood processing unit includes prepackaged "Y" tubings which are programmed to cycle the blood. (2) 
The aspirating device Is a special tubing connected to a plastic suction tip which allows mixture of 
heparin solution. (3) The reservoir may be either a standard cardiotomy reservoir or a Haemonetics 
autotransfusion reservoir with a 3L capacity. The Haemonetics reservoir consists of a reusable vacuum 
shell and a disposable set-up. When washing is completed, red cells are pumped into a transfer pack for 
transfusion to the patient. The Cell Saver I requires a trained operator to be present at all times. 
Haemonetics Cell Saver Ill. This system automatically washes and concentrates red blood cells with 
one-button operation and is programmable. It has a digital readout for wash volumes selected, pump 
speed, volume processed and volume returned. It uses the same disposable software as the Cell Saver 
I. The Haemonetics Cell Saver Ill requires minimal operator attention and comparatively less operator 
training. 
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PROBLEMS OF SCAVENGING 
Potential Adverse effects of scavenging and retransfusion include: 
1. Haemolysis: 
This may result from vacuum-induced trauma, contact of blood with air and tissues, the kinking of 
roller pumps, foaming in tubing and reservoirs, and turbulent blood flows (Fleming & Garcia, 
1980). 
Free haemoglobin levels in salvaged blood have been reported as high as 1 ,600mgjdl (normal, 
less than 20mgfdl [Brener et al, 1973]). Studies by de Jong et al {1980) demonstrated that 
perfusion with cardiotomy suction produces six times more haemolysis than perfusion without 
suction. These investigators concluded that suction Introduces a definite adverse effect during 
extracorporeal circulation. A general observation made during the early years of clinical 
cardiopulmonary bypass was that a large volume return from the cardiotomy suction correlated 
with increased abnormalities in coagulation. On the other hand, a very large return, sufficient to 
maintain continuous blood flow in the suction tube, appeared to cause less damage than when 
frequent breaks occurred in the blood column. This suggested that damage occurred at the 
blood-air interface. 
2. Red Cell Survival: 
Mati et al (1973) studied the survival of autotransfused red cells by radioactive chromium 
techniques. They reported on five patients with ruptured ectopic pregnancies who had salvaged 
peritoneal blood labelled and autotransfused, the percentage of red blood cells surviving on day 5 
was significantly less than that for labelled and autotransfused venous blood in control patients. 
By extrapolation, the half-life of peritoneal red blood cells was approximately eight days, whereas 
the half-life of venous red blood cells was approximately 60 days. The peritoneal blood obtained 
for these studies was less than six hours old. 
3. Coagulation Disorders: 
Duncan and associates suggested caution In using autotransfusions, inasmuch as three of eight 
deaths were thought to be· related to the use of the autotransfusion unit. All the patients had ' 
abnormal coagulation studies prior to death. The patients reported by Duncan had 
7,000-12,000ml of homologous blood transfused. It has been demonstrated In baboons that DIC 
can largely be prevented by washing the autologous blood using a continuous flow centrifuge to 
remove thromboplastic substances and prevent activation of the coagulation mechanism 
(Kingsley et al, 1978). Washing devices function by repeatedly suspending the collected material 
in saline and centrifuging away the supernant, leaving a washed red cell product. 
4. DPG: 
Orr {1978) demonstrated that levels of 2,3 DPG were significantly greater In autologous red blood 
cells when compared with stored homologous cells averaging 4.2 days old. Higher levels of 2,3 
DPG were also found in autologous blood collected by the Sorenson System (Noon, 1978). 
5. Mlcroemboli: 
The significance of microembolizatlon reported after Intraoperative salvage and autologous 
transfusion is not clear. Dowling {1973) reported three patients with pulmonary insufficiency after 
autonomous transfusion; however, two of these patients had large volumes of homologous blood 
transfused in addition to autologous transfusions. The third patient had a flail chest and 
pulmonary contusion. Post-traumatic pulmonary insufficiency did not occur in patients who were 
autotransfused only (I.e. received no homologous whole blood). 
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6. Air Embolism: 
Several cases of fatal air embolism have been reported in association with use of the Bentley 
system. These problems were usually related to operator error or to failure of the alarm to 
function or to clots obscuring the photoelectric cell (Thurer & Hauer, 198~). Other autologous 
transfusion systems do not appear to have a risk of air embolism in excess of that of routine 
transfusion. 
7. Sepsis & Malignancy: 
Several studies support the feasibility of autotransfusing contaminated blood. Klebanoff et al, 
1970 prepared a test mixture consisting of approximately 10ml or solid fecal material, 
approximately 30g of splenic tissue, 30g of liver, 10-15ml of bile and 10g of body fat suspended in 
whole blood to a volume of 100-150ml. After wounds were contaminated with this mixture, blood 
cultures of 10 dogs yielded positive results during the immediate post-transfusion period, but were 
negative at the end of 24 hours. There were no sequelae. However, it is recommended that 
gastrointestinal tract disruption is an absolute contraindication to scavenging (Morris, 198S). 
Other relative contraindications include evidence of injury to the liver, pancreas and urinary tract. 
Patients with malignancies are not candidates for intraoperative salvage and autologous 
transfusion. Yaw et al, 1971 demonstrated malignant cells in blood salvaged with the Bentley 
system. These malignant cells were readily identified in centrifuged blood removed from the 
pleural cavity after the sample had passed through the filter device. 
Morris (1985) recommended that certain precautions should be taken during autotransfusion 
practices. To reduce septic complications, autotransfusion blood should be reinfused within 4 
hours and use inline microemboli filters should be used to trap gross contaminants. The use of 
systemic broad spectrum antibiotics in cases of suspected contamination is mandatory. To 
reduce the amount of haemolysis, it is advocated that one minimises suction pressure to 15-30 
centimeters of water for closed thoracotomy chest tube drainage and 40-60 centimetres of water 
for open field aspiration. Aspiration of the autotransfusion from the bottom of the blood pool 
decreases the air fluid interface. To minimise the possibility of subsequent coagulapathies, it is 
advisable to limit autotransfusion to less than 4 litres of blood. 
CONCLUSION 
There appears to be well documented advantages for the patient in receiving his own scavenged blood. 
Yet only 23% of South African anaesthetists surveyed use scavenging techniques at all, only 2% using 
them frequently. The reasons may include complicated or lack of equipment, lack of training in the 
technique, the cost of the disposables involved may not make it cost effective, or there may be too few 
suitable patients seen. These questions should be addressed by each Anaesthetic Department and 
scavenging techniques should be encouraged where possible. · 
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MICRO FILTERS USAGE 
Survey Question 
When would you use micro-aggregate {effectively removing particles in the 10-30 micron range) 
blood filters? 
With every unit blood transfused 
RESULTS 
Filters every unit 
Answer W.Cape Natal NTvl STvl 
No % No % No No 
N/A 
No 143 94 41 79 5 
Yes 8 5 9 17 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
No 148 81 107 95 26 93 














JHB Baragwanath Total 
No % No % 
9 
16 60 21 88 281 
11 40 3 13 38 
3 
FILTERS 













Note that 87% (281) respondents would not use a microfilter for 
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Survev Question 
When would you use micro-aggregate (effectively removing particles in the 10-30 micron range) 
blood filters? 
If transfusing more than .................. units 
RESULTS 
Filters if more than 
Answer II.Cape Natal NTvl STvl OFS 
No % No % No No No % 
10 11 14 
5 6 1 3 
so 56 2 7 4 57 
5 6 14 
7 8 
3 3 
' 4 5 19 61 14 
4 5 3 
Answer 1-5 6-20 >20 
No % No % No % 
5 6 9 16 7 
5 6 4 7 
41 45 24 42 9 60 
7 8 2 4 
7 8 3 5 
1 2 4 
12 13 10 18 2 13 
6 7 2 3 20 
Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
180 
9 14 17 8 15 9 
9 2 29 1 8 10 6 
2 18 3 43 3 so 9 75 74 45 
3 27 9 6 
14 2 33 10 6 
3 2 
24 15 
4 36 8 10 6 
FILTERS 








>2 >3 >4 >6 >6 >8 >9 >10 
-All Areas 
Note that 60% (99) of respondents would use microaggregate 
filters when transfusing four or fewer units of blood. 
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Survey. Question 
·When would you use micro-aggregate (effectively removing. particles in the 10-30 micron range) blood 
~~ . . . 
Only with extra-corporeal circulation 
RESULTS 
Filters only with ECC · 
Answer \I.Cape Natal NTvl STvl 
No % No % No No 
N/A 
No 124 81 39 .75 5 
Yes 28 18 12 23 
spoilt 
A'nswer 1-5 6-20 >20 
No % No % No %. 
N/A 
No 151 83 84 74 23 82 






Pretoria Medunsa JHB Baragwanath Total 
No % .No % No .% No % 
9 
19 73 11 100 22 82 20 83 257 






Note that 83% (257) of respondents would not use 
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DISCUSSION 
Early blood bankers were aware that large blood clots formed during storage and filters were needed to 
remove this, potentially harmful, debris (Fantus 1938). Later, microaggregates (MA) composed of 
platelets, non-viable granulocytes and fibrin strands ranging in size from 20-200 microns were 
recognised. As MAs were thought to be clinically unimportant, early blood filters were designed with 
pore sizes between 140 and 300 microns, primarily to allow maximum flow rates whilst removing the 
larger debris (Walter & Batton 1966, Cooksey 1940). In 1961 Swank reported that MAs may have -
caused adverse effects following transfusion during bypass surgery. This was followed by Mosley & 
Doty (1970) reporting on deaths due to puhnonary emboli possibly caused by MAs. Since that time 
there has been much controversy as to the specific role of microaggregates and microaggregate blood 
filters (MABFs). - , 
Debris from transfused blood is removed primarily by the pulmonary capillary bed. Early MAs are 
composed mainly of degenerating platelets, whilst older MAs contain granulocyte and fibrin strands 
(Mosley & Doty 1970, Marshall et al 1976). The number of aggregates increases with the length of time 
the blood is stored. Their size varying from < 7 micron in diameter whilst their numbers may be in the 
order of 140 000 per ml (Ashmore et al 1972). However, even in the absence of transfusions the 
number of microaggregates normally increases after trauma, possibly due in part to release of serotonin 
and ADP from platelets at the site of injury (Swank et al 1963). Thus the clinical role played by 
exogenous microaggregates in transfused blood is not clear in trauma situations. 
MABFs in common use are classified as either screen or depth filters. Screen filters are made of woven 
polyester with a pore size of 40 microns and depth filters are composed of a variety of substances 
including dacron, wool, polyester wool or polyurethane in foam and effectively remove particles from 
10-30 micron size (Snyder & Bookbinder 1983).- The capacity of most filters is between 3 and 6 units 
with older blood occluding the filter sooner. The flow rates can be of the same order as the standard 
large pore filters because of their large surface areas. However the use of bulky filters may cause blood 
flow to channel so negating their effectiveness. 
The results of animal experiments and MABFs are confusing. Snyder & Bookbinder (1983) in their 
review suggest that animal experiments are, for a variety of reasons, not readily applicable to humans. 
Logically it would appear that blood should be filtered down to 40 microns as the average diameter of 
the pulmonary arteriole in adults is slightly greater than 40 microns. Each arteriole services 
approximately a dozen capillaries, and therefore, the same number of alveolae. Whilst the loss of 
individual pulmonary capillaries is of no significance, the loss of a number of pulmonary arterioles could 
be of major significance. However clinical data has failed to show that microemboli exclude 
pulmonaryarterioles in man. 
Cardiopulmonary Bypass 
In the early years of cardiopulmonary bypass,complications such as visual disturbances, renal 
dysfunction, amnesia, psychosis and delirium were attributed, in part, to MAs infused into the systemic 
arterial system (Swank & Porter 1963, Hill et al 1969). Osborn et al (1970) using an in.line MABF 
reported a decrease in the incidence of post-operative problems. Hill et al (1970) and others (Skagseth 
1974) reported a marked reduction in mortality and evidence of non-fat emboli when MABFs were used 
in the extra-corporeal circuit. Although some microembolic complications cannot be prevented by the 
use of MABFs (Siogoff et al 1982) it is recommended that the use of MABFs with cardiopulmonary 
bypass is both medically prudent and cost effective (Snyder & Bookbinder 1983). 
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Sub-massive transfusion 
Virglio et al {1977) studied 40 patients undergoing elective aneurysmectomy, being given between 6 
and 7 units of blood. Post-operatively there were no differences in pulmonary function between the 
MABF group (40 microns Pall screen filter) and a control group (170 micron filter). Other studies using 3 
units of blood In abdominal surgery (Takaori et al, 1977), 4-5 units in hip surgery (Snyder et al, 1979), 5 
units blood in aortic aneurysmectomy (Grindlinger et al, 1980), 1 unit blood (Browning et al, 1980), all 
found either no, or only minor changes in sensitive pulmonary function tests while comparing control to 
MABF groups. These changes in the pulmonary function tests were not clinically significant (Pa02, 
PaC02, morbidity, mortality or post-operative respiratory distress). Thus, in terms of patients' survival 
and morbidity there is little data to suggest the routine use of MABFs is justified In sub-massive 
transfusions. 
Massive transfusion <more than 10-12 units within 24 hours) 
Collins et al {1978) reviewed the data on the relationship between the Infusion of MA debris using 
standard 170 micron filters and the development of pulmonary dysfunction In wounded soldiers. They 
showed that, despite the Infusion of over two blood volumes to some casualties, no detectable decrease 
in Pa02 was found up to three days post-transfusion. 
Rosario et al {1978) reviewed autopsy slides of patients dying shortly after massive transfusion. Readily 
detectable microemboli were only seen after infusions of over 1 o units of blood given through the 
standard screen filters and the degree of microembolisation was proportional to the units of blood 
transfused. However, they found no correlation between the number of units received and the frequency 
of respiratory insufficiency and they felt that sepsis and shock were more important than transfused MA 
debris in the etiology of post-traumatic pulmonary insufficiency. 
Pepe et al {1982) in a study of patients with adult respiratory distress syndrome showed that, when 
multiple transfusions were the sole risk factor, the clinical syndrome only occurred in patients receiving 
more than 22 units of blood within 12 hours. Patients with sepsis, however, were at high risk of acute 
adult respiratory distress syndrome. 
It must be remembered that shock, soft tissue injury, and sepsis may all, on their own, cause a significant 
amount of endogenous MAs (Carrico, 1979) which MABFs will be unable to prevent. In fact MABFs may 
play an adverse role if transfusion of blood through the filters delays the speed of resuscitation and 
hypovolaemic correction (Collins, 1974). 
MABF's and Thrombocvtooaenia: 
Lim et al {1989) reported that iri patients with initial low platelet counts due to leukaemia or 
myelodysplasia the use of 40J.'m MABF's significantly reduced the fall in platelet count. This was in 
contrast to the use of 170J.'m filters In the same patients when ± 20 day old blood was transfused and a 
clinically significant fall In platelets occurred. Bareford et al (1987) suggest the major cause for the 
platelet fall Is the infusion of microaggregate debris which cause splenic sequestration of the patient's 
circulating platelets. The fall in platelet count on transfusion of blood via 170J.'m filters (average 15 x 1 o9 
platelets) would probably not be clinically significant in patients with a normal platelet count. In 
thrombocytopaenic patients, however, the drop could precipitate haemorrhaglc complications. 
CONCLUSION 
Snyder and Bookbinder (1983) conclude their review into MABFs by stating their routine use, even for 
massive transfusion, cannot be justified by present data. MABFs have only been shown to be useful for 
transfusion during cardiopulmonary bypass surgery to prevent arterial emboli. There may, however, be a 
role for MABFs In the prevention of febrile transfusion reactions, in the patients with pre-existing 
pulmonary disease where the normal filtration and degradation mechanisms are compromised, or in 
patients with pre-existing low platelet counts. 
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The present survey shows that most S.A. anaesthetists who responded to the question do not use 
microfilters under most circumstances. However 60% (99) stated they would use MABF's when 
transfusing four or fewer units of blood which Is a gross overusage of expensive disposables. This 
question however was not answered by 180 respondents. 
83% (257) of the respondents also replied they wouldn't use mlcrofilters for their main Indicated function, 
that of extra corporeal circulation. This agreed with the question where 79% (229) of respondents stated 
they never used microfilters. This may be due to Inexperience with cardiopulmonary bypass although all 
teaching hospitals visited performed operations requiring bypass and proportionally those who stated 
they wouldn't use MABF's present in equal numbers were in all three age experience groups. 
Thus the survey appears to Indicate the correct non-use of microfilters may be based as much on 
ignorance as definitive knowledge. 
CHAPTER SIX 
PLATELET USAGE 
* Platelet Elevation by Transfusion 
* Pre-operative Acceptable Levels 
* Platelet Inhibiting Drugs 
* Platelet Replacement during Operation 
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PLATELET KNOWLEDGE 
Survey Question 
On average in patients with thrombocytopoenia how much would you expect six units of random 




d) Don't know 
Platelet Raise Count 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
24 28 11 10 
60 78 22 3 11 
90 4 4 1 
Not know 42 28 17 32 4 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
24 34 18 29 26 2 7 
60 91 48 58 51 11 38 
90 6 3 3 3 2 7 








Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
2 
6 2 4 2 64 19 
11 6 15 13 160 48 
1 1 11 3 
8 30 5 39 8 29 8 33 93 28 
3 








24 60 90 NOT KNOW 
-All Areas 
Note that 48% (160) of respondents answered that the platelet 
count would be raised 60,000. 28% (93) of respondents did not 
know the answer. 
87 Platelet Usage 
DISCUSSION- PLATELET KNOWLEDGE 
Platelet Donation 
Platelets rapidly lose their viability in stored blood. Baldini et al (1960) estimated the platelet viability 
index to be 60% of normal after 3 hours of storage. After 24 and 48 hours the indices were only 12% and 
2% of normal respectively. 
Platelets may be harvested from a single donor by plateletpharesis either at random or selected on a 
HLA compatibility basis. They may also be separated from whole blood with pooling of cells from 
multiple donors to achieve a therapeutic dose (random single units). 
The number of platelets from a single donor plateletpharesis is equal to 5 or 8 random single donations. 
It has potential advantages for the recipient over the multiple donor product because of less exposure to 
infectious agents and a decreased likelihood of alia-immunisation. It is, however, more expensive 
(Western Province Blood Transfusion Service charges 1989, R511 for single donor compared with R396 
for 6 random units). Plateletpharesis also requires highly trained personnel, sophisticated equipment, 
and a greater donor commitment. The storage time for single donor platelets depends on the methods 
used for harvesting but, in some cases, the product must be used within 24 hours. HLA matched single 
donor products are the most effective therapy for patients who have become refractory to unselected 
single donor or multiple donor platelets. An HLA matched sibling should not be used as a donor if that 
sibling may later serve as a donor for some marrow transplantation. Multiple donor concentrates have 
the advantages of being cheaper, more readily available as they are derived from conventional whole 
blood donations and they can be stored for up to 5 days at 20-24°C. 
Platelet Transfusions: 
It is difficult to predict the ability of a platelet transfusion to increase the patient's platelet count because 
of many variables. Given the ideal situation of a healthy, unmedicated donor and recipient who has not 
received previous platelet transfusions, an increase of 5 000 to 1 0 000 platelets per mm3 for each unit of 
platelet concentrate infusion is to be expected (Barrer & Ellison 1977). The common practice is to 
transfuse one unit per 1 Okg body weight of multiple donor platelets or the concentrate from one 
platelet-pharesis donor. Where platelets are transfused for a bleeding episode, larger doses are 
recommended (Tomasulo, 1981). Cote et al (1985) suggest that 0,3 units of platelets per Kg in 
paediatrics should be the initial dosage. 
The donor platelets will circulate for ± 8 days in contrast to a normal platelet lifespan of 9 to 11 days. 
Efficacy is better in those platelets which have been stored less than 24 hours (Rapaport, 1987). 
Moreover as they are stored at room temperature the risk of contamination increases as the storage 
interval increases. A standard 170 micrometer filter is recommended for transfusion, . filters of smaller 
pore size are not indicated (Consensus Conference 1987). 
If platelet transfusion is considered necessary the operative procedure should be carried out within 
twelve hours (Grindon et al, 1985). 
CONCLUSION 
Only 48% of respondents knew the correct answer for how much six random units would raise the 
platelet count. The fact that 28% did not know the answer shows a lack of knowledge about a product 
which is possibly over used in the peri-operative period. These 93 who did not know included 14 (48%) 
of those In practice more than 20 years; 23 (20%) between 6 and 20 years and 55 (29%) in practice less 
than 6 years implying the lack of knowledge was widespread. 
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PLATELETS PRE-OPERATIVE ACCEPTABLE LEVELS 
Survey Question: 
For a non-emergency case what Is the minimum level of platelets you would consider to be 
adequate for elective surgery? 
a) No minimal requirement 
b) More than 50,000 
c) More than 75,000 
d) More than 100,000 
e) More than 150,000 
RESULTS 
Platelet Minimum Pre-op 
Answer W.Cape Natal NTvl STvl 
No % No % No No No 
N/A 
Nil 2 4 
>50 41 19 3 8 
>75 54 11 8 
>100 46 19 8 
>150 11 2 
Spoilt 
OFS Pretoria Medunsa JHB 
% No % No % No 
8 3 9 
5 6 
13 4 9 
5 4 
Baragwanath 


























No % No % No % 
'II Returns 
100 
3 2 2 2 3 
······························--·-
80 
62 33 37 33 4 14 
44 23 35 31 10 35 
68 36 29 25 12 41 60 






Note that 57% (95) of respondents would consider levels of 75,000 or more to be an 
adequate pre-operative platelet number. 33% (109) would require more than 100,000 
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Survey Question 
For which of the following circumstances would you require that platelets are available 
pre-operatively? 
Platelet count less than ................................................................................................................... . 
RESULTS 
Platelet Count 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total 
No % No % No No No % No % No % No % No % 
N/A 49 
10 2 4 
20 5 4 2 13 
25 2 3 
30 5 2 11 
40 4 2 1 1 2 12 
50 60 23 7 15 3 12 9 131 
60 2 2 
70 5 6 
75 32 3 4 2 2 3 3 49 
80 5 1 2 2 10 
100 13 3 4 4 2 4 2 32 
150 . 2 1 4 
Spoilt 4 
Answer 1-5 6-20 >20 
















3 2 1 
'Yo RETURNS 
100 
9 6 4 4 
3 2 
5 3 4 4 2 9 80 
6 4 5 5 4 
71 44 46 43 14 61 
2 1 60 
4 3 2 2 
27 17 17 16 5 22 131 
4 3 6 6 40 
20 12 12 11 
1 3 3 
20 
0 
N/A 10 20 25 30 40 50 60 70 
-All Areas 
Note that 61% (204) of respondents accept a level of 50,000 platelets or less. A further 
20% (57) accept a level between 50 and 75,000; 34% (49) of respondents did not answer 
this question. 
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Platelets- Physiology 
Platelets are formed in the bone marrow and are present in the blood in numbers of 240 000 ± 100 
OOOjmm3 in healthy subjects. They have a discoid form and contain cytoplasmic granules the contents 
of which include Adenosine Di-Phosphate (ADP), Platelet Factor 4 (PF4), serotonin, catechols and 
substances which modify vascular permeability and integrity (Marcus 1969). 
Platelets are activated by exposure to a suitable stimulus, usually contact with sub-endothelial basement 
membrane following vessel damage (Barrer & Ellison 1977). The platelet changes shape to become a 
spiney sphere which sticks to the damaged basement membrane and initiates aggregation with other 
platelets. This primary aggregation is a reversible process which is probably started by low levels of ADP 
release during the initial injury to the vessel. Calcium and fibrinogen must also be present for 
aggregation to occur. 
This primary phase of platelet activation culminates with the "release reaction" wherein the contents of 
their cytoplasmic granules are released extracellularly. If the stimulus is strong enough to cause a 
release reaction in many platelets large quantities of ADP are released causing a self-sustaining 
aggregation. This is termed· secondary aggregation. If the stimulus is weak and only a few platelets 
release ADP, the remaining platelets resume their normal shape and return to the circulation. 
Platelets not only form a plug initiating haemostasis they also participate in several steps in the 
coagulation cascade (Fig. 6:1). Platelet Factor 3 (PF3) is essential for activation of Factor X by the 
complex Factor JXA, VIII and calcium ion and for the conversion of prothrombin to thrombin by the 
complex of Factor XA, V and calcium ions. PF3 is a property of the lipoprotein in. the membrane of the 
platelets. PF4 is released from the platelet granular sites. 
The final step of clot retraction is due to a contraction of actin and myosin myofilaments found in the 
platelets. 
FIGURE 6.1 
Intrinsic Clotting System 
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Pre-Operative Platelet Transfusions: 
In assessing the need for platelet transfusion various factors need to be taken into account. 
1) Cause of the thrombocvtopaenia: 
Patients with increased platelet destruction due to splenomegaly who are about to undergo 
splenectomy are not usually given platelet transfusions prior to the spleen's removal because of 
the extremely short platelet lifespan. With the removal of the spleen the platelet count usually 
rapidly spontaneously reverts towards normal levels. Patients with idiopathic thrombocytopenic 
purpura, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura or 
haemolytic uraemic syndromes in general also do not respond to platelets. In addition, platelets 
may be harmful because of the risk of platelet antibody formation or transmission of disease 
(Grindon et al1985). 
2) The platelet count pre-operatively: 
If thrombocytopaenia is the sole abnormality a platelet count of 50 OOOmm3 or higher is unlikely to 
benefit from platelet transfusion (Consensus Conference 1987). Levels as low as 20 000 or even 
less have been accepted before the need for prophylactic platelet transfusion is undertaken. 
Whilst it is impossible to fix an absolute minimal platelet count below which the risk of 
haemorrhage contraindicates surgical procedures, a range of 55 000 to 75 000 is generally 
accepted (Miller et al 1971; Wilson et al, 1971). Thus the 41% (135) respondents who require 
pre-operative platelet counts of 100,000 or above would, if they adhered to this policy, be giving 
their patients platelets needlessly. Of those respondents who answered the question as to what 
figure they would use for the lower acceptable platelet level 81% (261) answered 75,000 or less 
with 61% (204) accepting 50,000 or less. Inexperience may be a factor in the knowledge of 
normal safe peri-operative platelet levels, as 34 of the 49 respondents who didn't answer the 
question had less than six years anaesthetic experience. 20 of the 32 who would require levels of 
more than 100,000 were also of less than six years experience. 
3) Concomitant Disease: 
Patients with advanced hepatic or renal insufficiency often have associated disorders of 
coagulation and platelet function. Platelet transfusion may be required pre-operatively to correct 
the bleeding time, although there appear to be no pertinent studies. 
4) Type of Operation: 
Controlled prospective studies have demonstrated no correlation between platelet counts and 
bleeding following cardiac pulmonary bypass (Uimas 1975, Haring et al1975) and no detectable 
benefit from prophylactic administration of platelets to such patients. Therefore, it seems there is 
no justification for prophylactic platelet administration in patients undergoing open heart surgery 
(Consensus Conference 1987). However, paediatric patients with cyanotic heart disease and 
polycythaemia often require platelets post bypass because of poorly functioning platelets, 
although the actual platelet count may be within normal limits. 
In neurosurgical procedures, where any haemorrhage into the CNS may be critical, prophylactic 
platelet transfusion to elevate a low platelet count may be justified (Consensus Conference 
1987). 
CONCLUSION 
It appears that between 20 to 40% of respondents take as their minimal pre-operative l~vel unacceptably 
high platelet counts. Although the majority of these were the least experienced anaesthetists (1-5 years 
experience) incorrect replies were also common amongst the other, more experienced, personnel. 
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Survey Question 
For which of the following circumstances do you require that platelets are available pre-operatively (not 
extra-corporeal operation)? • 
Platelet inhibiting drug 
RESULTS 
Platelet Inhibiting Drug 
Answer W.Cape Natal NTvl STvl OFS 
No % No % No No No 
N/A 
No 138 42 4 
Yes 13 9 1 
Spoilt 
Answer 1-5 6-20 >20 
No % No % No % 
N/A 
No 164 87 98 87 20 69 






Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
3 
24 10 24 22 282 86 













Note that 86% (282) of respondents would not require platelets 
to be available pre-operatively. 
. \ 
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Drugs and platelet function: 
The anaesthetist should be aware that various drugs affect platelet function by a variety of mechanisms 
such as inhibiting the release reaction (aspirin) (Table 6.2). These effects may be irreversible and persist 
as long as the effective platelet cohort survives i.e. about one week. It must be remembered that many 
"over the counter (OTC) preparations contain aspirin and may be used on a regular basis by patients 
who do not consider they constitute a medication. Thus OTC's must always be asked about when 
eliciting a medication history from a patient. Analgesics which are presumably safe include paracetamol, 
codeine and other opiates, synthetic narcotics, propoxyphene and acetaminophen. To assess in vivo 
the platelet function a modification of Ivy's Bleeding Time should be used (Ivy et al, 1941; Harker & 
Slichter, 1972). This method consists of applying a sphygmomanometer to the arm and keeping it 
inflated to 40mm of mercury. Duplicate, template, standardised incisions are made 1 mm depth and 
9mm long in previously cleaned volar skin of the forearm. The time required for cessation of bleeding is 
then measured by careful blotting -with filter paper every 30 seconds without disturbing the clot. The 
normal bleeding time in patients with a mean platelet count of 250,000 ± 40,000· platelets per microlitre 
was 4,5 ± 1,5 minutes (Harker & Slichter, 1972). This same method could be used during surgery, if 
microvascular bleeding appears to be a problem, to assess the need for platelet transfusion. As most 
patients undergoing surgery are hypothermic and as cooling decreases platelet aggregation, a normal 
bleeding time in a patient under anaesthesia would indicate there is no reason for a platelet transfusion. 
With the recent popularity of regular low dose aspirin in many adult males to try and diminish the risk of a 
myocardial infarction, many patients are presenting themselves for operations whilst on a platelet 
inhibiting drug. Unfortunately they may not have been informed to stop their medication a week prior to 
the operation. 
CONCLUSION 
The majority (86%) of respondents stated they would not require platelets to be available for patients 
who are on a platelet inhibiting drug. This corresponds with common clinical practice as many patients 
may be on such drugs when presenting for surgery. The anaesthetist, however, must have a high index 
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PLATELET REPLACEMENT DURING OPERATION 
Survey Question 
For which of the following circumstances do you require that platelets are available pre-operatively 
(not extra-corporeal operation)? 
One estimated blood volume replacement D 
RESULTS 
Platelet One Volume 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 
No % No % No No No % No % No % No % No % 
4 
94 61 39 74 2 24 92 19 70 8 73 18 64 19 76 232 68 
57 12 3 2 8 5 3 10 6 102 31 
Spoilt 4 
Answer 1-5 6-20 
No % No % No 
N/A 
No 125 67 73 65 25 
















Note that 31% (102) of respondents would require platelets to 
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Survey Question: 
For which of the following circumstances do you require that platelets are available pre-operatively 
(not extra-corporeal operation)? 
Procedure usually associated with large blood loss D 
RESULTS 
Platelet Large Loss 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 
No % No % No No No % No % No % No % No % 
4 
114 75 32 60 5 16 2 23 9 82 15 19 76 234 71 




Answer 1-5 6-20 >20 
%RETURNS 
No % No % No % 
100 
N/A 
No 145 78 71 63 19 66 
80 








Note that 71% (234) of respondents would not have platelets 
available if the procedure was expected to be associated with a 
large blood loss. 
• 
98 Platelet Usage 
Intra and post-operative platelet transfusion: 
Following one blood volume replacement 35-40% of platelets usually remain and the majority of patients 
who have received rapid replacement of 1-2 blood volumes do not develop microvascular bleeding as a 
result of thrombocytopaenia. Thus a plan regarding platelet use must be formulated prior to an elective 
surgical procedure which may involve massive blood loss based on actual platelet numbers and 
functions. Cote et al (1985) reported that most paediatric patients who started with a high platelet count 
may not require exogenous platelet transfusion until two or more blood volumes have been lost. 
However, the patient who started with a low platelet count (less than 150,000/mm3) may require platelets 
after only one blood volume transfusion. Thus a pre-operative platelet count is extremely important. 
They also suggested that prophylactic platelet transfusions should only be considered when the platelet 
count had decreased to less than 1 00,000 and considerably more bleeding is anticipated. The present 
survey showed 31% {1 02) of respondents appeared to be unaware that adequate number of platelets still 
remained after one blood volume exchange transfusion. 62 had less than six years anaesthetic 
experience but 37 had more than six years and 3 had more than 20 years experiences. Similarly 41% 
(91) would have platelets available for a large blood loss. This latter question must be criticised as being 
poorly worded as there are differing definitions of a large blood loss. Thus a two whole blood volume 
loss where platelets may well be required could fall into the definition of a large blood loss. This specific 
question will, therefore, not be analysed further. 
A standard 170p. filter is adequate for platelet transfusion. Microfilters should be used during blood 
transfusion only if the initial platelet count is low. Lim et al (1989) demonstrated a significant fall in 
platelet levels in leukaemia patients given blood transfusions via the standard 170p. filter compared to a 
40p. filter. This was postulated to be due to microemboli in the transfused blood causing aggregation of 
the recipient's platelets. They strongly recommended that microfilters be used routinely in 
thrombocytopaenic patients receiving blood transfusions. 
If abnormal bleeding occurs with a platelet count of more than 50,000/mm3, other causes of bleeding 
such as mechanical causes, disseminated intravascular coagulopathy or dilution of clotting factors 
should be sought (Cote et al, 1985). This is in agreement with the Consensus Opinion on Platelet 
Therapy (1987) which stated that platelet transfusion should not be administered in the absence of both 
documented thrombocytopaenia and clinically abnormal bleeding. 
Adjuvant Therapy 
In uraemia bleeding due to poor platelet function responds, in the majority of cases, to treatment with 
cryoprecipitate or 1-desamino-8-d-arginine vasopressin (DDAVP) and platelet transfusions may be 
avoided (Consensus Conference 1987). DDAVP has also been found to shorten the bleeding time in 
cirrhotic patients (Richardson & Robinson, 1985). 
PLATELETS CONCLUSION 
The correct usage of platelets was indicated by approximately 60-70% of respondents with the majority 
of those who didn't know or answered incorrectly having less than six years anaesthetic experience. 
However, there was a generalised tendency, independent of experience, amongst 30% of respondents to 
transfuse for one blood volume replacement. This is an overusage of an expensive component which 
carries a high risk of infection transmission. 
CHAPTER SEVEN 
FRESH FROZEN PLASMA 
* Usage as a Colloid 
* Usage with Blood Replacement 
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F.F.P. USAGE AS A COLLOID 
Survev Question 
Under what circumstances do you administer FFP? 
As a colloid volume substitute when red blood cells are not 
required 
RESULTS 
FFP as a Colloid 
D 
Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total. 
No % No % 
142 92 42 78 
12 8 12 22 
No No No % No % 
4 . 18 69 22 82 
8 31 5 18 
No % No % No % 
12 92 22 N 23 % 















No % No % No % 
169 89 95 83 22 76 
20 11 19 17 43 40 
PERCENTAGE BY AGE GROUP 
166 
<6 <20 >20 
-NOT USE -USE 
Note that there was no difference, proportionately, 
between the different age groups experience-wise and 
their use of FFP as a colloid. 
FFP 










Note that 14% (46) of respondents would use FFP as a colloid. 
100 Fresh Frozen Plasma 
Survey Question 
What colloid volume substitute do you use if blood is not required? 















No % No % 
166 88 98 86 


















Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
i 
23 10 . 21 22 286 86 











Note that 14% (46) of respondents do use FFP as colloid 
volume substitute for blood replacement. 
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DISCUSSION 
One unit of Fresh Frozen Plasma carries the same risk of disease transmission, and anaphylaxis as one 
unit of whole blood. Thus as safe and cheaper synthetic colloidal solutions are available the Consensus 
Conference on Fresh Frozen Plasma (1985) concluded there is no justification for the use of FFP as a 
volume expander. 
CONCLUSION 
The replies t6'both questions were consistent with 86% of anaesthetists surveyed stating they would not 
use FFP as a colloidal blood substitute. However, a disturbing 14% (46) would. These few were evenly 
distributed throughout the areas in all the two younger age groups. However there was a higher 
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FFP AND BLOOD REPLACEMENT 
Survey Question 
Under what circumstances do you administer Fresh Frozen Plasma (FFP)? 
Blood replacement is between 25-50% estimated blood volume 
RESULTS 
FFP 25-50% 
Answer w.cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 
No % No % No No 
97 63 44 82 5 
57 37 10 18 
No % No 
20 77 21 




No · % No % 
9 692279 












No % No % 
129 68 88 77 
















Note that 29% (95) of respondents would transfuse FFP when 
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Survey Question 
Under what circumstances do you administer FFP 
Blood replacement is between 50-100% estimated blood volume 
RESULTS 
FFP SG-100% 
Answer W.Cape Natal 
No X No X 
79 51 42 78 
75 49 12 22 
Answer 1-5 6-20 
No No 
105 56 67 59 











OFS Pretoria Medunsa JHB Baragwanath Total 













54 12 43 













Note that 44% (145) of respondents would transfuse FFP with a 
50-100% blood volume loss. 
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FRESH FROZEN PLASMA AND DRIED PLASMA 
Fresh frozen plasma is separated from whole blood within six hours of donation. It is frozen at 18-30°C 
and remains a viable product for up to one year. Dry plasma is separated from whole blood usually 
when the blood is time expired (Opperman 1981). All stable clotting Factors (1, II, VII, IX, X, XII and XIII) 
are represented equally in dried plasma and FFP. However the levels of labile Factors XI, V and XIII are 
far less in dried plasma. Twenty-four hours after thawing units of FFP, levels of Factor V and VIII may still 
average 76% and 67% or higher respectively (Milam et al 1980). Recommended levels of the various 
Factors required for haemostasis have been considered to be between 10% and 50% (Hondow et al 
1982, Smith & Bibwell 1979). 
It must be remembered that FFP is a hyperosmolar, hypernatraemic, hyperglycaemic, 
hyperphosphataemic and normokalaemic solution (Fig. 7.1 ). These abnormal characteristics may be 
important if large volumes of FFP are transfused. 
Figure 7.1 (Cochlan, 1985) 
Mean Normal (Physiological) 
Constituents Values Range) 
pH 7,067 7,38-7,42 
Sodium (mmol/1) 167,5 135-145 
Potassium (mmol/1) 4,0 3,5-5,0 
Chloride 76,0 95-105 
Glucose (mmol/1) 17,1 3,9-6,0 
Osmolality (mOsmjKg) 320,4 280-300 
Inorganic phosphate (mmol/1) 3,08 98-1,4 
APPROPRIATE USES OF FFP 
Uses recommended by the Consensus Report on FFP (1 985) include: 
a) Replacement of isolated Factor deficiencies 
b) Reversal of Warfarin effect 
c) Treatment of anti-thrombin-3 deficiency 
d) Treatment of specific immunodeficiencies 
e) Treatment of thrombotic thrombocytopaenic purpura. 
Use of FFP with blood transfusions 
There are various unreferenced statements advocating pre-established regimes for FFP transfusion 
(Wilson et al1971, Howland 1981, Gillet al1975). Commonly suggested FFP infusion rates include 1 
unit FFP for every 2 units of ABC/albumin mixture to 1 unit FFP for every 6 units ABC. • 
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In a prospective study of 25 patients with haemorrhagic shock Hehne et al (1979), showed a temporary 
improvement in Factors I, II, V and VII was achieved with at least 800ml of FFP per hour per 70 kg. body 
weight. (Range 800-2 OOOmls in 90-120 minutes). FFP was transfused only after the initial conventional 
therapy for shock had failed to control the bleeding. Although the effect was temporary the authors 
believed it to have been sufficient to restore haemostasis. Slower rates of FFP infusion or less FFP were 
found to be ineffective. This is one of the few reports to show efficacy for FFP in massive blood 
transfusions . 
. Mannuci et al (1982} compared sixty-six massively transfused patients who received 1 unit FFP to every 
3 units whole blood or ABC to sixty-four massively transfused patients who received only whole blood or 
ABC tran.sfusions. There were no significant differences between the two groups in coagulation profiles 
(except PTT, and plasma fibrinogen levels were more often abnormal in the FFP group!). There was also 
no difference In whole blood or ABC requirements between the two groups. Another groups of 42 
patients who received 3 units of platelet concentrations and 2 FFPs for every 1 0 units whole blood or 
ABC had no significant difference in coagulation profile or transfusion requirements when compared with 
those only receiving whole blood or ABC. The authors concluded that "Indiscriminate administration of 
components based on pre-established routine schedules was unjustified". · 
Harke & Rahman (1980) concluded that "even after substitution of more than 24 units with a mean age 
of 9 days, relevant haemostatic changes were not observed when transfusion was performed 
immediately" Miller et al (1971) infused 500-1 ,OOOml volumes of fresh frozen plasma but no platelets into 
combat casualties who were bleeding after receiving more than 20 units of blood. They demonstrated 
return to normal of the activated partial thromboplastin and prothrombin times without correction of the 
bleeding disorders. Subsequent administration of fresh blood which contained viable platelets resulted 
in correction of these bleeding disorders. Baunsteln & Oberman (1984) in a well referenced review 
concluded that there is insufficient agreement to permit specific criteria of FFP transfusions even in 
patients with coagulopathies secondary to massive transfusions. The transfusion of FFP to patients 
recovering up to 15 units of whole blood or ABC or frozen deglycerolized ABC Is probably unnecessary. 
The poor correlation between the quantity of stored blood transfused and associated coagulopathy may 
be due, in part, to the presence of stable and labile factors In stored whole blood. Factors I, II, VII, IX, X, 
XII and XIII are stable during storage. There are conflicting statements regarding Factor XI. Urbaniak & 
Cash (1977) and Counts et al (1979) consider Factor XI to be stable. Heustis et al (1981) consider 
Factor XI to have a half-life of 3 to 4 days in stored blood. A factor level of approximately 30% Is 
necessary for haemostasis (Urbaniak & Cash, 1977; Smith & Bidwell, 1979). 
Factor V has a reported storage half-life ranging from 3-5 days (Urbaniak & cash, 1977) to 10 to 16 days 
(Counts et al, 1979; Heustls et al, 1981). The level of Factor V in 21 day old blood may be 30% or 
more. The level required for haemostasis is between 10-15% (Urbaniak & Cash, 1977) and 50% 
(Hondow et al, 1982; Smith & Bidwell, 1979). 
Thus stored blood contributes significantly to the coagulation factor pool especially if they are less than 
10 days old (Hondow et al, 1982). De novo synthesis and internal reserves of coagulation factors also 
help maintain haemostasis in traumatlsed patients (Harker et al, 1980) and diminishes the need for 
Fresh Frozen Plasma. 
FFP and Open Heart Surgerv: 
Milam et al (1981) studied 75 patients who underwent open heart surgery but were not transfused. 
They found that levels of coagulation factors V, VII and fibrinogen fell 30, 40 and 37 percent respectively. 
However, none of the patients had abnormal bleeding or required replacement therapy. Ulmras and 
Sakhuja (1975) transfused only frozen deglycerolised RBCs and no plasma during and after 
cardiopulmonary bypass. They found no clinical difference in laboratory results and intra-operative or 
post-operative bleeding when compared with a control group who used whole blood. Several studies 
suggest that platelet deficiencies rather than coagulation abnormalities may be responsible for abnormal 
post-operative bleeding after cardiopulmonary bypass (Harker et al, 1980; Moriau et al, 1977). Snyder 
·et al (1986) suggest mild to moderate abnormalities of coagulation factors following bypass surgery can 
be tolerated and FFP transfusions "can be withheld". 
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Coagulation Coaqulopathy 
This complication may occur in 5-30% of traumatised patients (Counts et al 1979, Mannuci 1982, 
Sherman 1982, String et al1971) with a mortality as high as 80%. Its development relates closely to the 
location, extent of trauma, duration of oligaemic shock and underlying liver disease. Whilst FFP would 
appear to be a logical therapy for the replacement of coagulation factors, the efficacy of FFP in such 
patients is questionable and its specific indications remain unclear (Baunstein & Oberman 1984). 
De novo synthesis and internal reserves of coagulation factors contribute to the variability in coagulation 
factor levels associated with massive transfusions and thus the difficulties in recommending a set regime 
for FFP usuage. 
CONCLUSION 
The indiscriminate· use of FFP in so-called dilutional coagulopathy without documented significant 
coagulation factor deficiencies is not recommended by the majority of authors for transfusions of up to 
15 units of whole blood. Beyond this replacement volume the data is contradictory (Mannuci et al1980; 
Harke & Rahman 1980, Counts et al 1979 and Baunstein & Oberman 1984). The Consensus 
Conference on FFFP (1985) was of the opinion that pathological haemorrhage in patients receiving 
massive transfusions (more than 1 blood volume replacement within several hours) wa's caused more 
frequently by thrombocytopaenia than by depletion of coagulation factors. 
The majority of South African anaesthetists in the survey responded correctly that FFP should not be 
used even where 50-100% of blood volume has been lost. However, 29% {85) and 44% (145) replied that 
they do give FFP where blood loss is between 25-50% and 50-1 00% respectively. This indicates an 
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FFP AND CLOTTING STUDIES 
Survey Question 
Under what circumstances do you administer FFP? 






No % No % 
117 76 27 so 
37 24 27 so 
1·5 6·20 
No % No % 
140 74 64 56 
49 26 so 44 











OFS Pretoria Medunsa JHB Baragwanath Total 
No % No % 
15 58 16 59 







No % No % 
10 n 19 68 














Note that 68% (225) of respondents would not use abnormal 
clotting as an indication for FFP. 
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DISCUSSION 
Although abnormal clotting studies are frequent after operations such as open-heart surgery these may 
not be significant and correlate poorly with required replacement therapy (Milan et al, 1981; Ramsey et 
al, 1983). Counts et al (1979) and Wilson et al (1971) reported on two prospective studies of 
massively transfused patients. They found that the PT (prothrombin time) and PTI (Partial 
thromboplastin time) had poor sensitivites (40-63%) and poor positive predictive values (47-67%) as 
800ml of FFP per hour per 70Kg body weight In 25 patients with haemorrhaglc shock, who continued to 
bleed despite conventional therapy, caused a temporary and transient improvement in clotting factors 
which was clinically significant. 
Thus, abnormal clotting profiles may not be as important in determining the need for FFP during 
operation and in the immediate post-operative period as it is in the pre-operative period. 
CONCLUSION 
Although PT and PTI are not a sensitive predictor for the need for FFP they are in practice often the only 
automated ones rapidly available. So they should be used in the face of continued bleeding where FFP 
may be considered necessary. 32% of respondents indicate this Is what they do. However it Is 
important to know how much FFP to transfuse and also whether or not cryoprecipitate has been 
removed by the blood bank. The policy of removing cryoprecipitate, high in Factor VIIIC, VIII:VWF, and 
fibrinogen, is standard practice by the W.P.B.T.S. for all units of FFP. This means the dose of FFP plus 





* Dried Plasma 
* Albumin 
* Dextran 70 and 40 
* Haemaccel 
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COLLOIDS : GENERAL DISCUSSION 
The two main reasons for giving a colloid suspension are to increase t-he colloidal osmotic pressure and 
to decrease the viscosity and, therefore, improve that rheology of the circulation. 
There are three body compartments: the Intravascular space, the interstitial space and the intracellular 
space. One of the main theoretical advantages for colloid infusion is that the majority of the colloid is 
retained in the intravenous space. The relative volumes of the three compartments in an adult male are 
shown below: 
EXTRACELLULAR SPACE 191 
Intravascular Interstitial Intracellular 
Space Space Space 
51 141 231 
INTRAVASCULAR SPACE 
Measurement 
Most measurements and methods of assessing fluid status relate to the intravascular space, namely 
pulse, blood pressure, CVP, cardiac output, left and right atrial pressures, urine output and peripheral 
and central temperature differences. 
INTERSTITIAL SPACE AND INTRACELLULAR SPACE 
Measurement 
These are usually measured using isotope dilution techniques which are labourious, time consuming and 
need steady state conditions. Practical measurement in a clinical setting is difficult. Tissue turgor plus a 
chest x-ray may give some objective indication if the interstitial space is over-hydrated. 
The intravascular compartment and interstitial space together comprise the extracellular space. They are 
in equilibrium but with different compositions and functions. 
Effect of Intravenous Infusions 
Water from dextrose solutions is rapidly distributed to each of the three compartments and because the 
intracellular space is the largest, dextrose solutions will predominantly be distributed there. Isotonic 
saline solutions such as as plasmalyte B and Ringer's lactate also rapidly distribute in the extracellular 
space in a ratio of about 1 to 3 with the larger portion going into the interstitial space. This proportion is 
even greater in hypotensive patients (Shizgal et al 1977, VIrtue et al 1966). One hour after Infusion, 
only 8% of the Ringer's lactate given remained in the circulation, whilst 73% was found in the 
extravascular compartment. After 4 hours Ringer's lactate gave no plasma volume expansion but 67% 
was still in the extravascular space (Dawidzon et al 19808). Colloids, however, remain In the 
intravascular space because of their oncotic pressure. After 1 hour Dawidzon reported 40-63% 
(Dawidzon et al 19808) of colloid remained in the circulation with 12-44% in the extravascular space. 
After 4 hours most colloids still gave considerable plasma volume expansion. If the colloid used has a 
higher osmotic pressure than plasma (e.g. 20% albumin or high molecular weight dextrans) Interstitial 
fluid will move into the intravascular space expanding the plasma volume by more than the original 
volume of colloid transfused. This type of fluid Is called a plasma expander (Twlgley & Hillman 1985). 
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Survey Question 
What colloid volume substitute do you usually use if red blood cells are not required? . . 
Stablised Human Serum 
RESULTS 
Colloid SHS 
Answer W.Cape Natal NTvl STvl 
No % No % No No 
Spoilt 
No 68 53 5 
Yes 86 1 
Answer 1-5 6-20 >20 
No % No % No % 
Spoilt 
No 147 78 76 67 22 76 




Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
. 1 













Note that results are only shown for the Western Cape as SHS 
is only available in this area. 56% (86) of respondents do use 
SHS as a colloid for blood replacement. 
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Stabilised human serum. SHS is presented In 250ml solutions containing 50g of total protein. It contains 
immunoglobulins, IGG (7,5g per litre), IGA (1,65g per litre), IGM (1,25g per litre), sodium 120-140mmoljl, 
potassium 3-4mmol/l, calcium 1-1,15mmoljl, also alpha antitrypsin, haptoglobins, and alpha 2 
macroglobins. This solution is expensive but free from the risk of hepatitis transmission. However there 
was a small risk of HIV transmission until recent changes in sterilisation of the solution make it 100% free 
of transmissable disease (personal communication Dr. A. Bird, Medical Director, Western Province Blood 
Transfusion Service). At normal capillary endothelium permeability infusion results in intravascular 
retention of only 80% of the amount initially infused (Messmer, 1987). 
Protein solutions such as SHS are not completely inert and might trigger mild adverse reactions as well 
as life threatening reactions (Ring et al1982, lsibister & Fisher, 1980). , 
Messmer (1987) recommends that natural protein solutions, because they are in short supply and very 
expensive, should not be used for volume replacement. They should be reserved for patients with 
hypovolaemia in association with significant hypoproteinaemia (plasma protein content <5gj100ml). 
SHS also has a role in certain immunodeficiency diseases and for rapid reversal of warfarin or 
suxamethonium where clinically indicated. 
CONCLUSION 
A disturbingly high 56% of respondents in the Western Cape, where SHS is available, use SHS as a 
colloid for replacement of blood loss, when cheaper synthetic colloids are readily available. 
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DISCUSSION 
Once reconstituted (with saline) a bottle of dried plasma carries the same risk of disease transmission as 
one unit of whole blood. Because of its expense, and danger of infection transmission and anaphylaxis, 
and as other safer synthetic colloids are available, the use of dried plasma should be restricted to 
specific indications for replacement of coagulation factors. 
A disturbingly high number of respondents (54) replied they would use dried plasma as a colloid. 
Twenty-five of the 54 were in one specific area (Southern Transvaal). This implies the indication for dried 
plasma transfusions in this area requires to be re-examined. The 54 respondents were evenly divided 
between those anaesthetists with less than 6 years experience and those with between 6 and 20 years. 
There was, however, proportionately larger numbers of those with more than 20 years experience who 
would use dried plasma as a colloid substitute. 
Survey:Question 




Answer W.Cape Natal NTvl STvl OFS Pretoria Medunsa JHB Baragwanath Total % 












Answer 1-5 6-20 >20 
No % No % No % 
Spoilt 
No 170 90 99 87 24 83 












Note that 12% (39) of respondents do use albumin as a colloid 
for blood replacement. 
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DISCUSSION 
Albumin. Albumin is expensive to produce but has a long shelf life a lower sodium than fresh frozen 
plasma and is free of transmissable diseases. The usual concentration is 5% although 20% 
concentrations are available. It is readily metabolised by the liver - particularly in the metabolically 
depleted patient and rarely stays in the circulation for more than 24-48 hours (Schultz & Heremans, 
1966) although its theoretical half-life is 5-10 days. 5% albumin's osmotic pressure is the same as whole 
blood, but the 20% solution is hyperosmolar and so will cause some reduction of the extravascular 
(mainly intracellular) compartments by mobilising fluid into the intravascular space. Albumin solutions 
contain bradykinins and carry a small risk of an allergic reaction. 
The recommended usage for albumin is primarily for hypoalbuminaemic shocked states and protein-
losing enteropathy. Thus it is not indicated for the substitution of red blood cells as the majority, 88% of 
respondents, correctly indicated. The fact that 23 out of 26 at one institution (OFS) replied that they 
would use albumin indicated that that specific Department should look critically at its colloid transfusion 
guidelines. 
CONCLUSION 
88% of South African anaesthetists surveyed indicated they do not abuse albumin by utilising it as a red 
blood cell substitute. 
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Survey Question 
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Note that 96% (320) of respondents do not use Dextran 70 
as a colloid for blood replacement. 
OFS 
Yes 
Pretoria Medunsa JHB Baragwanath Total % 
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Pretoria Medunsa JHB Baragwanath Total % 
No % No % No % No % 
27 13 28 22 326 98 











Note that 98% (326) of respondents do not use Dextran 40 as a 
colloid for blood replacement. 
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DISCUSSION 
Dextrans are produced by the action of the bacterium leuconostoc mesenteroides on sucrose. The 
dextran molecule is a polysaccaride composed of glucose of varying chain lengths and the solution is · 
classified according to molecular weight.' High molecular weight dextran 150 and 11 o are no longer 
available because they were found to cause an unacceptable increase in plasma viscosity and 
aggregation of red blood cells. 
The two commonly used dextrans are Dextran 70 and Dextran 40. Dextran 70 has an average molecular 
weight of 70 000, but does contain some molecules smaller and others larger than this mean weight. It is 
prepared as a 6% solution in isotonic saline and has a colloidal osmotic pressure greater _than that of 
normal plasma. Consequently a 500ml infusion can be expected to increase the plasma volume by 
some 750ml. 
Dextran 40 has an average molecular weight of 40 000, the majority being excreted by the kidneys within 
six hours. Because of its smaller molecular size and the fact that it is made up of a 10% solution, Dextran 
40 will have a greater osmotic effect than Dextran 70. A 500ml infusion will Increase the plasma volume 
by ± 1,500ml. An infusion of Dextran 40 will decrease the aggregation of red blood cells by both its 
haemodiluting effect and by increasing the negative red cell charge. Intact intima is also negatively 
charged whilst damaged intima or exposed media is positively charged. It is thought that dextrans may 
form a monomolecular film over the site of damage and restore the continuity of the negative charge. 
Dextrans may also increase the negative platelet charge and so decrease platelet stickiness. Thus both 
Dextran 40 and 70 have antithrombotic effects .. 
The kidneys can excrete up to 5g of dextran per day, so the dextrans may stay in the circulation for a 
number of days depending on their molecular size. Fifty percent of Dextran 40 will be excreted within 3 
hours compared with 30% of Dextran 70 in 6 hours. This results in an effective half-life of approximately 
2 hours for Dextran 40 and 6-8 hours for Dextran 70. 
Adverse effects of Dextrans 
1. Haemostasis problems. The decrease in platelet stickiness which occurs with Dextrans is one 
mechanism interfering with haemostasis. Dextrans also interfere with the normal action of Factors 
VIII, V, fibrinogen and prothrombin. Thus, excessive dextran infusions can create an artificial Von 
Willebrand's Disease (Marshall & Bird 1983). 
It is recommended that dextrans should be limited to a maximum dose of 1,5g per Kg per day or 
less than 1500ml in the average adult (Isbister & Fisher 1980). 
2. Interfering with cross-matching. 
This sometimes occurred with the high molecular weight dextrans and inexperienced 
haematotology technicians. It is recommended that blood for cross-matching be taken prior to 
dextran infusions. 
3. Allergic reactions. 
Reactions typically occur after patients have received only a very small amount of solution. In first 
time responders the antibodies have probably been produced in response to ingested dextrans or 
in response to genetically similar bacterial polysaccarides. Many normal patients have circulating 
anti-dextran antibodies but only very few react adversely to dextran infusions: Severe 
anaphylactic reactions occur in only about 0,008% of patients but there is a higher incidence of 
minor reactions compared to the other colloids (0,07%-1,1%) (Ring & Messmer 1977). As a 
consequence the use of monovalent hapten has been advocated to block the antigen combining. 
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sites of preformed circulating dextran reactive antibodies (Messmer et al, 1980; Ljunstrom et al, 
1988). Hapten has been used in Sweden since 1982 and has led to a reduction in the reports of 
severe reactions to dextran from 22 per 100,000 units used between 1975 and 1979 to 1 ,2 per 
100,000 units between 1983 and 1985. The number of fatal reactions decreased from 23 to one. 
More than 600,000 units of dextran were used during each period (Ljunstrom et al, 1988). 
Hapten, at the time of the survey (September, 1989), was unavailable in South Africa. 
4. Renal Damage 
When renal perfusion is reduced, Dextran 40 may form a plug blocking the renal tubules. In 
addition to this mechanical damage, osmotic damage due to back diffusion of dextran from the 
tubules may occur. Renal failure may be the end result (Feest 1976). 
CONCLUSION 
Dextran 40 and 70 are little used as a colloidal substitute for blood loss by the South African 
anaesthetists surveyed. This may be due to lack of availability or the fear of a dextran-induced 
anaphylactoid/anaphylactic reaction the incidence of which ranges from 0,07% to 1,1% in patients 
without shock or trauma (Hedin et al, 1981; Ring and Messmer, 1977; Messmer et al, 1980). T~e 
Dextran-induced antibodies arise in response to immunisation with bacterial polysaccharides and are 
widely distributed in the normal human population (Hedin et al, 1979). Thus, prior to Dextran infusion, 
the pre-injection of a high dose of monovalent hapten-dextran (dextran 1, Mw 1 ,000) to block the binding 
sites of the circulating antibodies has been recommended (Messmer et al, 1980; Ljungstrom et al, 
1988). Unfortunately at the time of the survey (1989) Hapten was not available in South Africa. 
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Survey Question ' 


















































Note that Haemaccel was used proportionately more 
by those anaesthetists who had more than 20 years 
anaesthetic experience. 
D 
OFS Pretoria Medunsa JHB Baragwanath Total % 
No % No % No %. No % No % 
8 2. 5 56 17 












Note that 83% (276) of respondents do use 
haemaccel as a colloid for blood replacement. 
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DISCUSSION 
Haemaccel. This is a synthetic polymer of urea and polypeptides derived from degraded gelatin 
produced by heat desaturation or chemical hydrolysis of starches. The modified fluid gelatin is then 
suspended in isotonic saline. The average molecular size is 35 000 but there is a wide range 
(5,000-50,000). The smaller molecules are distributed to the extra cellular space more readily and are 
excreted more rapidly by the kidney. The higher molecular weight fractions are retained in the 
intravascular compartment. 
The gelatins are eliminated mainly by the kidneys (85%) with some excretion in the faeces and a small 
amount metabolised in the body. However, they do not appear to accumulate In patients with renal 
failure (Kohler et al 1978). The half-life Is shorter than other colloids, being 3-4 hours, necessitating 
more frequent infusions in hypovolaemia (Isbister & Fisher 1980). 
As approximately 70% of the molecules are below the renal threshhold, this provokes a mild osmotic 
diuresis. However, unlike Dextran 40, no cases have been reported of osmotic tubular damage. 
Haemaccel also does not affect the coagulation and fibrinolytic systems or blood cross-matching 
procedures. 
Rapid infusion of Haemaccel may be associated with histamine release. Many people have circulating 
anti-gelatin antibodies which have probably been formed in response to food stuffs or in response to the 
breakdown of their own connective tissue. Patients who have damaged connective tissue, such as those 
with rheumatoid arthritis or degenerative arthropathies, are reported to have anti-gelatin antibodies more 
often and at higher levels than the rest of the population. These patients have also been reported to be 
more likely than others to show adverse reactions to gelatin infusions (Schoning & Koch 1975). Ring & 
Messmer (1977) calculated the incidence of severe reactions to gelatin solutions was 0,038%, which 
was higher than any other plasma substitute. However in 1979 a change in the manufacture of 
Haemaccel decreased the excess hexamethylene di-isocyanate, the agent used to cross link the 
peptides. This appears to have markedly reduced the histamine release seen with this agent. Weis 
(1983) reported on a prospective multicentre trial showing an adverse reaction rate of 0.78% in 1,147 
patients. In eight of these nine patients, the reaction was cutaneous only; in the ninth a slight fall in lung 
compliance was noted. It would thus appear that in this respect the present Haemaccel is superior to 
that used prior to 1979. Prevention of anaphylactoid reactions by H1 and H2 receptor anatagonists has 
been shown to have a prophylactic effect (Schoning et al, 1982). 
CONCLUSION 
From the literature it would thus appear that haemaccel is a safer colloid to use from the point of view of 
the risk of anaphylaxis compared to the Dextrans it also does not interfere with clotting parameters. The 
fact that it is the principle colloid used by the South African anaesthetists surveyed may Indicate ready 






The Survey revealed that there appears to be a tendency for over transfusion in the peri-operative period, 
this was shown by: ' 
1. Pre-operative Minimal Acceptable Haemoglobin Level 
The minimum pre-operative haemoglobin level (Question 3) is taken as 10gjdl by 60% of 
respondents. This implies that some asymptomatic patients, with a chronic anaemia, about to 
undergo elective minor surgery, may be transfused up to 1 Ogjdl to avoid postponement or 
cancellation of their operation by the anaesthetist. This was partly confirmed by Question 4c 
where 45% of respondents stated they would transfuse pre-operatively a 30 year old female with 
memorrhagia and a haemoglobin of 8,5gjdl, booked for a D & C. A haemoglobin of 8gjdl In an 
asymptomatic patient undergoing elective minor surgery does not increase the anaesthetic risk, 
although the effect of altitude has not been well researched. 
A more critical approach to anaemia needs to be taken by the anaesthetist. A minimal acceptable 
haemoglobin needs to be calculated for each patient pre-operatively to avoid excessive 
transfusion in this period. 
2. Pre-operative Cross Matching of Blood 
There is a lack of Maximum Blood Ordering Schedules (Question 12) or a lack of awareness that 
such a schedule existed. This could Increase the amount of blood cross matched and not 
transfused. This would lead to an excessive waste of Blood Bank's personnel time, unnecessary 
expense for the patient and hospital services and a waste of a valuable product. Excessive cross 
matching pre-operatively may also influence some medical personnel to give the blood "because 
its there". 
It is impossible to give absolute blood requirements for each operation as it wili vary between 
patients and especially with the skill of the surgeon. However, the GSH recommended MSBOS 
(Appendix 2) is very similar to those reported in the literature. Using this as a guideline it was 
shown that the respondents cross matching for the more common operations such as 









PERCENTAGE WITHIN GUIDELINES 
. NEPH HYST THYROID CHOLE 
-ALL AREAS 
Note that the percentage of respondents who were within GSH 
recommended cross matching guidelines were 39%, n%, 87% 
and 87% for nephrectomy, hysterectomy, thyroidectomy and 
cholecystectomy respectively. 
Lack of MSBOS guidelines may encourage the ordering of one unit of blood pre-operatively. 
However, although one unit ordering does occur amongst the respondents of the survey, it 
accounted for less than 3% of the anaesthetists. 
X-MATCH ONE UNIT 




ANEUR NEPH HYST THYROID CHOLE COLON HIP 
-TOTAL ~ •6 YRS EJ <20 YRS ~ •20 YRS 
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Note that pre-operative cross matching of one unit of blood was 
only performed by a small number of anaesthetists and they 
tended to be the least experienced (<6 years). 
Maximum Surgical Blood Ordering Schedules should be drawn up for each operation with 
variations being noted for individual surgeons. These should be available for all members of the 
Anaesthetic and Surgical Departments. 
3. Pre-operative Blood Replacement 
Most respondents {60%) used an estimated blood loss of 10-20% blood volume during an 
operation as their end point, after which they would transfuse. Volume loss estimation is often 
inaccurate and may lead to excessive transfusion. Similarly a blood volume loss of 20% in a 
patient with a haemoglobin of 15g/dl will drop hisjher haemoglobin to 13g/dl. If isovolaemia is 
maintained with clear fluids there is no additional anaesthetic risk for the patient and thus a 
transfusion Is both illogical and creates additional hazards for the patient. 
Most patients can be allowed to bleed isovolaemically down to a haematocrit of 30% before 
transfusing. The haematocrit is a simple and reliable test to perform during an operation and 
serial haematocrit readings should be used as an objective measurement of blood loss when 
deciding when to transfuse. Unfortunately only 24% of respondents used a haematocrit of 30% 
as their guideline for blood volume replacement. This indicates poor anaesthetic practices 
which reflects badly on the academic Departments. 
The use of serial haematocrit estimations should be taught and encouraged. The estimation of 
blood volume loss as the only manner of calculating when to commence blood replacement 
should be discouraged. 
KNOWLEDGE OF BLOOD PRODUCTS 
There is a poor knowledge about blood as gauged by certain of the survey questions. Thus only 48% of 
respondents knew that one unit of blood raised the haemoglobin level by 1 gjdl. Suppression of the 
immune system by a blood transfusion was also incorrectly answered by the majority of respondents. 
Similarly on average only 30-40% of respondents knew the cost of the main blood components and 
40-50% did not know how disease transmission compared between whole blood and other products. 
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RAISE 1Gm SEPSIS RENAL CANCER 
-ALL AREAS 
Note that the majority of respondents answered incorrectly Note that the majority of respondents in all areas did not know 
the questions regarding the level of haemoglobin rise with the costs of blood or blood components. 
one unit of blood and the effects of immune suppression 
with a blood transfusion. COST KNOWLEDGE 
CORRECT REPLIES BY AREA 
PERCENTAGE CORRECT REPLIES 
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PERCENTAGE OF ALL REPLIES 
FFP FFP+PRBC CRYO ALB 
-ALL AREAS 
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Note that the majority of respondents did not know about the 
increased risk of transmission of infection with FFP +- PRBC 
and cryoprecipitate. 40% did not know albumin carries no risk 
for disease transmission. 
The above results clearly indicate a need for education of the anaesthetists about blood 
transfusion. This should occur at Departmental level and should include the costs and the 
dangers of transfusion. 
PLATELETS 
The replies regarding the usage of platelets were, on the whole, satisfactory. However, 109 respondents 
(68 with less than 6 years experience) would require pre-operative platelet levels of more than 
100,000/J.£1 and 26 (13 with less than 6 years experience) would require levels of more than 150,000/J.£1. 
This would mean unnecessary pre-operative platelet transfusions in patients who had normal bleeding 
times if these pre-operative ~out-off'' levels were adhered to. 
The. knowledge of how much six random units of platelets would raise the platelet count by (60,000/J.£1) 










PERCENTAGE OF TOTAL REPLIES 
282 
PRE-OP ORUG 1 B.VOL LGE LOSS 
-ALL AREAS 
Note that the majority of respondents were within recognised 
guidelines for the use of platelets regarding: the acceptable 
pre-operative platelet number; and whether or not to have 
platelets available for the presence of a platelet inhibiting drug; 
one blood volume replacement, or a large blood loss. 
There is therefore a need for education of anaesthetlsts about indications for and costs of platelet 
transfusion. 
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FRESH FROZEN PLASMA 
As also reported in the literature (see Chapter Seven) FFP appears to be overused during replacement 
for blood loss. The fact that dilutional coagulopathy does not normally occur before 1,5 to 2 blood 
volumes have been transfused was not appreciated by the majority of respondents. Also 14% of 









PERCENTAGE OF INCORRECT REPLIES 
145 
25-50% 50-100% AS COLLOID 
Note that a significant number of respondents transfuse. FFP 
with relatively small blood transfusions. 14% use FFP as a 
colloid. 
This again requires the individual Anaesthetic Departments to reassess their policy for FFP usage and 
rationalise it, where necessary. 
COLLOID USE 












Note that 12% of respondents used albumin. 16% used dried 
plasma and 56% in the Western Cape used SHS as a colloid · 
when safer and cheaper synthetic substitutes are available. 
The use of blood products as colloids needs to be addressed by the various Anaesthetic Departments 
with recommendations being made for their members. The use of cheaper and safer synthetic colloids 
should be encouraged where a colloid and not red blood cells is indicated. In the survey 83% of 
respondents used the colloid Haemaccel which was widely available in the teaching hospitals visited. 
RECOMMENDATIONS 
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RECOMMENDATIONS BASED ON THE SURVEY 
1. Education 
South African anaesthetists need to be reminded of the correct usage of blood and blood 
components. To help achieve this I have developed a booklet on blood component therapy in the 
peri-operative period (Appendix 3). I hope this booklet, if made available, will partly address this 
problem. 
2. Blood User Committees 
These need to become more active in the auditing of the use of blood and components in the 
peri-operative period. It does however require an enthusiastic team to work out protocols and 




Any patient receiving a transfusion with ABC's should have a haemoglobin or haematocrit within 
24 hours of the end of the transfusion. The post-operative value should not be greater than the 
pre-operative value. It has been suggested that the haematocrit should not exceed 36% in the 
intra-operative or 33% in the post-operative period (Giovanetti et al, 1988). 
Cross Matching 
The cross match to transfusion ratio should be examined continually. Where excessive blood is 
ordered pre-operatively an explanation should be sought by the Blood Bank from the doctor in 
charge of the case. Where consistently less blood is used than ordered for a specific operation 
the MSBOS for that operation should be revised. The GS.H. recommended MSBOS guidelines 
(Appendix 2) have also been added to the educational booklet (Appendix 3). 
Platelets 
Patients should have low platelet counts and evidence of abnormal bleeding prior to platelet 
transfusion. The charts of patients receiving platelet transfusions should contain a platelet count 
within 18 hours following transfusion. 
Fresh Frozen Plasma 
Patients receiving FFP or dried plasma should have had a PT and a PTT or specific coagulation 
factor assay immediately before and within four hours of FFP transfusion. 
The Committee should be able to access the files of patients who have had blood or blood 
component transfusions to evaluate the indications and appropriate_ usage. 
3. Autoloaous Transfusion 
The Blood User Committee should set standards and undertake education regarding autologous 
donations either by Intra-operative haemodilution, or scavenging, or pre-donation of blood by the 
patient in the weeks leading up to elective surgery. 
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4. Research 
Further research, of relevance in South Africa, which needs to be undertaken includes: 
1) Assessing the safe minimum acceptable haemoglobin level of patients for elective 
procedures especially at altitude. 
2) Finding the correct dosage of FFP which will have clinical significance during massive 
transfusion. This is of particular importance in areas such as the Western Cape where the 
FFP is cryoprecipitate poor. 
It is hoped that the information accumulated in this survey, plus the knowledge I have tried to impart 
during my lectures around South Africa, will help to focus on what are becoming increasingly scarce but 
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APPENDICES 
1. Survey Questionnaire 
2. Groote Schuur Hospital Recommended Maximum Blood Ordering Schedule 
3. Educational Booklet for Anaesthetists and Surgeons 
"Blood Component Therapy in the Peri-operative Period" 
UN!VERSITY OF CAPE TOWN Page 1 
' Department of Anaesthetics Medical School. ObseM:ItOIV Cope. South Africa 7925 
Telephones: Medical School: 47-1250 Ext. 143 
Groote Schuur Hospital: 47-3311 Ext. 2441 
Fox No. (021) 47-8955 
Head & Professor of Deportment: M.F.M. James, MBChB(Birm). FFARCS(Eng) 
SURVEY OF SOUTH AFRICAN ANAESTHETIST$ 
USE OF BLOOD COMPONENTS 
M.MED. THESIS 
Dr. Gordon Irving, MB.BS, MSc(Med.) FFA(SA) 
Registrar in Anaesthesia 
Groote Schuur Hospital, Cape Town 
As anaesthetists administer at least 50% of red blood cell products used in some countries, I thought it 
would be of value and relevance to investigate the transfusion practices and knowledge of blood 
component therapy amongst South African Anaesthetists. 
The survey is not intended to be ari inquisition into an individual anaesthetists' practices, but to ascertain 
if there are wide differences between recommended schedules and what is commonly practiced. If there 
are large differences, it should surely be beholden to us anaesthetists to rationalise the use of what can 
be a life saving, but certainly not innocuous, form of therapy. 
I would, therefore, be grateful if you would take the time to fill in the appropriate box(es) opposite the 
answer you consider to be correct and post it to me in the enclosed pre-paid addressed envelope. 
Please do not refer to textbooks or colleagues with regards to the answers. I would prefer to know what 
you would do, or your level of knowledge, AT PRESENT. Full results of the survey and 
recommendations will be published in due course. 




AREA W. Cape; E. Cape; Natal Coast; Natal Inland; N. Tvl; S. Tvl; OFS; SWA. 
Please mark with a tick in the appropriate box(es). 
1. Time in anaesthetic practise 
Less than 5 years 
6-20 years 
More than 20 years 
2. Employer-
Are you employed by the State 
If yes are you: part-tirt:~e 
Are you in a teaching hospital 






3. For a non-emergency, asymptomatic patient on average, what is your minimum pre-operative 
haemoglobin level which you consider to be adequate for elective minor surgery? 
a) No requirement if blood volume considered normal D 
b) 8g/100ml D 
c) 10g/100ml D 
d) 12gf100ml D. 
4. What course of action would you take in the following cases: 
Administer Require 
Transfuse General Blood Cross 
Pre-op Anaesthetic Matched 
a) A healthy three-month-old patient for hernia 
D D D repair haemoglobin 9,2g/1 OOm 
b) 15 year-old male with sickle cell anaemia for D D D 
arthroscopy of the knee, haemoglobin 7,5g/100ml 
c) 30 year-old female with menorrhagia for a D D D 
D & C, haemoglobin 8,5g/100ml 
d) 45 year-old male with end stage renal disease D D D 
for creation of an arterio-venous fistula in the arm, 
haemoglobin 6g/100ml. 
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5. For a non-emergency case, on average, what is the maximum pre-operative haemoglobin level 
above which you would suggest postponing the operation? 
a) No maximum requirement D 
b) 17-18gj1 OOml D 
c) 18-19gj100ml D 
d) 19-20gj100ml D 
6. For a non-emergency case what is the minimum level of platelets you would consider to be 
adequate for elective surgery? 
a) No minimal requirement D 
b) More than 50,000 D 
c) More than 75,000 D 
d) More than 100,000 D 
e) More than 150,000 D 
7. For which of the following circumstances do you require that platelets are available pre-operatively 
(not extra-corporeal operation)? 
a) Platelet inhibiting drug 
b) One estimated blood volume replacement 
D 
D 
,c) Platelet count less than ............................................................................................. ~ ................. . 
d) Procedure usually associated with large blood loss D 
8. On average in patients with thrombocytopoenia how much would you expect six units of random 
collected platelets raise the platelet count by? · 
a) 24,000 D 
b) 60,000 D 
c) 90,000 D 
d) Don't know D 
9. On average in patients with anaemia how much would you expect one unit of blood to raise the 
haemoglobin? 
a) 0,5g/100ml D 
b) 1g/100ml D 
c) 1,5g/100ml D 
d) Don't know D 
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10. A haemophiliac (Type A) presents for an elective dental clearance under general anaesthetic. 
What is the minimal level of Factor VIII you would consider necessary prior to operation? 
a) More than 25% D 
b) More than 50% D-
c) More than 75% D 
d) 100% D 
11. An average of how many units of blood would you cross-match for the following procedures? 
Assume it is an elective procedure in a patient with a normal haemoglobin pre-operatively. 
*Group & More than 
Hold 1 Unit 2 Units 4 Units 4 Units 
a) Abdominal aneurysm 
D D D D D resection 
b) Total hip replacement D D D D D 
c) Nephrectomy D D D D D 
d) Hysterectomy (Vaginal, 
CJ D CJ D D Abdominal) 
e) Thryoidectomy D D CJ D D 
f) Cholecystectomy r-D D CJ D D 
g) Colon resection D D D D D 
•·Group & Hold or Type & Screen 
12. Does your hospital have a Maximum Surgical Blood Order Schedule? (i.e. recommendations for 
maximum blood ordering for elective operations) 
I Yes I No I Don't know I 
Section II - During Operation 
13. Which methods of blood loss assessment do you usually employ during major abdominal 
surgery? (Tick as many as you use) 
a) Visual estimation D 
b) Measuring suction bottles D 
c) Weighing swabs D 
d) Serial haemoglobin estimation D 
e) Serial haematocrit (PCV) estimation D 
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14. During an operation NOT normally requiring blood replacement which of the following best 
describes your approach? (rick only one) 
a) Replace when blood loss is, or will be, by the 
end of the procedure 10% of estimated blood 
volume: 
b) Replace when blood loss is, or will be, by the end of 
the procedure, 20% of estimated blood volume 
c) Allow the patient to bleed to a haematocrit of 30% before transfusing: 
d) In adults administer blood only if more than one unit is required 
e) Administer blood only if vital signs change e.g. blood 
pressure drops or pulse rate increases significantly 
15. Under what circumstances do you administer Fresh Frozen Plasma (FFP)? 
a) Blood replacement is between 25-50% estimated blood volume 
b) Blood replacement is between 50-100% estimated blood volume 
c) Only on the basis of abnormal clotting studies 
d) As a colloid volume substitute when red blood 
cells are not required 
16. What colloid volume substitute do you usually use if red blood cells are not required? 
a) Albumin 
b) Stablised Human Serum 
c) ·Haemaccel 
d) Dextran 40 
e) Dextran 70 
f) Dried Plasma 
g) Fresh Frozen Plasma 
h) Other (Specify) 
17. Do you use autologous blood scavenging replacement techniques? 

















18. When would you use micro-aggregate (effectively removing particles in the 10-30JLm range) 
blood filters? 
a) With every unit blood transfused 
b) If transfusing more than .................. units 







19. What risk do the following blood products have of carrying transmissable disease when compared 
to one unit of whole blood? 
More Less Same Don't 
Risk Risk Risk Know 
a) Unit of fresh frozen plasma (FFP) D D D u 
b) 1 Unit FFP plus 1 Unit pre-packed 
D D D D red blood cells 
c) 1 Unit Cryoprecipitate (AHF 500 units) D D D D 
d) 100ml Albumin D D D D 
20. What is the cost to the hospital of the various blood components? 
Less than 
SOR RSG-75 R75-100 R10G-300 R300+ 
a) Fresh Frozen Plasma D D D D D 
b) Dried Plasma D D D D D 
c) Whole Blood ( > 96 hours) D D D D D 
d) Whole Blood ( < 96 hours) D D D D D 
e) Cross-match cancelled D D D D D 
f) Megapack platelets D D D D D 
21. Please answer the following questions True or False or Don't know: 
I True I I Falsel Don't know 
a) Blood transfusions increase the 
D D D post-operative sepsis rate 
b) Blood transfusions improve long-
D D D term renal transplant survival rate 
c) Blood transfusions worsen the 
prognosis in certain cancers being 
D D D operated upon (Colon, Breast, Lung, 
Sarcomas) 
22. Within the last five years have you ever received. incorrectly labelled blood (wrong patient or 
wrong folder number)? 
~ I Nol 
If Yes- how many times over the last 5 years? 
Once D ~than3D 3-9times D more than 9 times D 
15.6.89 
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It's not ignorance 
But the illusion of knowledge 
That many anaesthetists resort to 
When using blood components 
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BLOOD TRANSFUSION GENERAL INFORMATION 
Whole blood 
One unit of whole blood contains approximately 450ml of blood and 63ml of preservative. The 
haematocrit ranges from 36-40%. If mixed with Citrate Phosphate-Dextrose (CPO) pr~servative it has a 
shelf life at 1-6°C of 21 days and 35 days if mixed with CPD-A (Adenine). There should be more than 
70% red blood cell survival at the end of the storage period with surviving cells having a normal life span. 
Whole blood stored over 24 hours has few viable platelets or granulocytes. 25% of Factor VIII remains 
after 24 hours and 50% of Factor V after 14 days. All the remaining factors remain relatively constant 
during storage. 
Packed red blood cells 
These are prepared by removing 200-250ml of plasma. If stored with ADSOL (Adenine, saline, glucose 
and mannitol) the shelf life is 42 days with a haematocrit of 60% which gives an adequate flow for rapid 
infusion. If stored with residual CPO or CPO-A this results in a haematocrit of 70-80% which may have to 
be diluted with normal (0,9%) saline or, in special circumstances, albumin or compatable human plasma, 
to improve flow characteristics. Hypotonic solutions (e.g. 5% Dextrose in water) will cause haemolysis 
and other solutions containing calcium (e.g. Ringer's lactate) may initiate in vitro coagulation of the 
citrated blood. Thus these solutions must NOT be mixed with citrated red blood cells. 
Time limits for transfusion 
Any unit of blood, if not used, must not be allowed to warm up above 1 0°C or it cannot be reissued by 
the blood bank because of the risk of bacterial contamination. The rate of infusion depends on the 
clinical condition of the patient but should not be longer than four hours. 
Changing the 170J.Lm blood filter every four hours is recommended. The use of a microfilter (20-40J.Lm 
pore size) is only recommended for use during cardiopulmonary bypass as microaggregate debris has 
not otherwise been shown to cause clinically significant problems. 
Blood warming 
Ideally all blood should be warmed when given during an operation to try and limit the fall in body 
temperature associated with general anaesthesia. However there is no evidence that patients receiving 
1-3 units of blood over several hours receive any additional benefit from blood warming. Where possible 
blood should be warmed with a commerically available blood warmer which limits the temperature to 
40°C. A higher temperature may cause haemolysis. Blood should definitely be warmed where*: 
1) Adult patients receive rapid and multiple transfusions (rate over SOml jKgjhr) 
2) Exchange transfusions in infants 
3) Children receiving blood in volumes in excess of 15mljKgjhr 
4) Patients with cold agglutinins active in vitro at 3?0C 
5) Rapid Infusion through central venous lines 
*American Association of Blood Banks recommendation 
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Medication into blood units 
Medication should never be added to blood units as: 
1) · It may cause haemolysis if the drug has a high pH 
2) A drug reaction would be impossible to differentiate from a blood transfusion reaction 
3) Any blood reaction necessitating stopping the transfusion would mean the full dose of drug not 
being administered. 
PageS 




Pre-operative anaemia clinically significant? 









A chronic anaemia of 8gjdl in otherwise healthy individuals does not compromise oxygen delivery to the 
tissues during operation. 
Transfusion required to raise haemoglobin levellg/dl: 
4 mi/Kg body weight Packed red blood cells 
6 mi/Kg body weight Whole blood 
Optimal Blood Ordering: 
Group and screen where blood may be required. Cross-match, which is approximately twice the cost of 
Group and screen, where blood will be required. Use a Maximum Surgical Blood Ordering Schedule as 
a guideline. 
Optimal Peri-operative haematocrit/haemoglobin: 27-33% {9-11gjdl) 
Present blood loss 
PERI-OPERATIVE TRANSFUSION: 
Expected blood loss 
Blood Loss Significant 





PRE-OPERATIVE ANAEMIA - IS IT CLINICALLY SIGNIFICANT? 
Pre-ooerative assessment of Anaemia: 
A healthy person can tolerate anaesthesia safely with a chronic anaemia of 8g/dl or even less. 
However, for each patient, an ACCEPTABLE HAEMOGLOBIN limit should be set. This is the 
haemoglobin level which one will allow the patient to bleed down to isovolaemically during the 
operative period, without transfusing blood. This limit is based on: 
1. Cause of the anaemia? 
This diagnosis may have a direct bearing on the anaesthetic risk. Sub-acute bacterial 
endocarditis causes anaemia and is, itself, an absolute contra-indication to all but the 
most urgent surgery. Iron deficiency and malnutrition compromise the immune system 
and may prolong recovery. Liver thyroid and renal disease may all produce anaemia 
and may have a profound effect on the anaesthesia if not recognised pre-operatively. 
2. Chronicity 
Chronic anaemia implies a normal blood volume with the red blood cells having a right 
shift on the haemoglobin disociation curve due to increased 2, 3 DPG 
(Diphospho-glycerate). The haematocrit will be lower and there is a decreased viscosity 
which, together · with a concomitant vasodilation may improve oxygen tissue 
oxygenation to the various organs. 
Acute anaemia implies sudden blood loss due to trauma or rupture of a blood vessel 
e.g. ruptured ectopic pregnancy. The initial haemoglobin in these cases may be a poor 
indicator of the degree of blood loss but, taken in conjunction with the clinical signs of 
pulse, blood pressure, urine output and specific gravity, peripheral skin temperature and 
mucous membrane colour it allows an estimate of the total blood deficit to be made. 
Any acute blood loss if clinically significant should be treated by intravenous transfusion. 
Clear fluid replacement is adequate unless haemoglobin levels are 9 or less, when blood 
should be given because of the risk of dilutional hypoxia 1. 
3. Symptoms of Anaemia 
These include dyspnoea on effort, excessive tiredness, weakness and tachycardia at 
rest. They occur at different haemoglobin levels depending on concomitant medical 
disease. In the otherwise healthy individual mild, chronic anaemia (9-11 g%) may cause 
only pallor and tachycardia on exertion. A level of 7-8g% causes dyspnoea on exertion, 
6g% weakness, 3g% dyspnoea at rest and 2-2,5g% may cause congestive cardiac 
failure. Age affects the level of haemoglobin necessary to cause symptoms. Children 
appear to be remarkably resistant to the effects of anaemia, whereas the elderly may not 
tolerate even minor reductions in haemoglobin level. 
Any symptoms which are associated with anaemia should be noted and where 
appropriate the anaemia should be corrected prior to surgery. 
4. Concomitant Disease 
A history of myocardial ischaemia, peripheral vascular disease, cerebrovascular disease, 
or severe obstructive airways disease, will affect the tolerance of the individual to 
anaemia. Thus a higher minimal level of haemoglobin must be maintained in these 
patients than in the healthy individual. Severely wasted or elderly patients may be 
chronically dehydrated, giving a falsely high haemoglobin estimation. If the blood 
volume is not expanded prior to induction of a general anaesthetic, a marked fall in 
blood pressure may occur with significant ischaemic sequelae. 
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5. Smokers 
Heavy cigarette smokers who continue to smoke up until the operation and will continue 
in the early post-operative period will have a significant leftward shift of the haemoglobin 
dissociation curve due to carbon monoxide "poisoning". They are also mildly 
haemoconstricted giving a falsely high haemoglobin reading and a tendency to 
hypotension with the vasodilation effect of an anaesthetic. This group of patients is also 
at a higher risk of ischaemic. heart disease, obstructive airways disease, and 
cerebrovascular disease. Thus anaemia will be more poorly tolerated. Where feasible 
cigarettes should be stopped for 24-48 hours prior to operation. 
6. Type of Operation 
The extent of the operation, the expected blood loss and the surgical skill of the 
operator must be taken into account when considering the minimal acceptable 
haemoglobin levels. 
7. Danger of Antibodies 
In certain diseases such as end stage renal failure, the risk of creating cytotoxic 
antibodies with future difficulty in finding a compatable donor, as well as the danger of 
overload are present. A much lower haemoglobin (5-Sg/dl) is therefore usually 
accepted in this group of patients going for elective surgery. 
TREATMENT OF ANAEMIA 
Based on the above clinical observations is the pre-operative anaemia clinically significant: If the 
answer is 'yes', the question to ask is whether the operation is: not urgent, semi urgent, or urgent. 
1. Not Urgent Suraerv 
Patients with a haemoglobin of 8g/dl or less without symptoms of hypovolaemia or hypoxia 
should be investigated for a nutritional reason for their anaemia, such as iron deficiency, 
pernicious anaemia, intestinal malabsorption, or hereditary haemolytic anaemia. Nutritional 
therapy with postponement of their operation and not transfusion is the more appropriate 
treatment. 
Iron deficiency, the most common type of nutritional anaemia, should be treated with 
4-5mgjKgjday of elemental iron, three times a day. Because of gastrointestinal intolerance the 
dose should be built up gradually. As the marrow of a severely iron deficient patient needs time 
to 'wind-up' to produce red blood cells, a delay of up to 7-10 days may occur before. a rise in 
haemoglobin is noted. This rise should be of the order of 1-2gjweek. 
2. Semi Urgent Surgery 
Pre-operative transfusion should be by packed red blood cells given slowly (4 hours per unit), 
1-2 days prior to the operation to allow time for normalisation of fluid shifts. A diuretic may be 
ordered if there is a risk of cardiopulmonary embarrassment. 
3. Urgent Surgery 
If the anaemia is chronic i.e. normal blood volume, the transfusion should be commenced with 
packed red blood cells. If the anaemia is acute, as a result of haemorrhage, rapid replacement 
with whole blood should be commenced if the patient shows signs of shock, i.e. pulse > 100 
b.p.m., BP <100mm Hg systolic, skin periphery cold, mucous membranes pale, oliguric or a 
haemoglobin of 9g/dl or less. lsovolaemia should be maintained and central venous pressure 
lines or even Swan Ganz catheters may be required for monitoring. 
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How much blood to transfuse? 
To raise the haemoglobin 1g/dl requires: 4 mljKg body weight of packed red blood cells; 6 
mljKg body weight of whole blood. 
Optimum blood ordering for the operation 
Every hospital should have a Maximum Blood Ordering Schedule (MBOS) (see Appendix 1) which 
consists of a list of the recommended maximum number of units of blood which should be 
cross-matched pre-operatively for most commonly performed surgical procedures. Although this 
guideline may vary between Institutions they are usually rEfmarkably similar. Using a MBOS should 
reduce excessive ordering of blood and wastage of valuable Blood Bank personnel's time. 
Blood should be ordered as Group and Screen (Type and Screen) when doubt occurs if blood will be 
required. This consists of ABO and Rhesus typing plus a screen for unexpected, significant antibodies 
in the recipient's blood. The test takes about 1 hour. Blood administration following a negative 
antibody screen is 99,99% safe as regards having an incompatable transfusion2. However, most Blood 
Banks prefer to complete a full cross-match (± 1 hr), if time allows, prior to releasing the blood for 
transfusion. 
Blood Transfusion during operation 
The maintenance of isovolaemia by replacement of 1 ml of colloid or 2-3 ml of crystalloid for every 1 ml 
of blood loss should be routine throughout any operation. The extent of the blood loss is estimated by 
various means: visual assessment of blood on drapes and swabs; blood in the suction bottles; 
weighing swabs and by serial haemoglobin and haematocrit estimation. These latter two techniques 
are probably the most accurate although all the methods have drawbacks. 
Optimal haematocrit/haemoglobin values 
The haematocrit value at which peak oxygen transport occurs has been reported to be about 30% (Hb 
10 g/dl). A study of critically ill post-operative patients found a maximal survival rate in those patients 
who had a haematocrit between 27 and 33% (haemoglobin 9-11 gjdl)3. 
Mild anaemia (Hb 9-11 gjdl) Is not associated with peri-operative morbidity or poorer surgical healing. 
The frequency and severity of post-operative infections and the incidence of increased bleeding is also 
not increased with anaemia. 
Whole blood versus Packed cells 
Packed red blood cells can be used as equivalent to whole blood for up to 3-4 units of blood loss 
replacement. After this volume whole blood should be used because of the need for the coagulation 
factors present in the stored plasma. 
Fresh and old blood 
The term fresh blood varies with the Blood Banks but often means less than 96 hours old. "Super fresh 
means less than 24 hours old. However superfresh blood is rarely available because of the time 
required to do ABO and rhesus typing, screening for atypical antibodies and completing hepatitis and. 
HIV testing. Blood older than 24 hours has very few functioning platelets and labile factors V and VIII 
are diminishing rapidly. There is little advantage for fresh blood against old blood except in massive, 
rapid transfusions when blood less than 1 o days old should be used to limit the amount of potassium 
load transfused. 
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BLOOD PRODUCTS DANGER - HANDLE WITH CARE 
Possible adverse effects of any transfusion: 
1. INFECTION - Viruses - hepatitis B; Non-A. Non-8*; Cytomegalovirus*; HTLV 1 & 2*; Epstein 
Barr*; HIV**. 
- Protozoa- Toxoplasmosis*, Malaria* 
Bacteria - Syphilis 
*Not routinely tested for by the Blood Bank 
**patient with HIV may never seroeonvert. HIV testing is negative but the blood product is 
infective. 
The following products have the same risk of infection transmission as 1 unit of whole blood: 1 unit 
packed RBC; 1 unit FFP and 1 unit platelets. The following carry a much higher risk because they 
are produced from pooled donors; cryoprecipitate, factor concentrates and megapack platelets 
(six random units). 
2. IMMUNOLOGICAL DEPRESSION : When blood is transfused the immune system is suppressed 
causing: decreased five year survival and increased metastatic spread for cancer operations of 
colon, rectum, lung, breast and soft tissue sarcomas; an increased survival for renal transplants 
and an increased sepsis rate. Possible reasons are: activation of T suppressor lymphocytes, 
lowering circulating fibronectin and depression of Natural Killer cell activity. 
3. ALLOIMMUNISATION : To red cell and leucocyte antigens. The commonest source of serious or 
fatal haemolytic reaction is human error between taking blood and giving it to the patient. 
Reactions vary from mild fever chills and urticaria {1: 1 00) to fatal (1 :1 00,000 in USA). 
4. TRANSFUSION RELATED ACUTE LUNG INJURY (T.R.A.L.I.) : Acute pulmonary oedema due to 
leukoagglutinins in the recipients or the donor's blood. Within 2-4 hours of transfusion the patient 
develops respiratory distress, hypoxia, hypotension, fever and a chest x-ray picture· of pulmonary 
oedema but with no signs of circulatory overload. 75% of patients will need mechanical ventilation 
and the chest is usually clear within 48 hours (incidence 1 :5000). 
5. ANAPHYLAXIS : Probably caused by antibodies against plasma proteins WBC's and platelets. 
6. OTHERS :These include impaired red blood cell deformability, infusion of plasticizers, infusion of 
denatured proteins and vasoactive substances, graft vs host reactions, toxicity of new products, 
elevated ammonia and phosphate. In practice their effects are usually clinically insignificant but 
may be important in explaining some adverse reactions. 
Treatment of acute transfusion reactions 
(A.A.B.B. re~ommendations)4 
1. Immediate Steps For All Reactions: 
a) Stop transfusion 
b) Keep I.V. open with 0.9% NaCI 
c) Notify attending physician and blood bank 
if transfusion is terminated: 
d) Send freshly collected blood and any necessary urine samples to blood bank 
e) Send blood unit and administration set to blood bank. 
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Reaction Type Signs and Symptoms Aetiology Clinical Action 
Allergic pruritus, urticaria (hives) antibodies to plasma ~teps (a)-(c) (above); admini-
proteins ster antihistamines (PO, IM 
or IV); resume transfusion. 
If no improvement in 30 mins 
treat as below .. 
Allergic or Febrile anxiety, pruritus, fever, chills, antibodies to WBC, Steps (a)-(e) (above; admini-
agitation, flushing, hives, platelets, plasma ster antihistamines, anti-
tachycardia, mild dyspnoea, proteins - including pyrectics, vasopressors 
hypotension, anaphylaxis antibodies to 1 gA and corticosteroids as 
needed; avoid reactions with 
washed cells or other speci-
fically prepared components 
Acute Haemolytic anxiety, chest pain, flank gram negative sepsis Steps (a)-(e) (above); treat 
pain, headache, dyspnea from blood transfusion; shock with vasopressors, rv 
chills fever, red urine, intravascular haemo- with corticosteroids as 
agitation, shock, hypo- vascular haemolytic needed; maintain adequate 
tension, unexplained transfusion reaction airway, increase renal blood 
bleeding, haemoglobinaemia flow (IV fluids; furosemide, 
mannitol); maintain brisk 
diuresis; if DIC is present 
consider heparinization; 
renal status for acute renal 
failure requiring dialysis, 
administer blood 
components (platelets, 
plasma etc.) as needed 
Possible adverse effects of massive transfusions: 
1. Hyperkalaemia - The older the stored blood, the higher the potassium content. This increase is 
about 1 mmolfljday of storage (21 day old CPO. - A stored blood has a K+ content of 21,7 
mmoljl). This may be significant if the infusion rate is > 1 ,5.2mi/Kgjmin, monitor T waves and K+ 
levels- Treatment IV calcium. After redistribution and warming K+ rapidly re-enters red cells and 
potassium levels may become sub-normal. 
2. Hypocalcaemia. Due to citrate lowering the ionised calcium levels. This effect is transient and 
lasts± 10 minutes. May be significant if the infusion rate is > 1 ,5-2mi/Kgjmln, monitor 0 and T 
waves, treatment IV calcium. 
3. Acid Base Derangements - metabolic acidosis initially, alkalosis later 
4. Hypothermia 
5. Haemoglobin Oxygen Dissociation- A low 2, 3 O.P.G. shifts the oxygen dissociation curve to the 
left and decreases oxygen availability to the tissue 
6. Microembolisation - Shock in itself causes endogenous microemboli to form. Microfilters are not 
proven to be clinically effective except for use In coronorary bypass arterial lines 
7. Oilutlonal thrombocytopaenia - Unusual below 2 blood volume replacements if normal platelet 
count and function Initially - one whole blood volume replacement (1 0 units) with old blood lowers 
platelet levels only 30-40% 
8. Oilutional coagulopathy - This is unusual if whole blood is transfused. Even with 1 ,5 blood volume 
replacements (15 units), enough labile factors V and VIII are still present to Initiate clotting. Other 


















L-- No abnormal bleeding 
,..--- Operate within 12 hours 
1---- Type specific 
L-- Random Units 
(unless antibodies) 
Pre-operation - more than 55,000JLI/I if no immune or consumptive cause 
. Test for function 
Tenplate Bleeding Time - more than 10 minutes - (normal 2-9,5 minutes) means, platelet 
dysfunction or lack 
Dose: Single donor (donation by platelet-pheresis) 
Raises platelet count 60-70,000/JLI 
Random donor- single unit raises platelet count 5-10,000/JLI 
Dose = 1 Random unit/1 OKg body weight 
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PLATELETS - GENERAL INFORMATION 
Random Donor: 
Prepared from individual units of whole blood, each bag contains not less than 5,5 x 1010 platelets. 
Stored at 20-24°C with continuous agitation for up to 5 days depending on type of plastic blood bag. 
Each unit contains up to 50ml of plasma. · 
Repeated transfusions may cause alloimmunisation to HLA antigens which only responds to HLA 
matched platelets. 
Single Donor: 
These are collected from an individual donor during a 2-3 hour apheresis procedure. The platelets, 
collected in 200ml-500ml of plasma raise the recipients platelet count 30,000-60,000/JLI (70Kg adult) 
which is the equivalent of 6-8 units of random donor platelet concentrates. Single donor platelets are 
usually reserved for patients with platelet antibodies or where the risk of HLA antibody formation is to be 
avoided. 
The expected rise in platelets will be less if the patient has sepsis, DIC, splenomegaly, platelet auto or 
alloantibodies or is receiving chemotherapy. 
Reactions: 
Chills, fever and allergic reactions may occur. Avoid using non-steroidal antiinflammatories or aspirin 
containing compounds to treat any reactions because of the adverse effect on platelet function, 
acetaminophen, paracetemol and codeine may be used safely. 
Rapid infusion may cause circulatory overload. Rhesis negative females of childbearing age should only 
receive Rh-negative platelet concentrates because of the small amounts of red blood cells in the 
concentrates. 
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Transmission of hepatitis and HIV viruses etc., risk is increased with pooled random donor unit!). 
Platelets can be administered through a standard 170Jl.m blood filter at a rate of 1-2mljmin or as 
tolerated by the patient. 
DILUTIONAL THROMBOCYTOPAENIA FOLLOWING MASSIVE TRANSFUSION 
Although thrombocytopaenia is more commonly a cause of abnormal bleeding than clotting factor 
depletion following massive transfusion. In patients with a normal platelet count and function 
pre-operatively, after one blood volume replacement 35-4()% of platelets usually remain. Thus the 
majority of patients who have rapid replacement of 1-2 blood volumes do not develop microvascular 
bleeding as a result of dilutional thrombocytopaenia. Therefore platelets should probably not be 
transfused for abnormal bleeding without evidence of a low platelet count or an increased bleeding time. 
1. PLATELETS: 
Whether to transfuse platelets peri-operatively depends on several factors: 
a. Cause of the thrombocvtooaenia 
Patients with idiopathic thrombocytopaenic purpura, DIC, thrombotic thrombocytopaenic 
purpura, or haemolytic uraemic syndrome in general do not respond to platelet 
transfusions. In addition, platelets may be harmful because of the risk of transmission of 
infection. 
Patients with increased platelet destruction and splenomegaly who are booked for 
splenectomy are not routinely transfused with platelets prior to the operation because of the 
platelets extremely short lifespan. After splenectomy. platelet levels rapidly return to normal. 
b. Level of thrombocvtooaenia 
The minimal recommended platelet level prior . to surgery in most patients with 
haematological disorders is generally accepted as 50-75,000. 
c. Concomitant Disease 
Patients with advanced hepatic or renal insufficiency often have associated disorders of 
coagulation and platelet function. Platelet transfusion may be required pre-operatively to 
correct the bleeding time although there are few, if any, pertinent studies. 
d. Platelet Function 
Although there are hereditary causes of disorders of platelet function (thrombasthenia, 
Storage Pool Disease, Bernard Soulier Syndrome etc.,) clinically the commonest cause is 
drug induced. The drug often inhibits both primary platelet aggregation and the release 
mechanism. These effects are irreversible and the platelets are functionally deficient as 
long as the effective cohort survives (e.g.± one week). 
The doctor should be aware that the following drugs have been shown to cause platelet 
changes. 5 Many "over the counter" medications may contain substances such as aspirin 
which should be specifically asked about during the pre-operative work-up. Where possible 
the operation should be postponed for seven days until the effect of the drug has been 
eliminated. 
Analgesics which are presumably 'safe' include codeine, paracetemol, opiates, 
propoxyphene and acetaminophen. 
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MEDICATIONS WHICH INHIBIT PLATELET FUNCTIONS 
1. Anti-inflammatory agents: aspirin, ibuprofen, indomethacin, phenylbutazone, naproxen, 
sulphin-pyrazone and congeners, sulindac, suprofen. 
2. Anti microbials: amantadine, ampicillin, carbenicillin, cephalothin, methicillin, 
nitrofurantoin, penicillin gentamycin, streptomycin, ticarcillin. · 
3. CNS: amitriptyline and congeners, chlorpromazine, cyproheptadene, 
desmethylimiprame, imipramine, promethazine, reserpine, phenytoin, phenothiazines, 
phenobarbitone. 
4. Adrenergic Blocking Agents: phentolamine, propanolol. 
5. Miscellaneous: chloroquin, clofibrate, dextran, diphenhydramine, dipyridamole 
(Persantin), digoxin, gliclazide, heparin, papaverine, tolbutamide, corticosteroids, lithium, 
furosemide, colchicine, ethanol, caffeine, theophylline, antihistamines. 
Where one Is unsure as to the effects of a drug on platelet functioning a Tenplate Bleeding 
Test should be performed._ This consists of inflating a blood pressure cuff and maintaining 
it at 40mmMg. A template is used to produce one or two standardised cuts 1 x 9mm 
distal to the cuff. Blood is then blotted by filter paper every 30 seconds, taking care not to 
disturb any developing clot, until bleeding ceases. The normal bleeding time is 2-9,5 
minutes, a bleeding time of 10 minutes or longer indicates platelet lack or dysfunction. 
6. Type of Operation 
Conclusion 
a) Neurosurgical: Even small bleeds into the central nervous system· may have 
devastating effects. It is probably logical to raise platelet levels to correct any 
prolongation of the bleeding time prior to operation. 
b) Cardiopulmonary Byoass: Controlled prospective studies have demonstrated no 
correlation between platelet counts and bleeding following cardiopulmonary 
bypass, and no detectable benefit from prophylactic administration to such 
patients. Therefore there is no justification for prophylactic platelet transfusion in 
these patients except in certain patients with abnormal platelet function e.g. 
cyanotic heart disease. 
Haemorrhage due to thrombocytopaenia is never rapid and there is usually time to check the platelet 
function or level and then order platelets if these are abnormal. Platelet transfusion is only urgent if the 
site of bleeding is critical e.g. brain or retina. 
Platelets should not be administered pre-operatively in the absence of documented poor platelet 




FRESH FROZEN PLASMA (FFP) 
Multiple coagulation deficits (liver frenal disease) 
Replacement specific factor deficiencies 
Yes 
Reversal warfarinjsuxamethonium effects 
Massive blood transfusion (> 1,5-2 blood volumes) 
To reconstitute packed ABC's 
As a plasma volume expander 
As a source of protein 
No 
As a routine after cardiopulmonary bypass 
Small blood transfusions ( < 1 ,5-2 blood volumes) 
Dose: As clinically required -monitor prothrombin and partial thromboplastin times 
For massive transfusion related coagulation problems 800-1,000ml ±cryoprecipitate need to be 
given over 90-120 minutes (70Kg adult) 
Cross matching: ABO compatability with recipient important 
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FRESH FROZEN PLASMA - GENERAL INFORMATION 
Fresh frozen plasma (FFP) is prepared from whole blooo by separating and freezing the plasma within 
six hours of phlebotomy. It may be stored for up to one year at -180°C or lower. Under these conditions 
the loss of Factors V and VIII, the labile factors, is minimal. The usual volume is 200-250ml. 
FFP should be thawed between 30-3r'C with constant agitation and must be used within 24 hours of 
thawing to obtain maximum levels of coagulation factors. ABO compatible plasma should be used. 
CRYOPRECIPITATE POOR FFP 
Cryoprecipitate is prepared by thawing one unit of fresh frozen plasma at 40°C. After thawing, a white 
precipitate is formed (cryoprecipitate) which contains Factor VIIIC, Factor VIII:VWF (Von Willebrand's 
factor), fibrinogen, Factor XIII and fibronectin. The supernatant fluid is removed and refrozen at -180°C. 
The routine removal of cryoprecipitate from all units of FFP depends on the blood bank. Users of plasma 
should familiarise themselves with the local policy. 
When cryoprecipitate poor FFP is required for multiple coagulation deficits or for pathological bleeding 
after massive transfusion (more than 1.5~2 blood volumes) cryoprecipitate should be transfused 
concurrently. 
DRIED PLASMA 
. Plasma is separated from whole blood, usually when the blood is time expired and dried. It can be 
reconstituted with crystalloid solutions and has the advantage of a long shelf life without freezing. All 
stable clotting Factors are present (1, II, VII, IX, X, XII and XIII) but Factors V, VII and XI are deficient. 
FILTER 
A standard 170J.Lm blood filter should be used. 
MASSIVE TRANSFUSIONS 
The main cause of pathological haemorrhage in patients receiving massive blood transfusion (more than 
1.5 blood volumes rapidly) is thrombocytopaenia rather than depletion of coagulation factors. Thus FFP 
is not required in this situation. 
Indications§~ 
Multiple coagulation defects (e.g. chronic liver and renal disease) 
Protein losing enteropathy 
Reversal of warfarin effect 
Reversal of scoline (suxamethonium) apnoea 
Replacement of isolated factor deficiencies 
Certain immuno deficiencies 
Massive blood transfusion ( > 1.5 blood volumes or 15 units of blood in an adult) 
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Situations where FFP is NOT indicated2..M~ 
As a plasma volume expander 
To reconstitute packed red blood cells 
As a source of protein for nutritionally deficient patients 
In the initial stages of treatment of Disseminated Intravascular Coagulation (DIC) where the 
primary therapy should be directed at the initiating disease process such as: sepsis, malignancy, 
hypotension or obstetrical complications 
For small blood transfusions ( < 1.5 blood volumes or 15 units in an adult) 
As a routine after cardiopulmonary bypass operations 
Dose for Massive Transfusions: 
BOOml-2,000 (4 to 8 packs of FFP) for a 70Kg adult over 90-120 minutes. This causes a temporary but 
possibly significant improvement in clotting factors. Slower rates of infusion or smaller volumes of FFP 
have been found to be ineffective9. 
Problems with FFP: 
Infection: one unit of FFP carries the same risk of disease transmission as one unit of blood 
Hypervolaemia. 
Allergic reactions 
Others - Each unit of FFP is hyperglycaemic (17, 1 mmol/1), hypernatraemic (168mmol/1) 




~ !a Life Problems Recommended Uses 
Albumin 5-10 days 25% solution very hyperosmolar Hypoalbuminaemic shocked 
BLOOD Very expensive states 




t--SHS (PPF) 5-10 days Expensive As above plus certain immuno-
_) Mild adverse reactions deficiencies 
May not be readily available 
'--FFPor Infection transmission Not recommended for use as a 
Dried _anaphylaxis colloid 
Plasma 
SYNTHETIC Oextran 70 6-12 hrs Platelet dysfunction High risk deep vein thrombosis 
COLLOIDS Tissue dehydration 
anaphylaxis Shocked states where blood 
(Immunoglobulin mediated. not indicated* 
Block by pre-load 
with HAPTEN 1) 
Maximum dose 1,5gfKgjday lsovolaemic haemodilution* 
(± 1500ml in average adult) 
*Pre-load with HAPTEN 1 if 
available 
Oextran 40 2-3 hrs Tissue dehydration High risk of deep vein 
Renal failure if dehydrated thrombosis 
Haemaccel 3-5 hrs Anaphylactoid (histamine Shocked states where blood 
release) block with anti not indicated 
H1;H2 drugs lsovolaemic haemodilution 




Derived from donor plasma from outdated blood or plasmapharesis. It is heated to 60°C for 1 o hours to 
inactivate viruses. It is free of transmissable diseases and has a long shelf life. 
Albumin is available in 5% (!so-osmotic with plasma) or occasionally 20% (hyperosmotic) solutions. 
Indications: 
Patients should be hypovolaemic AND hypoproteinaemic- it is readily metabolised in the liver and rarely 
stays in the circulation more than 24-48 hours in these patients. -
/ 
Problems: 
Hyperosmolar 25% albumin will cause a reduction of the extravascular (mainly intracellular) body 




Filter: No filter or crossmatching required. 
Plasma Protein Fraction (PPF). Stabilised Human Serum (SHS) 
Prepared in a similar way to albumin but with fewer fractionation steps. It contains about 83% albumin 
and 17% globulins. There is no risk of disease transmission with SHS~ Shelf life is 5 years at 2-25°C if 
protected from the light. 
Indications: Protein losing enteropathies, certain immunodeficiency diseases, reversal warfarin and 
suxamethonium, hypoalbuminaemic shocked states. 
Problems: 
Expense (about 4-5 times as expensive as synthetic colloids) 
Hypervolaemia 
Infusions of more than 10ml may produce hypotension due to both sodium acetate and Hageman 
factor fragments. · 
Filter: No filter or crossmatching required. 
Dried Plasma and Fresh Frozen Plasma 
Because of the risk of d,isease transmission and anaphylaxis neither FFP nor dried plasma should be 




These are produced by the action of the baterium leuconostoc mesenteroides on sucrose. The dextran 
molecule is composed of varying chain lengths of glucose polymers. They are classified according to 
molecular weight. 
Dextran 70 - average molecular weight 70,000 prepared as a 6% solution in isotonic saline. It is 
hyperosmolar, a SOOml infusion will increase the Intravascular volume by about 750ml. 
Dextran 40 -average molecular weight 40,000 prepared as a 10% solution in isotonic saline. A SOOml 
infusion will increase the intravascular volume by about 1,500ml. 





- 2 hours because of rapid renal excretion 
- 6-12 hours. 
Limited to 1,5g/Kg body weight/day ( < 1,500ml in 70Kg adult) 
Haemostasis 
Causes a decrease of platelet stickiness and in high doses ( > 1,500ml) interferes with the 
action of Factors VIII, V, fibrinogen and prothrombin 
Crossmatching interference 
Only occurred with very high molecular weight dextrans (no longer available) and 
inexperienced haematology technicians. 
Allergic Reactions 
Usually occur with infusion of only a small volume of dextrans due to circulating 
anti-dextrans with a fatality rate of 3,4 per 100.000 units infused antibodies. Severe 
anaphylaxis occurs in about 0,008% of patients. The use of monovalent Hapten to block 
antigen combining sites of preformed circulating reactive antibodies is recommended 
prior to dextran infusion.10 & 11 
Renal Damage 
If renal perfusion is decreased, Dextran 40 may form a plug blocking the renal tubules 
which together with osmotic damage may precipitate renal failure. 
Hypervolaemia 
Dehydration - because of the intravascular shifts at the expense of the extravascular 
space, Dextran 40 and 70 should be avoided in dehydration states. 
Advantages Free from disease transmission 
Decreases post-operative deep vein thrombosis 
Haemaccel 
A synthetic polymer derived from degraded gelatin produced by heat desaturation and cross-linked with 
hexamethylene di-isocyanate to form molecules with urea bridges (average molecular weight 35,000, 
range 5,000-50,000). lso-osmotic with plasma, a 500ml infusion will raise the intravascular volume by the 
same amount. 
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As clinically necessary 
Since a change in manufacture in 1981 which decreased excessive cross-linkages, the 
number of adverse reactions due to histamine release has decreased. No fatalities have 
been reported since the change in formulation and those reported are mainly 
cutaneous. 12 Prevention of cutaneous anaphylactoid reactions is possible by H1 and H2 
antagonists. 
ADVANTAGES Free from disease transmission 
No interference with haemostasis 
Renal function maintained or improved 
Unaffected by storage temperature. 
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PRE-OPERATIVE ASSESSMENT OF THE PATIENT WITH A BLEEDING PROBLEM 
Screening 
A simple clinical history and examination may be all that is required. In the absence of positive findings 
further expensive investigations are probably unnecessary. Specific questions to ask include: 
Do you bleed a lot from small cuts? 
Do you bruise very easiiy? 
Are you, or is anyone in your family a "bleeder"? 
Have you ever had teeth extracted, if so, how long did you bleed afterwards and did you bleed 
again the next day? 
Do you suffer from nose bleeds? 
What do you use for pain or headaches, how much and how often? 
What medicines, including over the counter preparations, are you taking 
Specific examination: 
Look for bruising, petechiae and signs of liver failure. 
Haematological Tests: 
Negative history and examination Platelet count and possibly platelet function test are all that is 
required. 
Positive history or examination. The following need to be done: 
1. Haematologists opinion if: There is a history of a genetic bleeding disorder; or there is 
severe systemic disease with manifestations of, or predisposition to liver failure, DIC or 
fibrinolysis. 
2. Routine automated full blood count and platelet count. 
3. Routine automated clotting tests -
"Extrinsic" function- prothrombin time or INR not >60% of control 
"Intrinsic" function- partial thromboplastin time not >40 seconds 
"Common" pathway - thrombin time should be 9-20 seconds 
4. If impaired platelet function is suspected, do a bleeding time, should be < 10 minutes 
Interpretation of routine tests: 
Abnormal PTT, PT and TT 
Abnormal PTT and PTT, normal TT 
Abnormal PTT, normal PT 
Abnormal PT, normal PTT 
Factor deficiencies, severe liver disease, DIC; severe inhibitor, 
hyprofibrinogenaemia 
Vitamin K defect, liver disease, inhibitor present, factor defects 
Deficiency in factors VIII, IX, XI, XII, Fletcher, Fitzgerald 
Deficiency factor VII. 
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SPECIFIC HAEMATOLOGICAL DISORDERS 
Von Willebrand's Disease (Factor VIII: C and VIII: VWF lack) 
Caused by congenitally deficient levels of Von Willebrand Factor 0/WF), a high molecular weight protein 
which is closely bound to Factor VIII and which is required for optimal platelet adhesion. It is associated 
with low levels of Factor VIII:C (procoagulant activity) and an increased bleeding time. Treat 
- peri-operatively with cryoprecepitate not Factor VIII concentrates, as the latter does not contain Factor 
VIII:VWF Normalise procoagulant activities and bleeding time before operation. 
Haemophilia :Type A (Factor VIII:C procoagulant activity lack) 
--
When the deficient factor VIII is infused pre-operatively the volume required depends on: patient size, 
desired elevation in factor VIII level and preparation potency. About 10% of haemophiliacs have an 
inhibitor to factor VIII where replacement fails to achieve the expected level. These patients need to be 
managed in association with an experienced haematologist. 
For dental extraction a single infusion to raise the factor VIII level above 50% is required followed by the 
fibr,inolytic inhibitor epsilon aminocaproic acid at a dose of 100mgjKgjday for 10 days. This should 
obviate the need for further factor VIII replacement. For major surgery it is common to infuse sufficient 
factor VIII to raise the level to 80-1 00% and then give boosters every 12 hours to maintain levels above 
50% for 10-14 days. 
Haemophilia : Type B (Factor IX lack) 
Replacement involves similar formulas as those for calculating Factor VIII requirement. Factors IX has a 
half-life of 18-24 hours in vivo but is maintained at a stable level throughout the dating pericx:l of a unit of 
blood, or fresh frozen plasma. 
Vitamin K Lack 
Due to inadequate intake, malabsorption (steatorrheoa) or inadequate utilisation Oiver disease). 
Necessary for Factors II, VII, IX and X but requires adequate hepatic function to provide the gamma 
carboxy glutamic acid modification. -
Chronic Liver Disease 
Patients with liver disease have multiple haemostatic defects as most coagulant factors. except Factor 
VIII are produced in the liver. They also may have: impaired Vit K utilisation; increased fibrinolysis activity 
because of decreased metabolism of plasmin and decreased synthesis of plasminogen activators; and 
thrombocytopaenia due to hypersplenism which may be refractory to platelet transfusion. 
Peri-operatively Vit K and FFP can be given to try to normalise coagulation. Monitor with prothrombin 
and partial thromboplastin times. 
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Chronic Renal Failure 
Normochromic, normocytic anaemia in the range of 5-Sg/dl refractory to therapy except with 
recombinant erythropoietin, occurs in almost all patients with chronic renal failure who have plasma 
creatinine concentrations above 3,5mgjdl. The degree of anaemia often parallels the degree of renal 
dysfunction but remains relatively constant after end stage renal failure has occured. As the anaemia Is 
of slow onset it is well tolerated, and due to the risk of cytotoxic HLA antibodies being produced blood 
transfusions are usually not given. 
Disseminated Intravascular Coagulation (DIC) 
Sepsis, malignancy, hypotension or obstetrical complications may be associated with activation of the 
coagulation system and damage to various organs by clot deposition. Excessive consumption of 
fibrinogen, Factors V, VIII and platelets may also occur, with associated bleeding. Treatment is by 
treating the primary pathology,but fresh frozen plasma, cryoprecipitate or platelet concentrates may all 
be required if the patient has to be prepared for surgery. To normalise PTI or ACT (activated clotting 
time) replace Factors V, VIII with FFP or cryoprecipitate. To normalise fibrinogen give FFP or 
cryoprecipitate until fibrinogen > 200mg%. Give platelets until count > 1 00,0001 J.LI. If intravascular 
phospholipids are involved heparin may be required. 
Polycvthaemia Rubra Vera 
Any patient pre-operatively with a haemoglobin above 17g/dl in a male 16gjdl in a female (add an extra 
1 gjdl if patient lives considerably above sea level) requires an explanation for the high level. If the 
patient has hypoxaemia due to cyanotic heart disease or other right to left shunt heart conditions, 
, pulmonary disease, hypoventilation syndrome or sleep apnoea and if only the red cell number is 
increased no further explanation is required. It is, however, important in most instances to verify an 
absolute increase in red cell mass as the cause, as there are situations where a decrease in plasma 
volume may cause a similar haematological picture (relative polycythaemia, dehydration, cigarette 
smoker etc.,). If, however, other cell lines such as white cells and platelets show proliferation, 
Polycythaemia Rubra Vera (PRV) needs to be excluded as a diagnosis. The complication rate of 
operations on uncontrolled PRV patients has been reported to be as high as 79% with a 36% mortality 
due to both excessive thrombosis and haemorrhage. Controlled (more than 4 months) PRV patients had 
a complication rate of 5% with no deaths 13. 
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AUTOLOGOUS TRANSFUSION 
The indications include {1) patients wishing to avoid potential complications such as transmission of 
infection or exposure to allergens by receiving homologous blood transfusion; {2) patients who have red 
cell antibodies incompatable with most donor blood. 
Pre-donation Autologous Transfusion: 
A healthy patient with a haematocrit above 34% can donate a unit of his own blood weekly for up to 3-5 
weeks. The last donation being made 3 days prior to operation. If necessary the blood can be frozen for 
use at a later date. This ensures: 
a) He has his own blood available during the operation. 
b) His haematocrit is rheologically more suitable for tissue perfusion whilst not compromising his 
oxygen carrying ability. 
c) His bone marrow is producing large amounts of new blood cells. 
d) His oxygen dissociation curve is pushed to the right by the increase in 2,3 DPG. 
The problems include: inconvenience to the doctor and extra expense to the patient and blood bank. It 
may be difficult or impossible if there is poor venous access, pre-existing anaemia or infection, 
semi-urgent surgery or where there is a severe vasovagal response to phlebotomy. 
The use of recombinant erythropoietin may allow more blood to be donated safely and may be indicated 
in patients with a low initial haematocrit. 
Blood Scavenging: 
Transfusion of the patient's own shed blood by intra-operative salvage can be used in certain 
circumstances e.g. bleeding into the pleural cavity or peritoneal cavity where no bowel soiling has 
occurred. Intra-operative scavenging is contraindicated where there is a risk of the blood being 
contaminated by tumour cells or bacteria. There are various types of machine available but all salvaged 
blood must be filtered before reinfusion. 
lntra-operative:·Haemodilution: 
Haemodilution should be carried out in an isovolaemic fashion, immediately prior to operation. Equal 
volumes of a colloid such as Haemacell or Dextran 70 (lmljml of blood removed) or crystalloids 
{2-3mljml of blood removed) being infused as blood is removed by phlebotomy. The end point should 
be a haematocrit of 27-33% (Hb of 9-11gjdl). This autologous blood (1-3 units) is stored beside the 
patient and can be re-infused at any time. Any blood loss during surgery is replaced first by the last unit 
of blood removed (which contains the least red blood cells). The autologous blood, which still contains 
viable platelets, can be re-infused after the operation when surgical bleeding has diminished to ensure 
maximal conservation of the red cells. 
Page 26 
REFERENCES 
1. Knottenbelt J.D. A Guide to intravenous fluid therapy In trauma patients with haemorrhage shock. 
VMO.CME; 7:652-658, 1989 . 
2. Boral L.l., Henry J.B. The type-and screen: a safe alternative and supplement in selected surgical 
procedures. Transfusion 17: 163-168, 1977 
3. Czer L.S.C., Shoemaker W.C. Optimal hematocrit value in critically ill post-operative patients. 
Surg.Gynecoi.Obstet. 147: 363-367, 1978 
4. Blood Transfusion Therapy: A Physicians Handbook: American Association of Blood Banks, Ed. 
Snyder E.L. 1985 
5. Rao A.K., Walsh P.N. Acquired quatitative platelet disorders. Clin.Haematol. 12:201, 1983 
· 6. Platelet Transfusion Therapy- Consensus Conference. J.A.M.A. 257(13): 1777-1780, 1987 
7. Fresh Frozen Plasma: Consensus Conference. J.A.M.A. 253(4): 551-553, 1985 
8. Baunstein A.M., Oberman H.A. Transfusion of plasma components. Transfusion 24: 281-286, 
1984 
9. Hehne H.J., Nyman H.B., Burri M., Wolff G. Management of bleeding disorders in traumatic·· 
haemorrhagic shock states with deep frozen fresh plasma. Eur.J.Int.Care Med. 2: 157-161, 1979 
10. Messmer K., Ljungstrom K.G., Gruber U.F., Richter W., Hedin H. Prevention of dextran-induced 
anaphylactoid reaction by hapten inhibition. Lancet 1: 975-979, 1980 
11. Morrell D.F. The bleeding patient : A practical approach. Practical Anaesthesia Update 1990. Ed. 
Rocke D.A., Daniel C.H. 
12. Ljunstrom K.G., Renck H., Henin H., Richter W., Wiholm B.E. Hapten inhibition and dextran 
anaphylaxis. Anaesthesia 43: 729-732, 1988 
13. Weis K.H. Haemaccel 35 : Nebenreartionen in eiwermultizentrischen, prospektiven studie. 
Anaesthesist 32: 488-493, 1 983 











GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR_ ELECTIVE OPERATIONS 
4 UNITS 3 UNITS 
Oesophaegectomy Total colectomy 



























Incisional/large para-umbilical hcrni<' 
Non-toxic thyroidectomy 
Laparotomy 
B/K & A/K amputation 
NO GRClJP & SCREEN 
Groin hernia 
Varicose vein 
Salivery gland surgery 
Laparoscopy 




GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
OBSTETRICS & GYNAECOLOGY 
I 
I 5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCREEN 
Caesarean Section for placenta Cone Biopsy* 
praevia 
Hysterectomy abdominal or vaginal 
I Radical vulvecton~ Elective Caesarean section 
~ertheim's Hysterectomy Termination of pregnancy over 12 weeks 
Simple vulvectomy 
CARDIAC SURGERY 
·closed heart operations 
2 Units ~hole Blood & 
2 Units Red Blood Cells 
• only if problems anticipated 
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
ORTHOPAEDICS 
-· 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCREEN 
-
Forequarter amputation Forequarter amputation Amputation A/K & B/K 
En block excision tumour Bone grafting (major) 
' Retrograde Kuntscher nailing 
Open reduction fracture Moore's Prosthesis 
Open reduction of upper limb fractures 
Zimmer Screwplate 
Dislocation hip-central dis- En bloc excision tumour 
location 
Arthrodesis of hip Lumbar spinal fusion 
Hip disarticulation Open reduction fracture dislocation 
hip - posterior 
Retrograde Kuntscher nailing 
Arthrodesis of hip 
Open reduction of lower l i"mb fractures 
(femur or tibia) 
~ 
-- ----- ------
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR . ELECTIVE OPERATIONS 
PLASTIC SURGERY 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCREEN 
• 
Breast reconstruction Breast reconstruction 
' I 





5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP · & SCREEN 
.. 
Cystectomy O~x~n Prostatectomy Transurethral resections of prostrate, 
bladder tuoours 
Radical abdominal Nephrectomy I Urethroplasty ! 
lymphadenectomy Nephrolithotomy 
I ' Urinary diversion 
Ureterectomy 





5 UNITS 4 UNITS 3 UNITS 2 UNITS I GROUP & SCREEN 
Pulmonary resection, Pulmonary· decortication Mediastinal tumour Pulmonary resection Pleurectomy I 
major, ·inflammatory non-inflanmatory I I .. 
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
Llh.L. 
5 UNITS 4 UNITS 3 UNITS 2 UN ITS 
Angiofibroma excision Mas to dectomy (urgent) 
Comnando nryngectomy 
Paraganglioma excision M andibulectomy 
Laryngopharyngectomy Maxillectomy 
Tetrpo ral bone excision 
Del topectoral flap 
Myc cutaneous flap 
Nc ck dissection 
NEUROSURGERY 
.. 
I 5 UNITS 4 UNITS 3 UNITS 2 UNITS 
Large cerebral arterio- Cerebral aneurysm 1 
Transsophenoidal hYPophysectomy 
Vascular Cerebral Tumours 
GROUP & SCREEN 
Hemiglossectomy 
Partial Pharyngectomy 




GROUP & SCREEN 
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
GENERAL SURGERY 
I 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCREEN 
I 
Aortic aneurysm Oesophagectomy Total colectomy Dr. Intraperitoneal abscess Vagotomy 
Gastrectomy 
Aorto-femoral bypass Pancreaticoduodenectomy AP resection Liver abscess S)'q)Bthectomy 
Cholecystectomy 
Mastectomy & axillary clearance lncisional/large para-umbilical hernia 
Radical gastrectomy Non-toxic thyroidectomy 
Hindquarter amputation Adrenalectomy Laparotomy 
B/K & A/K amputation 
Major liver resection Distal pancreatectomy NO GROUP & SCREEN 
t.S.D. exploration 
Porta-systemic shunts Groin hernia 
Varicose vein 
Salivery gland surgery 
Laparoscopy 





GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
OBSTETRICS & GYNAECOLOGY 
5 UNITS 4 UNITS 
CARDIAC SURGERY 
Closed heart operations 
2 Units Yhole Blood & 
2 Units Red Blood Cells 
...___ --~~-- ------- - ~---
* only if problems anticipated 
Burns ond skin grafting in children: 
3 UNITS 2 UNITS 




- ~-- ~--- --~ ------ ---------
GROUP & SCREEN 
Cone Biopsy* 
Hysterectomy abdominal or vaginal 
Elective Caesarean section 
Termination of pregnancy over 12 wee~s 
Simple vulvectomy 
i 
Add together the percentage area of donor site and recipient site. If this area is equal to 32%, one blood volume needs to be 
cross matched and will probably be required 
during the procedure. 
Therefore Cross Match= Total Area (Donor site+ recipient site) x 80 (blood volume in ml/Kg> 
(in ml) 32 
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
ORTHOPAEDICS 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GRClJP & SCREEN 
Forequarter amputation Forequarter amputation Amputation A/K & 8/K 
En block excision tumour Bone grafting (major) 
Retrograde Kuntscher nailing 
Open reduction fracture Moore's Prosthesis 
Open reduction of upper l irrb fractures 
Zimmer Screwplate 
Dislocation hip-central dis- En bloc excision tumour 
location 
Arthrodesis of hip Lumbar spinal fusion 
Hip disarticulation Open reduction fracture dislocation 
hip - posterior 
Retrograde Kuntscher nailing 
Arthrodesis of hip 
Open reduction of lower lirrb fractures 
(fenur or tibia) 
I 
GROOTE SCHUUR HOSPITAL 
GUIDEliNES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
PLASTIC SURGERY 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GROOP & SCREEN 
Breast reconstruction Breast reconstruction 
Maxillo-facial surgery Musculocutaneous flap 
-------
UROLOGY 
5 UNITS 4 UNITS 3 UNITS 2 UNITS GROOP & SCREEN 
Cystectomy Open Prostatectomy Transurethral resections of prostrate, 
bladder tunours 









5 UNITS 4 UNITS 3 UNITS 2 UNITS GROOP & 
i 
SCREEN 
Pulmonary resection, Pulmonary decortication Mediastinal tunour Pulmonary resection - Pleurectomy 
major, inflammatory non- inflammatory 
GROOTE SCHUUR HOSPITAL 
GUIDELINES FOR MAXIMUM BLOOD ORDERING FOR ELECTIVE OPERATIONS 
LlhL. 
.5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCREEN 
Angiofibroma excision Mastoidectomy (urgent) Hemiglossectomy 
Coomando Laryngectomy Partial Pharyngectomy 
Paraganglioma excision Mandibulectomy Frontal sinus obliteration 
Laryngopharyngectomy Maxillectomy Parotidectomy 





5 UNITS 4 UNITS 3 UNITS 2 UNITS GROUP & SCRE
EN 
-Large cerebral arterio- Cerebral aneurysm 
Transsophenoidal hypophysectomy 





BLOOD REPLACEMENT : 
To raise haemoglobin level1gjdl 
4mljKg body weight Packed Red Blood Cells 
6mljKg body weight Whole blood 
OPTIMAL: 
Peri-operative haematocritjhaemoglobin* (Dependent on patient) 
Hct 27-33% (Hb 9-11gjdl) 
PLATELETS: 
FFP: 
Level Pre-operative replacement level if no immune or consumptive cause- 50-75,000/J.LI 
Functional Test- Tenplate Bleeding Time (normal 2-9,5 minutes) 
Dose Single random unit raises count 5-10,000/J.LI 
Usual dose 1 unit/1 OKg body weight 
Main Indications 
Multiple coagulation defects 
Reversal warfarinjsuxamethonium effects 
Massive blood transfusions(> 1,5 blood volumes) 
Dose 800mi-2,000ml (4-8 packs of FFP) for 70Kg adult over 90-120 minutes 
COLLOIDS: 
Blood derivatives 
Albumin, SHS (PPF) - Expensive, use in hyproproteinaemic shocked states 
Synthetic Derivatives 
Dextran 70 - Danger immunoglobin mediated anaphylaxis 
Limit to 1 ,5Kgjday (± 1 ,500ml) 
Haemaccei H istamine release may be a problem 
BLOOD REPLACEMENT 
1 mi blood loss replace with 2-3ml crystalloid or 1 ml colloid 
